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The universe is no narrow thing and the order within it is not constrained by any 
latitude in its conception to repeat what exists in one part in any other part. Even 
in this world more things exist without our knowledge than with it and the order 
in creation which you see is that which you have put there, like a string in a 
maze, so that you shall not lose your way. For existence has its own order and 
that no man's mind can compass, that mind itself being but a fact among others.” 
 
Cormac McCarthy “Blood Meridian; or, the Evening of Redness in the West” 
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Abstract 
p16INK4a (p16) traps the cell at the restriction point of the cell cycle by binding to 
cyclin-dependent kinase 4/6 thus preventing the phosphorylation of the 
retinoblastoma protein (pRB). As p16 accumulates the cell stops dividing and 
becomes senescent. This study investigates the modulation of p16 function by 
the putative membrane protein ABCB5 and a group of five putative oncogenic 
microRNAs (oncomiRs).   
 
ABCB5 is a poorly characterised member of the B-subfamily of human ATP 
Binding Cassette transporters. ABCB5 is reportedly transcribed into four 
transcripts, one of which could potentially encode a full-length transporter 
(ABCB5fl) whilst a second could encode a half-transporter (ABCB5β). The other 
two transcripts (ABCB5α and ABCB5γ) could only encode short polypeptides. 
Exogenous expression of ABCB5fl and ABCB5β was achieved in HEK293T 
cells, but the recombinant protein expressed poorly and localised to the 
endoplasmic reticulum. Point mutations introduced into the ATP catalytic 
domain failed to improve expression levels suggesting that protein function was 
not deleterious to the cell. Exogenous expression in HEK293T cells also allowed 
commercial antibodies purportedly raised against ABCB5 isoforms to be tested. 
Several were found not to recognise ABCB5 necessitating re-interpretation of 
published data. However, one antibody recognised both ABCB5fl and 
ABCB5β, and was subsequently used to evaluate protein expression levels in 
other cell types. 
 siRNA knockdown of ABCB5 in human mammary epithelial cells (HMECs) 
caused a concomitant reduction in p16 expression and an increase in cellular 
proliferation. Differential siRNAs and RT-qPCR analyses demonstrated ABCB5β 
to be the relevant transcript with respect to the reduction in p16 expression; 
however, no native ABCB5β protein was detected in HMECs. Together these 
data lead to the hypothesis that the ABCB5β transcript may act as a long non-
coding RNA to regulate p16.  
 
Exogenous expression of each of five distinct putative oncomiRs in HMECs was 
found to increase cellular proliferation and, surprisingly, increase p16 
expression. These results mirror a phenotype commonly observed in p16-positive 
basal-like breast cancer (BLBC), an aggressive form of breast cancer with poor 
prognosis and few treatment options. Bioinformatic analysis of the predicted 
target genes for these oncomiRs identified multiple transcriptional regulators of 
pRB. These predictions, together with the work performed in a cellular model of 
p16-positive BLBC, suggest that the oncomiRs may cause unrestricted cell 
proliferation by indirectly reducing transcription of the pRB gene, RB1. In the 
absence of pRB, p16 expression is induced via a previously reported oncogene-
induced senescence-like positive feedback loop. These data, and previously 
published observations, suggest that a similar mechanism may explain the basis 
of p16-positive BLBC. 
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Nomenclature 
3’-UTR 3’ untranslated region 
5’-UTR  5’ untranslated region 
4-PB  sodium 4-phenylbutyrate 
ABC  ATP binding cassette 
ADAR  adenosine deaminases acting on RNA 
Ago2  Argonaute-2 
ANOVA analysis of variance 
antimiR anti-miRNA 
ATP  adenosine triphosphate 
BLBC  basal-like breast cancer 
BSA  bovine serum albumin 
CDK  cyclin-dependent kinase 
cDNA  complementary DNA 
C. elegans Caenorhabditis elegans 
ChIP  chromatin immunoprecipitation 
CK  cytokeratin 
CML  chronic myelogenous leukaemia  
DAPI  4’,6-diamidino-2-phenylindole 
DMEM Dulbecco’s modified Eagle’s medium 
D/P  Drosha/Pasha complex 
DPBS  Dulbecco’s phosphate buffered saline 
dsDNA double stranded DNA 
 10 
E. coli  Escherichia coli 
EDTA  ethlyenediaminetetraacetic acid 
EGF  epidermal growth factor 
EGFR  epidermal growth factor receptor 
EGFP  enhanced green fluorescent protein 
ER  endoplasmic reticulum 
FBS  fetal bovine serum 
fl  full-length 
GWAS genome-wide association studies 
HDAC  histone deacetylase 
HEK293 human embryonic kidney 293 cells 
HEK293T human embryonic kidney 293 cells expressing the SV40 large T antigen 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
HER2  human epidermal growth factor receptor 2 
HMEC  normal 184 human mammary epithelial cells 
HRP  horseradish peroxidase 
IF  immunofluorescence  
INK/ARF INK4b-ARF-INK4a 
LB  lysogeny broth 
LDH  lactate dehydrogenase  
lncRNA long non-coding RNA 
LSC  limbal stem cell 
MAPK  mitogen-activated protein kinase 
MDR   multidrug resistance 
MEBM mammary epithelial basal medium 
 11 
MEGM mammary epithelial grown medium 
miRISC miRNA induced silencing complex 
miRNA micro RNA 
MMIC  malignant melanoma initiating cells 
mRNA  messenger RNA 
ncRNA non-coding RNA 
OIS  oncogene-induced senescence 
oncomiR oncogenic miRNA 
OR  oestrogen receptor 
p16  p16INK4a 
p21  p21CIP1 
P4  passage 4 
P5  passage 5 
P6  passage 6 
P10  passage 10 
P11  passage 11 
P20  passage 20 
P28  passage 28 
PACT  protein activator of PKR 
PBS  phosphate buffered saline 
PcG  polycomb group 
PCR  polymerase chain reaction 
PEI  polyethyleneimine 
PFA   paraformaldehyde  
PR  progesterone receptor 
 12 
pre-miRNA precursor miRNA 
pri-miRNA primary miRNA 
qPCR  quantitative PCR 
RT-qPCR reverse transcription quantitative PCR 
RBP  RNA-binding protein 
RIP  RBP immunoprecipitation 
RISC  RNA induced silencing complex 
RLC  RISC loading complex 
RNAi  RNA interference 
RNA-seq RNA sequencing 
RPMI  Roswell Park Memorial Institute 
r-point  restriction point 
RT  room temperature 
RT-PCR reverse transcription PCR 
SASP  senescence-associated secretory phenotype 
S. cerevisiae Saccharomyces cerevisiae 
SCC  squamous cell carcinoma 
SCF  seed compliment frequency 
SD  standard deviation 
SDS  sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
shRNA short hairpin RNA 
siRISC  siRNA induced silencing complex 
siRNA  small interfering RNA 
TBRP  Tar RNA binding protein 
 13 
TBS  Tris buffered saline 
TBS-T  Tris buffered saline supplemented with 0.2% Tween 20 
TdT  terminal deoxynucleotidyl transferase 
TMH  transmembrane helix 
TNBC  triple-negative breast cancer 
tRNA  transfer RNA 
UTR  untranslated region 
UV  ultraviolet 
V5-6His V5 and 6-histidine tag 
VEGF  vascular endothelial growth factor 
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1  Introduction 
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1.1 The ABCs of ABCs 
ATP Binding Cassette (ABC) proteins are a superfamily of integral membrane proteins, 
which use energy derived from the hydrolysis of ATP to perform a variety of functions 
in cells, but are primarily concerned with the transport of molecules across membranes 
(Linton and Holland, 2011).  ABC proteins have been found in all organisms studied to 
date (Higgins, 1992), and often play crucial roles in organism survival. For example, 
Rad50 plays a key role in the repair of double strand breaks in Saccharomyces 
cerevisiae (S. cerevisiae) (Hopfner et al., 2000), and a wide array of proteins such as the 
ABC importer Znu (Desrosiers et al., 2010) are important for bacterial cell growth. 
1.2 Mammalian ABC proteins 
Humans have 48 ABC transporters genes, split between seven distinct subfamilies 
(Dean et al., 2001), most of which are currently believed to translocate molecules across 
the cell and intracellular membranes (Linton and Holland, 2011). ABC transporters in 
humans are mostly primary active pumps that comprise, minimally, four domains: two 
transmembrane domains (TMDs) each with six transmembrane helices that span the 
membrane and often impart specificity for the transport substrate, and two nucleotide 
binding domains (NBDs) that reside in the cytosol and hydrolyse ATP to drive the 
transport mechanism (Zolnerciks et al., 2011). Many of the human ABC transporters are 
important in normal physiology, and as such, their dysregulation or mutation can have 
health consequences, such as cystic fibrosis, which most commonly arises as a result of 
a deletion of codon 507 in ABCC7 (Bobadilla et al., 2002).  
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1.3 The ABCB subfamily of proteins 
The ABCB subfamily of ABC transporters is unusual in that in contains both full- and 
half-transporters (Dean et al., 2001), and is the third largest subfamily, containing a 
total of 11 proteins (ABCB1 – ABCB11). Members of the subfamily are localised 
throughout the cell, with ABCB1, ABCB4 and ABCB11 in the plasma membrane 
(Thiebaut et al., 1987, Buschman et al., 1992, Gerloff et al., 1998), ABCB2 and ABCB3 
in the endoplasmic reticulum (ER) (Lankat-Buttgereit and Tampé, 2002), ABCB6, 
ABCB7, ABCB8 and ABCB10 all within the mitochondria (Zutz et al., 2009), and 
ABCB9 found in the lysosomal compartments (Zhang et al., 2000).  
 
ABCB1 plays an important role in multidrug resistance (MDR) in cancer, as it can 
transport a wide array of chemically diverse molecules, such as anthracyclines, 
epipodophyllotoxins and taxanes (Ambudkar et al., 1999). ABCB2 (TAP) and ABCB3 
(TAP2) are half-transporters that dimarise to form the TAP1/2 (ABCB2/ABCB3) 
heterodimer, which also transports a wide array of antigenic peptides into the ER lumen 
for loading onto the major histocompatibility complex class I molecules, which is an 
essential process for antigen presentation (Lankat-Buttgereit and Tampé, 2002). 
ABCB4 and ABCB11 are both involved in bile secretion from the gall bladder in the 
liver, and transport phosphatidyl choline and bile salts (van Helvoort et al., 1996, 
Gerloff et al., 1998), respectively. ABCB6, ABCB7, ABCB8 and ABCB10 are thought 
to transport to molecules involved with Fe-S biosynthesis and iron metabolism (Zutz et 
al., 2009), and ABCB9 is highly expressed in testes although its function is, as of yet, 
unknown (Zhang et al., 2000). 
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One of the most recently discovered members of the ABCB subfamily is ABCB5, 
which was first identified in 2001 based upon its sequence homology to the other 
ABCB family members (Dean and Allikmets, 2001).  
1.4  ABCB5  
The ABCB5 gene is located on chromosome 7p21, has 28 exons, and spans 141.8 kb of 
DNA. All of the ABCB full transporters originated from a single gene with a common 
ancestor in non-vertebrates that can be examined as far back as Caenorhabditis elegans 
(C. elegans), and yeast (Moitra et al., 2011). The only non-mammalian ABCB5 can be 
found in Xenopus, suggesting that the gene may have been lost in some linages (Moitra 
et al., 2011). This same study also identified high levels of selection in both the TMDs 
and NBDs of ABCB5, signifying that these domains have kept their functional 
significance throughout evolution (Moitra et al., 2011).  
1.5 ABCB5 isoforms 
From the ABCB5 gene, four isoforms are known to be transcribed: full-length 
(ABCB5fl; NM_001163941.1); alpha (ABCB5α; ΝΜ_001163942.1); beta 
(ABCB5β; ΝΜ_178559.5); and gamma (ABCB5γ; ΝΜ_001163993.2; Figure 1-1; 
Figure 1-2; Figure 1-3). Of the four isoforms, ABCB5fl and ABCB5β are reported to be 
active transporters (see Section 1.7.2). 
 
  
Figure 1-1. Exon and intron arrangement of the four ABCB5 isoforms. 
Cartoon showing the relative sizes of each of the 28 main exons (green) giving rise to ABCB5fl, and the mixture of introns (orange) and exons that 
comprise ABCB5α , ABCB5β  and ABCB5γ . Translational start sites are denoted by (AUG), translational stop sites are marked by (STOP). Distance 
between exons is not indicative of intron length.  
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Figure 1-2. Relative mRNA size of the four ABCB5 isoforms. 
Cartoon illustrating the relative mRNA sizes of each of the ABCB5 isoforms. 
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Figure 1-3. Topography of the four ABCB5 isoforms.   
Transmembrane regions and nucleotide binding domains (NBDs) are represented in green and blue, respectively. Each NBD contains seven 
distinct and highly conserved motifs for nucleotide binding and hydrolysis. Red lines indicate the coding sequence of ABCB5α , ABCB5β , and 
ABCB5γ  isoforms, compared to ABCB5fl. Purple ‘Y’s represent predicted glycosylation sites. 
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 1.5.1 ABCB5fl 
The 5401 nt mRNA of ABCB5fl is generated when the full 28 exons of the ABCB5 gene 
are spliced together (Figure 1-1; Figure 1-2). This mRNA is then translated to create a 
protein of 1257 amino acids (Figure 1-3). The ABCB5fl protein has two TMDs and two 
NBDs, providing it with a structure similar to ABCB1, ABCB4 and ABCB11. Each of 
the TMDs contains six predicted transmembrane helices, and each of the NBDs contains 
the seven motifs required for effective ATP binding and hydrolysis: A-loop, Walker A. 
Q-loop, ABC signature, Walker B, D-loop and H-loop.  
 
In order to gain a better appreciation of the structure of ABCB5fl, the three-dimensional 
structure was predicted using the crystal structure of the Mus musculus homologue of 
ABCB1, Abcb1a, as a template (Figure 1-4). This was carried out by uploading the 
amino acid sequence of ABCB5fl (NP_001157413.1) to the I-TASSER protein 
structure prediction serverI , alongside Abcb1a. In the predicted three-dimensional 
structure both NBDs appear more disorganised than in Abcb1a, although this is likely 
due to an imperfect prediction algorithm. 
1.5.1.1 Nucleotide binding domains of ABCB5fl 
ABCB5fl would contain two NBDs, both of which include the seven conserved motifs 
present in the majority of ABC proteins (Figure 1-5) (Kerr, 2002). Each NBD is split 
into two subdomains. The F1-type ‘core’ subdomain contains the Walker A 
(GxxGxGKS[S/T]) and Walker B (hhhhDE) motifs (where x is any amino acid, and h is 
                                                
 
I The I-TASSER protein structure prediction server can be found at http://zhanglab.ccmb.med.umich.edu/I-TASSER/ 
(accessed April 2011). 
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any hydrophobic amino acid), along with the A- Q- D- and H- loops. The α-helical 
subdomain contains the ABC signature motif (LSGGQ), which aligns with the Walker 
A motif of the opposite NBD when both NBDs come together in a head-to-tail 
arrangement to bind ATP (Zolnerciks et al., 2011). Together, the presence of all of the 
Figure 1-4. Predicted three-dimensional structure of ABCB5fl. 
ABCB5fl three-dimensional model, based on the crystal structure of the ABCB1 mouse 
homologue Abcb1a (PDB number: 3D5U), generated using I-TASSER protein structure 
prediction server (Roy et al., 2010)I . Blue – nucleotide binding domains; green – 
transmembrane regions.  
essential motifs on the two NBDs suggest that ABCB5fl should be able to bind and 
hydrolyse ATP to power substrate transport. 
1.5.1.1 Transmembrane domains of ABCB5fl 
ABCB5fl is predicted to include 12 transmembrane helices (TMHs), grouped into two 
transmembrane domains of six helices each (Moitra et al., 2011). The aforementioned 
                                                
 
I The I-TASSER protein structure prediction server can be found at http://zhanglab.ccmb.med.umich.edu/I-TASSER/ 
(accessed April 2011). 
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predicted structure of ABCB5fl (Figure 1-4) shows that the TMHs are likely to be 
arranged in a similar manner to those of Abcb1a. 
 
Figure 1-5. Conserved motifs in the nucleotide binding domains of ABCB transporters. 
The Walker A (green), Q-loop (red), ABC signature (orange), Walker B (blue), D-loop 
(purple) and H-loop (yellow) motifs are conserved across ABCB family transporters. 
ABCB6 is a half-transporter and therefore does not have a second NBD. 
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1.5.1.2 Glycosylation of ABCB5fl 
Glycosylation is known to be important for correct trafficking and function in multiple 
ABC transporters (Wojtowicz et al., 2012, Beers et al., 2013), and other membrane 
proteins (Hoosdally et al., 2009). ABCB5fl has two potential N-linked glycosylation 
sites present in the first extracellular loop (Figure 1-3). Because of the nature of its 
truncation, ABCB5β does not have these two potential glycosylation sites. There are 
multiple alternative sites throughout the protein, however none of these are predicted to 
be extracellular and so are unlikely to be available for glycosylation. 
1.5.2 ABCB5α  
ABCB5α is generated when a 306 nt section of intron 9 is spliced to exons 11, 12, 13 
and 14 and a 1328 nt section of intron 14 (Figure 1-1). This splicing event creates an 
mRNA of 2247 nt (Figure 1-2), which could then be translated to produce a protein of 
131 amino acids (Figure 1-3). The resulting protein would contain the Q-loop, ABC 
signature motif, Walker B, and D-Loop of NBD1, but no transmembrane helices. 
Without any transmembrane helices this protein would be unable to act as a half-
transporter, or even attach to a membrane. This small protein was originally suggested 
to play a role by interacting with either mRNA or proteins (Gottesman, 2004, Chen et 
al., 2005a), although, as of yet, there is no empirical data to support this postulation. 
1.5.3 ABCB5β   
ABCB5β is just over half the length of ABCB5, arising from a splicing of the same 306 
nt section of intron 9 found in ABCB5α, to exons 11 – 28 (Figure 1-1). The resulting 
mRNA sequence (4375 nt; Figure 1-2) could encode an 812 amino acid, C-terminal 
portion of the full-length protein with NBD1 (minus the Walker A motif), TMD2 and 
NBD2 present (Figure 1-3). The truncation of the N-terminal end would position the Q-
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loop of NBD1 at the N-terminus (Chen et al., 2005). Due to its size and domain 
composition, ABCB5β has been suggested to function as a half-transporter, which 
could dimerise to produce a functional transporter, similar to the drug efflux pump 
ABCG2 (Woodward et al., 2011, Moitra et al., 2011) and the peptide transporters 
ABCB2 and ABCB3 (Lankat-Buttgereit and Tampé, 2002). Indeed, some published 
studies have claimed to measure transport function in ABCB5β+ cells (see Section 
1.7.2). 
1.5.4 ABCB5γ  
ABCB5γ is formed when the same 306 nt section of intron 9 present in ABCB5α and 
ABCB5β is spliced to exons 11, 12, 13 and 14, and an 805 nt section of intron 14 
(unrelated to the section of intron 14 present in ABCB5α; Figure 1-1). This pattern of 
splicing creates an mRNA of 1724 nt, which potentially encodes a protein of 126 amino 
acids. This potential protein encodes a similar section of ABCB5fl to ABCB5α, 
including the Q-loop, ABC signature, Walker B and D-loop motifs of NBD1, although 
with a shorter amino acid sequence after the D-loop. As of yet, no suggestions as to the 
function of this protein have been made, although if translated, it is likely that it could 
act in a similar manner to ABCB5α given the near identical sequence.  
1.6 ABCB5 tissue expression pattern 
Compared to many other genes, ABCB5 is expressed at relatively low levels, and in 
only within certain compartments of the body.  At present ABCB5β and 
ABCB5α expression has only been  detected in normal melanocytes, placenta, retinal 
pigment and epithelial cells (Chen et al., 2005a, Volpicelli et al., 2014). High 
expression in melanoma cells however has been reported multiple times (Frank et al., 
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2003, Chen et al., 2005a, Frank et al., 2005, Schatton et al., 2008, Lin et al., 2013), and 
it has been suggested that because expression of ABCB5α or ABCB5β  is usually 
specific to pigment cells, that it may be involved in melanogenesis (Chen et al., 2005a). 
It should be noted that although the ABCB5α transcript would be unlikely to encode an 
ABC protein, it was the most common isoforms of ABCB5 found expressed in a human 
melanoma cDNA library (Chen et al., 2005a).  
1.7 Cancer treatment and chemotherapy resistance 
Throughout history surgical resection has been the first choice for cancer treatment 
(Daviel and Parsons, 1755, Papavramidou et al., 2010), as it is provides rapid relief 
from tumour bulk for the patient (Zabel and Debus, 2004), and is commonly a very 
effective course of action (Cushing et al., 1999, Simmonds et al., 2006). However, 
tumours that cannot be treated surgically (such as leukaemia), tumours that have 
characteristically undefined edges (such as glioblastoma multiforme) (Lacroix et al., 
2001), and tumours that have metastasised pose problems for this course of action. 
Treatment with toxic xenobiotic compounds (chemotherapy) and radiation 
(radiotherapy) are often therefore utilised instead of, or, in addition to, surgery. 
 
The treatment of cancer with chemotherapy also has problems associated with it, such 
as the commonly known adverse side effects associated with treatment. One of the most 
difficult issues to overcome with chemotherapy is the multi-drug resistance (MDR) of 
some tumours (Baguley, 2010). MDR in cancer arises when the chemical compounds 
used to kill tumour cells are no longer effective, often because they are removed from, 
or compartmentalised within, the cancer cells by ABC transporter activity (Szakács et 
al., 2006), thus protecting the cell from damage.   
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1.7.1 ABC proteins in multi-drug resistance 
ABC transporters were first recognised as having an important role in MDR, when 
Dano (1973) recognised the extrusion of daunomycin from MDR Ehrlich ascites tumour 
cells. Further study showed that it was the transport function of ABCB1 which was 
removing the compound from the cells (Juliano and Ling, 1976).  
 
Since this original finding, several other ABC transporters have been linked to MDR in 
specific tumours, such as ABCG2 in breast cancer (Maciejczyk et al., 2012), while 
others are found more ubiquitously, such as ABCB1 (Scherf et al., 2000). Currently 
ABCA2 (Boonstra et al., 2004), ABCB1 (Ambudkar et al., 1999), ABCB5 (Frank et al., 
2003, Frank et al., 2005), ABCC1 (Borst et al., 2000), ABCC2 (Cui et al., 1999, Borst 
et al., 2000), ABCC4 (Borst et al., 2000, Chen et al., 2001), and ABCG2 (Staud and 
Pavek, 2005) are reported to be up-regulated in cancer cell lines selected for MDR. 
Additionally, ABCB11 (Childs et al., 1998), ABCC3 (Borst et al., 2000), ABCC5 
(Borst et al., 2000), ABCC6 (Belinsky et al., 2002), ABCC10 (Hopper-Borge et al., 
2004), and ABCC11 (Guo et al., 2003) have all been described as conferring drug 
resistance to transfected cells. 
 
All of these proteins are reported to transport multiple xenobiotic compounds including 
drugs from different chemical classes. As such, their expression in response to one 
chemotherapy regime can also render others ineffective. In an effort to combat MDR as 
a result of ABC transporter expression, inhibitors have been trialled in patients 
diagnosed with drug resistant cancers, however nearly all of these trials were found to 
be unsuccessful, either due to the tolerable doses of inhibitor being too low to produce 
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an effect (O'Brien et al., 2010), or due to the adverse side effects in participating 
patients (Dalton et al., 1995).  
1.7.2 Evidence for ABCB5fl and ABCB5β  in MDR 
Although ABCB5 is one of the least well-characterised members of the B-subfamily, 
some experiments have been carried out with the objective of elucidating the function of 
the two largest isoforms. Due to their similarity with the other ABCB family 
transporters, it was postulated that both ABCB5fl and ABCB5β would be able to 
transport chemotherapeutic substrates, with ABCB5β dimerising to form a full 
transporter (Moitra et al., 2011). 
 
The majority of research into the function of these proteins has been carried out in cell 
lines with endogenous ABCB5β expression. The first study was carried out in tandem 
with MCF-7 cells transfected with ABCB5β, and G3361 melanoma cells that 
endogenously expressed ABCB5β, but not ABCB5fl (as evaluated by antibody binding) 
(Frank et al., 2003, Frank et al., 2005). These studies reported that ABCB5β could 
efflux both rhodamine-123 and doxorubicin from the cells, and also suggested a role in 
the regulation of progenitor cell fusion (see Section 1.8).  
 
Subsequently, two separate groups carried out studies into the function of ABCB5fl and 
ABCB5β, with exogenously expressed protein. Both concluded that ABCB5β was 
unable to transport the previously tested substrates from the transfected cells (Chen et 
al., 2009, Gillet et al., 2009, Kawanobe et al., 2012). One of these groups additionally 
found that ABCB5fl expression in naive cells could confer resistance to a variety of 
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chemotherapeutic compounds, such as anthracyclines, epipodophyllotoxins, and taxanes 
(Kawanobe et al., 2012). 
1.8 ABCB5β , progenitor cell fusion, and membrane potential 
The first two papers to report the function of ABCB5β also described a link to the 
fusion of progenitor cells, and the regulation of membrane potential in expressing cells 
(Frank et al., 2003, Frank et al., 2005). Initial characterisation of G3361 melanoma cells 
found that a small subset of the cells expressed ABCB5β, and this was found to 
coincide with CD133 expression, a known marker of stem and progenitor cells (Corbeil 
et al., 2000, Sanai et al., 2005). These ABCB5β+ and CD133+ cells were commonly 
observed to be binucleate or polynucleate, and through experimentation using 
differentially labelled cells (labelled with DiI and DiO), this was found to be due to the 
fusion of the ABCB5β+ progenitor cells (Frank et al., 2003).  
 
To further investigate the role of ABCB5β in progenitor cell fusion, the group assessed 
whether the function of ABCB5β regulated the membrane potential of these cells, as it 
had previously been shown that membrane potential is critical in cell fusion (Liu et al., 
2003). When cells were treated with an antibody targeting ABCB5β, there was a 
significant increase in depolarised cells within the population (Frank et al., 2003, Frank 
et al., 2005), suggesting that ABCB5β functions to maintain membrane potential.  
1.9 ABCB5β  in cancer stem cells 
After the small population of ABCB5β+ cells in the G3361 melanoma cell lines was 
first suggested to mark progenitor cells (Frank et al., 2003), much of the following 
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studies carried out have been concerned with using ABCB5β expression to mark CSCs 
(cancer stem cells) in different tumours. The majority of these studies have investigated 
the expression of ABCB5β in the CSC-like sub-population of melanoma cells, namely 
the malignant melanoma initiating cells (MMICs).  
 
These studies reported that by targeting the small subset of ABCB5β+ cells within the 
tumour, tumours growth could be inhibited, and that these MMICs had a higher 
tumourogenic capacity than ABCB5- bulk tumour cells when used as a xenotransplant 
into NOD/SCID mice (Schatton et al., 2008, Gazzaniga et al., 2010, Vásquez-
Moctezuma et al., 2010). The ABCB5β+ MMICs were also identified as being able to 
evade the host anti-tumour immune system, and were suggested to play a critical role in 
melanoma immune evasion via immunomodulation, advancing tumour growth and 
therapeutic resistance (Schatton and Frank, 2009). ABCB5β+ MMICs have also been 
found circulating in the peripheral blood of melanoma patients, which is reported to 
correlate with disease recurrence and progression (Ma et al., 2010, Cigna et al., 2011, 
Freeman et al., 2012, Reid et al., 2013). 
 
ABCB5β expression has also been reported to mark a higher risk population in patients 
with acute leukaemia (Farawela et al., 2014, Yang et al., 2012), and oral squamous cell 
carcinoma (Richard et al., 2013). In one study, ABCB5 was found to be significantly 
down-regulated in breast carcinoma, compared to normal breast tissue controls. This 
work did not distinguish between the different isoforms. More intriguingly however, 
up-regulation in ABCB5 in breast carcinoma was found to correlate with the ability of 
the tumour to metastasise to the lymph nodes (Viktor Hlavac, Czech Republic National 
Institute of Public Health, personal communication) 
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In addition to marking CSCs and possible roles in MDR, ABCB5 has been linked to the 
regulation of the cell cycle, in particular, the switch between a proliferative and 
senescent phenotype. 
1.10 The cell cycle 
The eukaryotic cell cycle is described by the series of stages that a cell goes through 
leading up to its division (Figure 1-6 panel A), and is controlled by a large regulatory 
network, with many features being conserved from yeast to humans (Bertoli et al., 
2013). The five stages of the cycle are most commonly referred to as Gap 1 (G1), DNA 
synthesis (S), Gap 2 (G2), Mitosis (M), and quiescence, otherwise known as Gap 0 (G0). 
Progression through the cell cycle is regulated by changes in gene expression as a result 
of the specific activities of cyclin-dependent kinases (CDKs), which are differentially 
expressed throughout the cell cycle (Lim and Kaldis, 2013). These changes in gene 
expression cause the various cyclins to accumulate at different points in the cycle 
(Figure 1-6 panel B), thus they regulate CDK activity, and control progression through 
the cell cycle.  
 
The activity of CDKs indirectly regulate the expression of many genes which are 
important for cellular processes that occur in the subsequent phase of the cell cycle. In 
the majority of eukaryotes, the transcription of these genes occurs in three waves 
(Bähler, 2005) at the main phase transition points during the cell cycle, G1 to S, G2 to 
M, and M to G1, where new expression profiles of genes are required for the next phase 
(Wittenberg and Reed, 2005). 
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Figure 1-6. The cell cycle. 
A. The cell cycle consists of four main sections, G1 (Gap 1); S (DNA Synthesis); G2 (Gap 
2); and M (Mitosis), and one subsection, G0 (Quiescence, or Gap 0). The R-point (red line) 
controls the cells passage from G1 to S phase, with certain conditions causing the cell to 
enter senescence. B. Expression of the different cyclins drives the cell cycle at different 
points. Cyclin D (orange line) is present throughout the cell cycle, with the exception of 
the M to G1 phase transition peaking in late S phase. Cyclin E (purple line) is present in 
G1 and S phase, reaching its maximum level at the phase transition. Cyclin A (green line) 
expression increases steadily from mid – late G1 to peak at early – mid G2, and then 
drops rapidly during the transition from G1 to M phase. Cyclin B (blue line) expression 
increases from the beginning of S phase until the G2 to M phase transition, after which it 
declines sharply. 
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Uninhibited cell cycling, with unrestricted growth is common, and gives rise to 
tumourous cells, the majority of which are cleared by the immune system before they 
become an issue for the host organism (Jewett et al., 2012). The derepression of genes 
associated with enhanced cellular proliferation is a hallmark of cancer, and is commonly 
the first step in the cancer pathway. It is therefore important for the cell to closely 
regulate the cell cycle, and this is achieved through the use of checkpoints and CDK 
inhibitors. 
1.11 Cell cycle regulation 
There are three important points in cell cycle regulation, two DNA damage checkpoints, 
and a ‘restriction point’ (R-point), after which the cell is committed to complete the 
cycle independently of external signals from the environment (Johnson and Skotheim, 
2013). At the DNA damage checkpoints, the structure of the DNA is assessed to ensure 
that correct cellular function and viability is maintained (Elledge, 1996). If this system 
finds genetic faults, the G1 or G2 phases can be stalled whilst the damage is repaired, or 
else the cell will enter apoptosis (Massagué, 2004, Bertoli et al., 2013). The importance 
of these checkpoints can be easily illustrated by the high frequency of mutations found 
in the constituent regulatory proteins after oncogenesis has occurred (Lukas et al., 
1996). 
1.11.1 The restriction point 
The R-point is close to the point of G1 to S phase transition, at which time the cell must 
either commit to entering the cell cycle and complete cell division, or stop cycling and 
senesce.  In order for the cell to carry out DNA replication in the S phase, various genes 
related to the process must first be transcribed. The transcription of these genes is 
controlled by the E2F family of transcriptional regulators, some of which act as 
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transcriptional activators (E2F1, E2F2, and E2F3A), whilst others act as transcriptional 
repressors (E2F3B, E2F4, E2F5, E2F6, E2F7 and E2F8) (Chong et al., 2009). The 
action of these proteins is controlled by the pocket proteins, which include pRB, p107, 
and p130, and act by binding to, and inhibiting, the expression of the E2F target genes 
(Helin et al., 1993, Graña et al., 1998).  
 
During most of the cell cycle the activator E2F proteins are bound and inhibited by 
hypo-phosphorylated pRB (Figure 1-8). At the R-point pRB is hyper-phosphorylated by 
the complex of cyclin depended kinase 4 or 6 and cyclin D (D-CDK4/6) (Helin et al., 
1993). Once pRB is released, the transcription of S phase genes by the activator E2F 
proteins can commence, resulting in an ‘all or nothing switch’ that commits the cell to 
complete a cycle (Eser et al., 2011). This ‘all or nothing switch’ is achieved by the 
expression of cyclin-E as one of the first events following pRB release, as this forms a 
positive feedback loop leading to a large increase in E-CDK2 activity, thus amplifying 
the signal to enter S phase from G1. This rapid amplification in the signal telling the cell 
to continue with the cell cycle results in a strong amplification of all S phase genes, 
allowing the cell to progress in a timely manner (Eser et al., 2011). 
1.11.2 Inhibitors of cyclin-dependent kinases 
In much the same way as pRB negatively regulates the activator E2F proteins, CDK 
inhibitors (CKIs) restrain CDK activity by negatively regulating their association with 
cyclins, preventing the downstream phosphorylation of their targets (Lim and Kaldis, 
2013). CKIs are divided into two separate classes, depending on their structure and 
CDK specificity. The INK4 family members p15INK4b, p16INK4a (p16), p18INK4c and 
p19INK4d target CDK4 and CDK6, whilst the CIP/KIP family members p21CIP1 (p21), 
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p27KIP1  and p57KIP2 have a broad specificity, targeting complexes containing cyclins A, 
B, D and E (Sherr and Roberts, 1999). 
1.12 p16 structure 
p16 was first identified as a protein with a molecular weight of approximately 16 kDa 
containing four ankyrin repeats (Figure 1-7), and was named after its molecular weight 
and its targeting of CDK4 (Serrano et al., 1993). Ankyrin repeats are motifs of 33 amino 
acids, comprising two α-helices separated by loops, which commonly fold together to 
form ankyrin repeat domains (Breeden and Nasmyth, 1987, Lux et al., 1990). Ankyrin 
repeats have been identified as one of the most common structural motifs in proteins, 
and are known to mediate protein–protein interactions in bacteria, archaea and 
eukaryota (Mosavi et al., 2004).  
Figure 1-7. Three-dimensional structure of p16. 
Solution NMR structure of p16 (PDB: 2A5E) (Byeon et al., 1998). Ankyrin repeats are 
shown in red, blue, purple and orange. Image generated from PDB entry 2A5E using 
PyMol (Schrödinger, DE).  
1.13 p16 function 
p16 is an important CKI which negatively regulates the cell cycle, controlling cell 
passage through the R-point of G1 (Serrano et al., 1993, Gil and Peters, 2006). In the 
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absence of p16, pRB is hyper-phosphorylated by D-CDK4/6, allowing the cell to 
proceed past the R-point of the cell cycle via the release of the activator E2F proteins 
(Ishida et al., 2001, Müller et al., 2001, Cobrinik, 2005).  
 
In the presence of p16, the cell cycle is blocked, causing senescence. This occurs by the 
protein binding to CDK4/6, preventing its association with cofactor cyclin D, therefore 
stopping the cyclin D-CDK4/6 complex from forming a kinase (Figure 1-8). The cell 
cannot pass the R-point due to the lack of E2F activity and the cell becomes senescent. 
Although senescent cells remain metabolically active, they stop reacting to mitogenic 
stimuli; they can be identified by the expression of markers such as p16 and β-
galactosidase, and become enlarged and flattened. 
 
Although the main role of p16 is to inhibit the kinase activity of CDKs, recent studies 
have uncovered novel p16-interacting proteins. For example, p16 interacts directly with 
the proliferating cell nuclear antigen, an accessory protein for DNA polymerase δ 
(Souza-Rodrígues et al., 2007). This interaction inhibits DNA polymerase activity and 
effectively prevents DNA replication, presenting an alternative route to p16-mediated 
cell cycle arrest. p16 has also been found to bind directly to mini-chromosome 
maintenance proteins 6 and 7 (MCM6/7), which are important subunits of the DNA 
helicase complex MCM, involved in DNA replication initiation. This binding has been 
shown to prevent the assembly of MCM7 onto chromatin during G1 (Braden et al., 
2006) and it has been suggested that the interaction of p16 and MCM6 may have the 
same effect (Braden et al., 2006, Souza-Rodrígues et al., 2007). 
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Figure 1-8. Action of p16 within the cell. 
During G1 of the cell cycle, the hypo-phosphorylated form of pRB negatively regulates 
the E2F transcriptional activators. The D-CDK4/6 complex of cyclin D and CDK4/6 hyper-
phosphorylates pRB at the R-point, releasing the E2F transcription factors and allowing 
transcription of the S phase genes. When expressed, p16 prevents the association of 
cyclin D and CDK4/6, preventing downstream phosphorylation of pRB, and subsequent 
transcription of S phase genes. p16 expression is in turn negatively regulated by 
polycomb repression complexes 1 and 2 (PRC1/2), which epigenetically regulate the 
INK/ARF locus, from which p16 in transcribed. Red lines represent epigenetic 
repression. 
1.14 p16 expression 
1.14.1 The INK4b-ARF-INK4a locus 
The p16 gene is encoded on the INK4b-ARF-INK4a (INK/ARF) locus of chromosome 
9p21 (Figure 1-9), along with two other major tumour suppressor genes: p15INK4b, which 
is induced by transforming growth factor beta and also acts on CDK4/6; and p14ARF 
(p19ARF in mice), which is translated from an alternative reading frame on the locus. 
p14ARF acts to inhibit the E3 ubiquitin ligase MDM2, which targets p53 for degradation; 
p14ARF therefore has a stabilising effect on the tumour suppressor p53 (Hannon and 
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Beach, 1994, Stott et al., 1998). It is thought that p16 and p15INK4b arose by tandem 
duplication of the p15INK4b gene, explaining the similarity of these proteins in both 
sequence and function (Gil and Peters, 2006).  
 
In addition to the three tumour suppressor genes in the locus, the lncRNA (long non-
coding RNA) ANRIL is also encoded. ANRIL binds to the polycomb group (PcG) 
protein CBX7, found in polycomb repressor complex (PRC) 1, and SUZ12, a 
component of PRC2 (see Section 1.14.3). The binding of ANRIL to these complexes is 
thought to act as a scaffold allowing the correct association of the component proteins 
(see Section 1.20) (Yap et al., 2010). 
 
Figure 1-9. Genes of the INK/ARF locus. 
The genes of the INK/ARF locus encode three tumour suppressor genes p16INK4a (green), 
p15INK4b (orange) and p14ARF (blue/green). Although the first exons of p16INK4a and p14ARF 
are different, they share two 3’ exons, although they are transcribed from different 
reading frames. The lncRNA ANRIL (red) is transcribed from the locus in the antisense 
direction and spans 126 kb. 
 
1.14.2 Activation of p16 expression 
p16 expression is often provoked in response to DNA damage, and can be induced by 
several transcription factors such as ID, ETS2 and MYC (Gil and Peters, 2006, Irelan et 
al., 2009). One of the best-understood pathways to p16 expression is the RAF-MEK-
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ERK kinase-signalling cascade in response to activated H-RAS. The mutant form of 
BRAF found in human naevi and melanoma has also been found to strongly activate 
p16 via this pathway (Michaloglou et al., 2005).  
1.14.3 Repression of p16 expression by polycomb proteins 
The p16 gene, along with the rest of the locus, is tightly regulated at the level of gene 
expression by the polycomb repressor complexes, PRC1 and PRC2 (Jacobs et al., 1999, 
Gil et al., 2004). PRC2 acts by di- and trimethylating lysine 27 the H3 histones present 
along stretches of DNA that contain CpG islands (areas of DNA which contain a high 
frequency of cytosine – guanine repeats) (Riising et al., 2014). These trimethylations 
are recognised by PRC1, which binds to, and forms polycomb bodies on the chromatin 
that further prevent gene transcription (Wang et al., 2004, Simon and Kingston, 2009).  
 
Although both PRCs contain a small number of core subunits, in humans there are a 
wide variety of auxiliary subunits that can affect function. The exact composition of 
these complexes is thought to be different depending on the target gene (Gil and Peters, 
2006, Simon and Kingston, 2009). One of the PcG proteins within PRC1 is the 
oncogene BMI1, which has repeatedly been found to play an important role in 
controlling p16 expression and senescence (Jacobs et al., 1999, Li et al., 2013b). 
Similarly, expression of the PcG protein CBX7 has also been found to down regulate 
p16 expression, although it does not appear to require BMI1 to function (Gil et al., 
2004), suggesting that both these PcG proteins are independently important for 
epigenetic suppression of the INK/ARF locus. In addition to the PcG proteins that act to 
repress the INK/ARF locus, the lncRNA (see Section 1.20) ANRIL has also been found 
acting in concert with PRC1 (Yap et al., 2010), to increase function of CBX7, and 
repress the INK/ARF locus.  
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1.15 Senescence 
1.15.1 Replicative senescence 
Much of the research carried out to date on senescence has been concerned with normal 
human fibroblasts. Senescence was first identified by Hayflick and Moorhead, who 
observed that serially passaged human fibroblasts only divided a finite number of times 
(Figure 1-10 panel A) (Hayflick and Moorhead, 1961). In normal cells, the telomeric 
structures of the chromosomes are shortened after each mitotic cell division. This 
constant degradation eventually renders cell division impossible, leading to replicative 
senescence (Harley et al., 1990). Senescence is commonly believed to be an irreversible 
cellular state, although genomic mutations and epigenetic changes can cause cells to 
spontaneously escape senescence and develop a more tumourous phenotype (Romanov 
et al., 2001).  
 
Senescent cells have a mixture of both phenotypic, and genetic changes, when 
compared to their proliferative selves. When senescent, cells are commonly recognised 
to have an enlarged and flattened appearance with prominent nucleoli and cytoplasmic 
granules (Chandler and Peters, 2013). As senescent cells contain many lysosomes, the 
cells can be assayed for senescent associated β-galactosidase activity (Dimri et al., 
1995), although critics have shown that false positive results can be observed in 
quiescent cells, casting the efficacy of this assay into doubt (Yegorov et al., 1998). The 
major genetic changes in senescence are the activation of the two primary tumour 
suppressor pathways, the p53/p21 and p16/pRB pathways (Campisi, 2013), which 
restrict cellular proliferation. As such, expression of p16 is now commonly used as the 
gold standard of marking senescent cells as it is often undetectable in normal cells 
(Collins and Sedivy, 2003). 
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Figure 1-10. The Hayflick limit and senescence. 
A. Normal cells grow undergo a period of exponential replication until a situation, such 
as critically short telomere length occurs, after which cells become senescent (red). 
Replication ceases, but metabolism remains active. An oncogenic event, such as the 
induction of TERT expression can allow the cells to escape senescence completely 
leading to unrestricted proliferation, and cell immortalisation (green). Oncogenic stimuli, 
such as the mutation of a tumour suppressor gene or activation of an oncogene, can 
cause proliferating cells to enter senescence prematurely, termed oncogene-induced 
senescence (OIS; blue). Further mutations can allow cells to bypass OIS and continue 
growth until they enter replicative senescence as a result of telomere shortening. B. 
Epithelial cells undergo a two-step pattern of senescence, with a first stage (M0) caused 
by p16 activity (red), which is escaped by epigenetic silencing of the p16 gene (blue). A 
second senescence is entered when telomeres become critically short (M1), this in turn 
can be escaped via TERT activity, leading to unrestricted proliferation, and cell 
immortalisation (green). 
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Additionally, senescent cells secrete a variety of chemicals collectively described as the 
senescence-associated secretory phenotype (SASP), which include cytokines, growth 
factors, chemokines, extracellular matrix proteins and proteases (Coppé et al., 2010). 
The wide array of released SASP factors have been suggested to convey both beneficial 
and negative effects to surrounding cells. The SASP has been found to stimulate 
proliferation (Bavik et al., 2006), and angiogenesis (Coppé et al., 2006), as well as 
signalling other cells to also enter senescence (Liu et al., 2007). Other research has 
suggested that the SASP may be important in paracrine senescence across tissues, 
increasing the senescence footprint of pre-cancerous lesions and promoting clearance by 
the immune system within these areas (Acosta et al., 2013). This study also showed that 
some cells are more susceptible to paracrine senescence, with the concentration of 
extracellular growth factors playing an important role in how each cell will respond to 
the pro-senescence SASP signal. 
1.15.2 Epithelial cell senescence 
Unlike fibroblasts, which commonly enter senescence as a result of telomere shortening, 
epithelial cells exhibit a two-step pattern of senescence, where cells senesce once after 
an initial growth phase (termed M0), and again following a second limited phase of 
proliferation, at which point the Hayflick limit is reached (termed M1; Figure 1-10 
panel B) (Huschtscha et al., 1998, Romanov et al., 2001).  
 
During M0, the cells exhibit the hallmarks of senescent cells, i.e. the expression of p16 
whilst becoming enlarged and flattened. Cells in M0 senesce in response to activation of 
the p16/pRB pathway, but not the p53/p21 pathway. The cells can only escape 
senescence as a result of loss-of-p16 activity, commonly caused by specific 
hypermethylation of the p16 promoter (p15INK4B is not affected) (Huschtscha et al., 
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1998). The cells subsequently continue to divide until the telomere length becomes 
critical (Kiyono et al., 1998). Experiments in human mammary epithelial cells have 
shown that inactivation of p53 does not aid the cell in passing M0, although its loss can 
result in massive cell death when the critical telomere length is met (Garbe et al., 2007). 
p53+ epithelial cells can only escape M1 if the barrier of critical telomere length is 
overcome, either by activation of TERT or a viral oncoprotein such as E6 (Kiyono et 
al., 1998, Romanov et al., 2001). 
1.15.3 Oncogene-induced senescence 
In addition to the “natural” causes, such as telomere shortening, senescence can be 
caused prematurely in response to oncogenic signals, such as strong or unbalanced 
mitogenic signals, often termed oncogene-induced senescence (OIS; Figure 1-10 panel 
A) (Blagosklonny, 2003). The first study of OIS showed that an oncogenic H-RAS 
mutant, which permanently stimulated the mitogen-activated protein kinase (MAPK) 
pathway, would induce senescence (Serrano et al., 1997). Other components of the 
MAPK pathway, such as MEK (Lin et al., 1998), BRAF (Michaloglou et al., 2005) and 
RAF, (Zhu et al., 1998) have subsequently also been shown to produce a similar effect 
when mutated or overexpressed. Induction of senescence due to unrestrained 
proliferation also often occurs following the loss of a tumour suppressor protein, such as 
PTEN (Chen et al., 2005b, Vredeveld et al., 2012), from the cell.  
 
Some early studies suggested that OIS was a purely in vitro phenomenon, resulting 
from cellular stresses attributed to cell culture with non-human serum, on plastic dishes, 
and with supraphysiological levels of pO2 (Sherr and DePinho, 2000). It was postulated 
that OIS was not representative of the situation found in vivo, however, subsequent 
research has found many oncogenes, which when induced produce the senescence 
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phenotype (Jacobs et al., 2000, Shvarts et al., 2002). Moreover, nearly all tumours have 
been found to feature mutations in the p53/p21 and p16/pRB pathways, which let the 
tumour to bypass OIS in vivo to allow unrestricted cell growth (Sherr and McCormick, 
2002). 
1.16 Expression of p16 in ageing 
1.16.1 Expression of p16 in murine ageing 
Studies in mice have shown that p16 expression and the associated senescence of cells 
is important in a number of age-related disorders such as type 2 diabetes mellitus 
(Krishnamurthy et al., 2006a, Chen et al., 2011) and atherosclerosis (Kuo et al., 2011). 
In one important study, transgenic mice were engineered to clear all p16-expressing 
cells by drug-induced caspase activity (Baker et al., 2011). Upon administration of the 
drug to old mice, they became significantly healthier, showing increased muscle fibre 
diameter and increased fat deposition, both phenotypes associated with healthy mice. 
Life-long clearance of these senescent cells delayed the onset of age-related phenotypes, 
while delayed administration of the drug until later in life attenuated the progression of 
age-related disorders that had already become established. This single study 
demonstrates how important the role of p16-mediated senescent cells are in normal 
ageing, and also how they can be detrimental to health. 
1.16.2 Expression of p16 in human ageing 
As in mice, expression of p16 has been found to increase with age in a variety of 
tissues. Expression in infants is limited to the thymus, occasionally pancreatic epithelial 
cells (Nielsen et al., 1999, Kanavaros et al., 2001). With increasing age, expression of 
p16 is observed across a host of cell types throughout the body (Nielsen et al., 1999), 
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although this is especially notable within the kidney, with the renal cortex often found 
to have high expression in older patients (Chkhotua et al., 2003, Melk et al., 2004). In 
addition to the kidney, increasing expression has been observed in the breast duct, 
cervix, salivary gland, pancreas and testis (Nielsen et al., 1999), and is thought to be 
associated with a wide array of age-related disorders.  
1.16.3 Association of p16 with age-related disorders 
Recent genome-wide association studies (GWAS) have identified a host of diseases that 
are linked to the INK/ARF locus, including many age-related disorders (Jeck et al., 
2012), such as Alzheimer’s Disease (Züchner et al., 2008), atherosclerosis (Liu et al., 
2009), coronary artery disease (Pasmant et al., 2011), myocardial infarction (Ogawa et 
al., 2010), stroke (Helgadottir et al., 2008), type 2 diabetes mellitus (Chen et al., 2011), 
glaucoma (Osman et al., 2012), aneurysms (Helgadottir et al., 2008), and endometriosis 
(Nyholt et al., 2012). Together, these human genetic studies, and those performed in 
mice, provide a strong argument for research into p16-mediated senescence with a view 
to modulation of this system, in order to attenuate disease.  
1.17 Expression of p16 in cancer 
1.17.1 Expression of p16 in murine cancer 
Both mice and humans have the INK/ARF locus, but the relative importance of its 
constitutive genes are different in the two species. For example, in mice p19ARF (p14ARF 
in humans) holds the most crucial role of the INK/ARF genes in the suppression of 
tumour formation (Sharpless et al., 2004), where as this falls to p16 in humans 
(Hussussian et al., 1994). Knockout mouse models of both p16 and p19ARF are found to 
grow spontaneous tumours at higher frequencies than their wild type counterparts 
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(Sharpless et al., 2001, Krimpenfort et al., 2001), although the p19ARF-null mice are 
found to generate them at higher rates (Sharpless et al., 2004).  p16-null mice were not 
found to grow tumours in early life, suggesting that in mice this gene plays a more 
active tumour-supressing role in later life  (Krimpenfort et al., 2001). 
1.17.2 Expression of p16 in human cancer 
Expression of p16 in humans is essential for protection against tumourogenesis, and is 
one of the most influential proteins in causing the cell to enter OIS. As such, p16 is one 
of the most commonly mutated, deleted, or epigenetically down regulated genes in 
human cancers (Esteller et al., 2001, Forbes et al., 2006). Its inactivation is therefore 
thought to be one of the most important steps in the bypass of OIS, and subsequent 
development of many human tumours (Kamb et al., 1994, Ruas and Peters, 1998). 
Mutations and deletions of p16 have been catalogued in a wide array of both 
haematological and solid tumours, with incidences of deletion widely ranging from 1% 
(thyroid cancer) and 2% (breast cancer) to 58% (T-cell acute lymphoblastic leukaemia), 
depending on the cancer (Ruas and Peters, 1998).  
1.18 Breast cancer 
Breast carcinomas are a highly heterogeneous group of cancers, with variable 
behaviour, treatment response, and prognosis (Payne et al., 2008). Currently there are 
three major prognostic markers used to classify breast cancers: oestrogen receptor (OR), 
progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).  
 
The OR is currently the most important of the three markers, as its expression signifies 
a lower mortality risk tumour (Dunnwald et al., 2007), which can be treated using 
oestrogen antagonist or aromatase inhibitors, which prevent the conversion of 
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androgens to oestrogen (Fisher et al., 1988, Anderson et al., 2001). The OR is expressed 
in around 70% of all breast tumours, meaning that the 30% of tumours which lack 
expression cannot be targeted using hormone therapy (Osborne, 1998), and therefore 
must be treated with generic chemotherapy that is susceptible to multidrug resistance, 
often mediated by ABCG2 (breast cancer resistance protein) (Doyle and Ross, 2003). 
PR expression is also commonly used to assess whether the OR pathway is active, as it 
is also regulated by oestrogen (Horwitz et al., 1978). Much like the OR, expression of 
the PR is thought to mark a less aggressive tumour phenotype that may be responsive to 
hormonal therapy, even in OR-negative cancers (EBCTCG, 1998).  
 
HER2 is a tyrosine kinase and important for the differentiation, adhesion and motility of 
cells (Hanna et al., 1999). Overexpression of the gene is observed in around 20% of 
breast tumours (Slamon et al., 1987), with HER2 positivity being associated with a poor 
prognosis, due to higher grade tumours, lymph node involvement and higher rates of 
recurrence and mortality (Payne et al., 2008), Expression on HER2 in breast cancers 
does however identify tumours which can be treated with trastuzumab (commonly 
referred to as Herceptin, one of its trade names), a monoclonal antibody for HER2, 
which binds to the receptor, and inhibits the proliferation of the cancer cell (Hudis, 
2007). 
1.18.1 Basal-like breast cancer 
Basal-like breast cancer (BLBC) is a clinically aggressive subtype of breast cancer that 
accounts for around 15 – 20% of all breast cancers (Fulford et al., 2006). The majority 
of these tumours also belong to the triple negative breast cancer (TNBC) subtype, so 
called as they lack expression of OR, PR, and HER2 (Abd El-Rehim et al., 2004, 
Nielsen et al., 2004, Abd El-Rehim et al., 2005). BLBCs are also characterised by the 
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expression of CK 5/6 and 17, EGFR, VEGF and c-kit (Nielsen et al., 2004, Brenton et 
al., 2005, Linderholm et al., 2009). 
 
One significant problem with BLBCs is that they cannot be treated with traditional 
targeted therapies for breast cancer, such as trastuzumab, tamoxifen, or aromatase 
inhibitors, as they do not express OR or HER2. This currently leaves surgical resection, 
radiotherapy and generic chemotherapy as the current best available treatments. 
1.18.2  p16 expression in basal-like breast cancer 
Unlike nearly all other tumours, expression of p16 in BLBCs is commonly observed, 
and its overexpression is consistently found to correlate with a poor patient prognosis 
(Hui et al., 2000, Milde-Langosch et al., 2001). Higher expression of p16 is also 
suggested to mark a more homogenous subgroup of BLBC, which could potentially be 
targeted (Abou-Bakr and Eldweny, 2013). 
 
 It has been hypothesised that the lack of a functional p16/pRB pathway may play an 
important role in the biology of this tumour subtype (Gauthier et al., 2007), through the 
widespread inactivation of pRB, rendering the high expression of p16 redundant 
(Subhawong et al., 2009). Although there is currently strong evidence that p16 
expression in BLBC suggests a poor prognosis, any underlying mechanism behind this, 
and its relevance to disease aggressiveness are, as of yet, unknown.  
1.19 RNA interference 
During this study, one of the main methods of investigation was RNA interference 
(RNAi) by both short interfering RNA (siRNA) and microRNA (miRNA). The system 
of RNAi was first described in C. elegans by Fire et al. (1998), although some 
 60 
components of the pathways were previously known under other names. RNAi is a 
powerful tool, which can be utilised to help understand the roles of specific genes 
within the cell by simulating loss of function. This system is commonly utilised through 
the introduction of exogenous miRNAs (see Section 1.19.1), anti-miRNA (antimiRs), or 
siRNAs (see Section 1.19.2). There are many pitfalls, which have to be navigated when 
RNAi is being utilised, however, if due care and attention are paid when planning 
experiments, there are few techniques as potent for interrogating the impact of single 
genes within the context of the cell. 
 
1.19.1 miRNA  
miRNAs are endogenously expressed, single stranded RNA molecules which act to 
repress gene expression (Bartel, 2004). Unlike the focus of siRNAs, which ideally serve 
to target only a single gene, miRNAs actively target hundreds or thousands of genes, 
depending on their sequence (Baek et al., 2008). A major functional difference between 
siRNAs and miRNAs is that the miRISC complex, which comprises the RNA induced 
silencing complex (RISC; described below) and miRNA, can destabilise or 
translationally inhibit mRNA in addition to targeting them for degradation (Eulalio et 
al., 2008). A wide array of cellular pathways are known to be affected by miRNAs, with 
their role in oncogenesis being especially prominent (Lu et al., 2005, He et al., 2007, 
Kumar et al., 2007).  
 
miRNA coding sequences are commonly found in gene introns, gene antisense strands 
or in between genes, and are often found in clusters with multiple miRNA genes tightly 
packet into a section of the genome. They are transcribed by RNA polymerase II or III, 
to create primary miRNAs (pri-miRNAs), of which the pri-miRNAs generated by RNA 
 61 
polymerase II are commonly polyadenylated and capped, much like mRNAs (Cai et al., 
2004). The transcription of miRNAs can be controlled by many factors, including 
transcription factors (He et al., 2007) and promoter methylation (Saito et al., 2006), 
allowing for miRNAs to be regulated independently of one another, even within the 
same cluster (Song and Wang, 2008).  
 
The pri-miRNA is cleaved in the nucleus by the Drosha/Pasha microprocessor complex 
(Lee et al., 2003), comprised of the RNase III enzyme Drosha, and the RNA binding 
protein Pasha (commonly called DGCR8), both of which are essential for miRNA 
processing (Gregory et al., 2004). pri-miRNAs contain a ~33 bp hairpin structure with a 
terminal loop and a single-stranded stem at each end which is essential for Pasha 
binding and Drosha cleavage (Han et al., 2006). The 5’ and 3’ arms of the pri-miRNA 
are cleaved by the RNase activity of Drosha (Han et al., 2006), leaving the hairpin loop 
structure intact, now termed the precursor miRNA (pre-miRNA). 
 
pri-miRNAs and pre-miRNAs can be edited by adenosine deaminases acting on RNA 
(ADARs) to cause adenosine (A) to inosine (I) base changes within the pri-miRNA 
sequence, potentially altering subsequent processing and targeting of the mature 
miRNA (Yang et al., 2006, Kawahara et al., 2007). 
 
The pre-miRNA is exported from the nucleus by the Exportin-5 and Ran-GTP complex 
(Yi et al., 2003), which recognises the processed pre-miRNAs irrespective of sequence 
(Lund et al., 2004, Zeng and Cullen, 2004). For the pre-miRNAs to be properly utilised, 
a they must first be processed again to their mature form, and loaded into the RISC 
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Figure 1-11. Mammalian pathways of miRNA mediated RNA interference. 
miRNA molecules involved in RNAi are endogenously transcribed from the genome by 
RNA polymerase II/III in the nucleus. The tails of the resulting pri-miRNA are cleaved by 
the Drosha/Pasha complex to produce pre-miRNA. Pre-miRNAs are then either exported 
from the nucleus by Exportin5 in complex with Ran:GTP, or modified by ADAR1/2 and 
then exported. In the cytosol, the pre-miRNAs are cleaved by Ago2 activity of RLC to 
produce a mature miRNA. Mature miRNAs or anti-miRNAs can be introduced into the cell 
by transfection. miRNAs or anti-miRNAs in complex with Ago2 associate into RISC to 
form miRISC or anti-miRISC. miRISC will target mRNAs using the guide strand resulting 
in their degradation or repression of translation. anti-miRISC will act to degrade targeted 
pre-miRNAs before they are incorporated into RLC. 
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assembly. pre-miRNA processing in the cytoplasm and loading onto RISC is carried out 
by the multi-protein RISC loading complex (RLC). RLC contains the RNase Dicer,  
RNA-binding proteins TRBP (Tar RNA binding protein) and PACT (protein activator 
of PKR), and the core component Argonaute2 (Ago2) (MacRae et al., 2008). Although 
TRBP and PACT are not essential for pre-miRNA processing by RLC, they do increase 
its efficiency and facilitate the recruitment of Ago2 (Chendrimada et al., 2005, Lee et 
al., 2006).  
 
Once the pre-miRNA is loaded into the RLC complex, the RNase activity of Dicer 
cleaves off the loop section of the hairpin, leaving a ~22 bp section of double stranded 
RNA (Hutvágner et al., 2001). After the miRNA has been fully processed Dicer, TRBP 
and PACT dissociate from the miRNA complex, and an RNA helicase, such as RNA 
helicase A, is recruited to unwind the double-stranded RNA (Robb and Rana, 2007), 
which the Ago2 subunit of RISC facilitates by dissociating from the passenger strand 
(Rand et al., 2005). Although the miRNA duplex could produce two different mature 
miRNAs, this is usually not the case, as one of the strands is used for targeting whilst 
the other is degraded (Schwarz et al., 2003). The strand which the RISC complex 
chooses depends on the thermodynamic stability of the base pairs at each end of the 
miRNA duplex; where the strand with the least thermodynamically stable 5’ end is 
typically loaded as the targeting strand (Khvorova et al., 2003).   
 
Once the final steps of processing and unwinding are complete, the miRISC complex is 
available for mRNA targeting, where upon binding the Ago2 subunit can degrade or 
translationally inhibit the mRNA (Bagga et al., 2005, Chendrimada et al., 2007, Eulalio 
et al., 2008). The majority of miRNAs target the 3’ UTR of mRNAs, with the seed 
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region (nucleotides 2-7) of the miRNAs being the most important region for target 
recognition (Lewis et al., 2003). As the seed region is only 6 nt, and perfect binding of 
the rest of the miRNA to the target mRNA is not required for Ago2 action, miRNAs can 
have a wide array of target genes with diverse sequences.  
 
1.19.2 siRNA  
Exogenously introduced siRNAs utilise the endogenous cellular RNAi machinery to 
knockdown genes according to their target sequence (Figure 1-12) (Sigoillot and King, 
2011). siRNAs are composed of a guide strand – the targeting sequence of the siRNA – 
and the passenger strand – the guide strand’s complementary sequence. This use of the 
endogenous machinery can explain to some extent, why off-target effects can be 
observed in siRNA experiments – due to close but imperfect sequence identity, or the 
overloading of the RNAi machinery. It is therefore critical to control for these off-target 
effects. 
 
Sequence independent off-target effects are often due to the abnormally high levels of 
siRNA passing through the cellular RNAi pathways during these experiments. 
Unusually high levels of siRNA will displace the endogenous miRNAs that are the 
typical substrate of RISC. This displacement can change normal patterns of gene 
expression within the cell. It should also be noted that studies have found that 
transfecting cells with siRNA can up-regulate the expression of some miRNAs, again 
possibly causing a change in gene expression patterns (Khan et al., 2009). 
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Figure 1-12. Mammalian pathway of siRNA-mediated RNA interference. 
RNA molecules involved in RNAi can be introduced by transfection (siRNA) or infection 
(shRNA encoded by a lentiviral vector). The coding sequence for the shRNA is 
transcribed in the nucleus and transported by Exportin5 in complex with Ran GTP into 
the cytoplasm where Ago2 activity in complex with Dicer and TRBP cleaves it into its 
mature form: siRNA. RISC forms a complex with a Ago2 bound single strand of siRNA; 
this then targets mRNA for cleavage and degradation. 
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Furthermore, introduction of exogenous siRNA has been shown to provoke a cell-stress 
response when used at high concentrations (Persengiev et al., 2004), thus, it is important 
to use the lowest concentration of siRNA possible to produce effective knockdown of 
the target mRNA. 
 
Sequence dependent off-target effects can also be a problem. Exogenously introduced 
siRNAs can act in a similar manner to endogenous miRNAs; either through perfect base 
pairing and cleavage of the regulated mRNA by the Ago2 subunit of RISC, or by the 
interaction of the seed region (bases 2 – 8 of the guide strand) of the siRNA with target 
sequences, in a similar manner to miRNA (see Section 1.19.1) (Doench et al., 2003). As 
the length of the sequence identity required for the latter mechanism of action is 
relatively small – seven bases for some siRNAs – (Jackson et al., 2003), there is a large 
potential for each siRNA to non-specifically down regulate hundreds of different genes 
within the cell (Doench et al., 2003, Burchard et al., 2009, Sigoillot and King, 2011). 
Transcriptional profiling has shown that each siRNA has a distinct pattern of effect 
within the cell, and even though the target gene is down regulated, other genes can also 
be affected by as much as 1.5 – 4 fold (Jackson et al., 2003). More recently, it has been 
confirmed that the seed region of the siRNA is important in causing these off-target 
effects (Jackson et al., 2006). It is, therefore, important when designing oligonucleotides 
for RNAi to keep the seed complement frequency (SCF) to a minimum (Anderson et al., 
2008).  
 
Some level of off-target effect is almost unavoidable with RNAi experiments; therefore 
it is important to confirm that any subsequent changes in gene expression or phenotype 
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are not due to the panel of possible off-target effects described above. To address this, 
the use of multiple siRNAs, with different sequences, in independent experiments to 
target the same gene is standard practice. With proper validation of the results by 
establishing that both the mRNA and protein levels of the target gene are reduced by 
qPCR and western blotting respectively, confidence in the conclusion that the observed 
phenotype is due to the knockdown of the intended gene can be increased (Mohr et al., 
2010, Jackson and Linsley, 2010). 
1.20 lncRNA 
A third type of regulatory RNA in the cell is the lncRNA. These are 200 bp to 100 kb 
ncRNAs which regulate cell function, through numerous mechanisms and actions 
(Wang et al., 2011, Geisler and Coller, 2013). It has been suggested that as the 
noncoding portion of the transcriptome is so large (~80%) (Bernstein et al., 2012) that a 
significant amount of it may comprise as of yet unknown lncRNAs (Geisler and Coller, 
2013). Although only relatively few of the known lncRNAs have had functional roles 
assigned to them (Ponting et al., 2009), their implications are many, including: cell 
cycle regulation, pluripotency, meiotic entry, telomere length and transposon silencing 
(Wilusz et al., 2009). 
 
Although lncRNAs have been found to have a multitude of effects within the cell, their 
modes of function are even more diverse (Geisler and Coller, 2013). One of the most 
common modes of action for lncRNAs (such as ANRIL) is functioning as a scaffold, 
onto which other RNAs and proteins can then join (Yap et al., 2010). Once in a complex 
with other RNAs or proteins the lncRNA can then act as part of a complex, with 
established roles so far including: regulation of mRNA transcription (Tsai et al., 2010, 
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Latos et al., 2012), regulation of mRNA processing (Tripathi et al., 2010), modulation 
of post-transcriptional modification pathways (Poliseno et al., 2010), regulation of 
protein activity (Kino et al., 2010), organization of protein complexes (Tsai et al., 2010, 
Yap et al., 2010) and signalling (Huang et al., 2013). 
1.21 Aims 
The aim of the first project was to further characterise the poorly understood human 
ABC transporter ABCB5, in terms of its expression and subcellular localisation within 
expressing cells utilising a transient transfection system to allow easy and fast genetic 
manipulation of the protein, In addition to this, the possible link between ABCB5 
knockdown and p16 expression levels was to be studied. The aim of this was to find a 
process by which p16-expressing senescence cells could be modulated, potentially 
using the plasma membrane localised ABCB5 as a target.  The overall hypothesis for 
this work was that as ABCB5 is reportedly expressed at the plasma membrane, it could 
be used to target therapies for age-related disorders known to involve the expression of 
p16, a tumour suppressor protein that is known to act within the cell nucleus, and thus is 
not available for direct targeting.  
 
The aim of the second project was to investigate the role of five putative oncogenic 
miRNAs in HMECs and p16+ BLBC. The five miRNAs were previously suggested to 
invoke a phenotype of increased p16 expression and proliferation when transfected into 
HMECs, closely resembling the phenotype observed in p16+ BLBC. As miRNAs can 
regulate hundreds or thousands of genes, the identity of their predicted downstream 
targets may provide clues as to the genetic changes involved in the formation of BLBC, 
and the importance in such genes in cancer progression and for potential diagnosis. The 
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hypothesis for this project was that as the five putative oncogenic miRNAs cause 
BLBC-like phenotype in HMECs, the targets giving rise to this change could be 
identified and then investigated as potential targets for targeted therapy against BLBCs. 
 
The detailed aims of the two projects undertaken are more fully introduced at the 
beginning of their respective chapters. 
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Chapter Two 
 
 
2  Materials and methods 
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2.1 Cell strains 
2.1.1 XL10-Gold® Ultracompetent E. coli cells 
Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 gyrA96 relA1 lac 
HTE [F’ proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
2.1.2 Mammalian cell lines 
An overview of the mammalian cell lines used within this study is given below (Table 
2-1), including known mutations that may be relevant to the study. 
Cells Cell Type p16 
status 
p53 status B-RAF 
status 
HEK239T Embryonic kidney wt wt/E1B55K UN 
WM1158 Melanoma NM wt V600E 
A375M Melanoma NM wt V600E 
K562 Chronic myeloid leukaemia ∆ NM UN 
A431 Squamous cell carcinoma wt ∆ wt 
Mel224 Melanoma UN wt wt 
Mel505 Melanoma UN wt wt 
HMEC Mammary epithelium wt wt wt 
MDA-MB-468 Breast carcinoma wt R273H V600E 
Table 2-1. Mammalian cell lines used in the investigation. 
HMEC – human mammary epithelial cells; NM – nonsense mutation; ∆ – deletion of gene; 
UN – unknown; E1B55K – adenovirus gene that represses p53 activation. 
2.1.2.1 HEK293T  
Human embryonic kidney 293 cells (Graham et al., 1977) stably and constitutively 
expressing the SV40 large T antigen (HEK293T) allowing for the expression of 
transfected plasmids containing the SV40 origin of replication were obtained from the 
Imperial Cancer Research Fund cell production unit (UK). 
2.1.2.2 WM1158 
The Wistar Institute Melanoma cell line 1158 (WM1158) was established from a 
human, stage II metastatic melanoma in 1985 by the laboratory of Dr. M. Herlyn at the 
Wistar Institute, Philidelphia, USA (Masters and Palsson, 1999). These cells were 
 72 
kindly provided by Dr. Daniele Bergamaschi (Blizard Institute, London, UK). All 
WM1158 cells were used for experiments between passages 14 and 20. 
2.1.2.3 A375M 
The human A375M cell line was isolated from a lung metastasis in a nude mouse 
following injection of the parental human melanoma cell line A375 (Kozlowski et al., 
1984). These cells were kindly provided by Dr. Daniele Bergamaschi (Blizard Institute, 
London, UK). All A375M cells were used for experiments between passages 11 and 20. 
2.1.2.4 K562 
The cell line K562 grows in suspension and was the first human immortalised 
myelogenous leukaemia line to be established. The line was derived from a 53-year-old 
female chronic myelogenous leukaemia (CML) patient in blast crisis in 1975 (Lozzio 
and Lozzio). These cells were kindly provided by Dr. Paul Allen (Blizard Institute, 
London, UK). All K562 cells were used for experiments between passages 18 and 25. 
2.1.2.5 A431 
The hypertriploid, human A431 cell line was established from a squamous cell 
carcinoma (SCC) in an 85 year old female patient (Giard et al., 1973). This cell line was 
kindly provided by Prof. Harry Navsaria (Blizard Institute, London, UK). All A431 
cells were used for experiments between passages 14 and 20. 
2.1.2.6 Mel224 
These melanoma cells were kindly provided by Dr. Daniele Bergamaschi (Blizard 
Institute, London, UK). All Mel224 cells were used between passages 12 and 18. 
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2.1.2.7 Mel505 
These melanoma cells were kindly provided by Dr. Daniele Bergamaschi (Blizard 
Institute, London, UK). All Mel505 cells were used between passages 12 and 18. 
2.1.2.8 Human mammary epithelial cells 
Normal 184 human mammary epithelial cells (HMECs; (Stampfer et al., 1980), were 
isolated from reduction mammoplasty tissue and were kindly provided by Dr. Martha 
Stampfer (Lawrence Berkeley National Laboratory, Berkeley, CA, USA). These cells 
exhibit a p16-mediated senescence in response to extended in vitro cell culture, 
providing an ideal platform on which the processes of normal human cell biology, 
aging, senescence and carcinogenesis can be studied. All HMEC cells were used for 
experiments between passage 4 and 13, the majority being at passage 6. 
2.1.2.9 MDA-MB-468 
The MDA-MB-468 cell line was isolated in 1977 from a pleural effusion of a 51 year 
old woman with metastatic adenocarcinoma of the breast (Cailleau et al., 1978), and 
lacks expression of HER2, OR and PR. These cells were purchased from AATC, VA, 
USA. MDA-MB-468 cells were used in experiments between passage 19 and 25. 
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2.2 Plasmids 
The vectors used for the transformation of bacteria, and the transfection of mammalian 
cells are described in Table 2-2.  
Vector Resistance 
Marker 
Size of 
insert (bp) 
Source 
pcDNA3.1 expressing V5-6His protein tag 
pcDNA3.1-V5-6His Ampicillin 0 MG 
pcDNA3.1-ABCB5fl-wt_V5-6His Ampicillin 5401 MG 
pcDNA3.1-ABCB5β-wt_V5-6His Ampicillin 4375 MG 
pcDNA3.1-ABCB5fl-E550Q_V5-6His Ampicillin 5401 This study 
pcDNA3.1-ABCB5fl-E1181Q_V5-6His Ampicillin 5401 This study 
pcDNA3.1-ABCB5fl-E550/1181Q_V5-6His Ampicillin 5401 This study 
pcDNA3.1-ABCB5β-E736Q_V5-6His Ampicillin 4375 This study 
pcDNA3.1 expressing EGFP protein tag 
pcDNA3.1-EGFP Ampicillin 0 MG 
pcDNA3.1-ABCB5fl-wt_EGFP Ampicillin 5401 MG 
pcDNA3.1-ABCB5β-wt_EGFP Ampicillin 4375 MG 
pcDNA3.1-ABCB5fl-E550Q_ EGFP Ampicillin 5401 This study 
pcDNA3.1-ABCB5fl-E1181Q_ EGFP Ampicillin 5401 This study 
pcDNA3.1-ABCB5fl-E550/1181Q_ EGFP Ampicillin 5401 This study 
pcDNA3.1-ABCB5fl-E736Q_ EGFP Ampicillin 4375 This study 
pcDNA3.1 expressing Venus protein tag 
pcDNA3.1-CD36_Venus Ampicillin 4727 MS 
Table 2-2. List of vectors used in the investigation. 
The sequences of all vector inserts used in the investigation were confirmed by DNA 
sequencing. MG – Prof. Michael Gottesman (Bethesda, MD, USA); MS – Dr. Marjolein 
Snippe (London, UK). 
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2.3 Primers 
A list of the oligonucleotides used in this investigation is provided in Table 2-3. 
Name Sequence (5’ – 3’) 
Mutagenic Primers 
ABCB5fl_E550Q-F CCAAGATTCTGATTTTAGATCAGGCTACGTCTGCCCTGG 
ABCB5fl_E550Q-R CCAGGGCAGACGTAGCCTGATCTAAAATCAGAATCTTGG 
ABCB5fl_E1181Q-F CCCAAAATTTTATTGTTGGATCAGGCCACTTCAGCCCTCG 
ABCB5fl_E1181Q-R CGAGGGCTGAAGTGGCCTGATCCAACAATAAAATTTTGGG 
ABCB5β_E736Q-F CCCAAAATTTTATTGTTGGATCAGGCCACTTCAGCCCTCG 
ABCB5β_E736Q-R CGAGGGCTGAAGTGGCCTGATCCAACAATAAAATTTTGGG 
Sequencing Primers 
ABCB5_42F TCAGAGAAATGGAACTGCAG 
ABCB5_601F GTGAAGGGCTGGAAACT 
ABCB5_1041F AACCTTCGCAATAGCCCGAG 
ABCB5_1603F ATTGCTCGTGCCTTAGTT 
ABCB5_2177F CCACATTAAAGCATGATGCAG 
ABCB5_2742F GCACAGATTATTGGAAGCTG 
ABCB5_3268F CGTTCCCAAATAGCAATC 
ABCB5_3706F ACTCATCAAGAGCTCCTGAG 
ABCB5_161R GGCTCCATTGACCAGTGATG 
ABCB5_1781R CAGCATTCCATCCTTTAGGG 
Endpoint PCR Primers 
ABCB5-EPF GTGAAGGGCTGGAAACT 
ABCB5-EPR ATGCCAAAATCCTTTGCA 
5’ RACE Primers 
RACE-GSP1 TCTTGACTAACCACTCCAA 
RACE-GSP2 TCGATAATGCCGCACATTTA 
RACE-GSP3 CGCACATTTAAAGCTCTGATG 
Table 2-3. List of primers used in the investigation. 
All primers were designed for the study using MacVector software (MacVector Inc, NC, 
USA). All primers listed were purchased from Sigma-Aldrich, UK. 
2.4 TaqMan Gene Expression Assays 
For TaqMan Gene Expression Assay (Life Technologies Ltd, UK) the following 
primers and probes were used Table 2-4. 
Name Forward (5’ – 3’) Probe (5’ – 3’) Reverse (5’ – 3’) Type 
Targeting Genes 
tmGAPDH proprietary proprietary proprietary PD 
tmp16 proprietary proprietary proprietary PD 
tmABCB5 proprietary proprietary proprietary PD 
tmABCB5fl
only 
CACGTCTCCTCTTATAA
TGGCTTCA 
ATGACCATCC
TAGAACATG 
CCCAGCTTTGGAATA
GGCACTTAT 
CM 
tmABCB5β
only 
TGTGTTCTTTTTTATTT
GGTCATATCTTCCATTC 
TAGGCTCACA
GAGAGATATT 
TCTTTCTGCAGTTATA
TAAGAAAGACAATAGA 
CM 
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Table 2-4. List of TaqMan primers and probes used in the investigation. 
PD – pre-designed by the manufacturer; CM – custom made. Custom primers were 
designed by Life Technologies Ltd (UK), to target the 5’ DNA coding sequence unique to 
ABCB5fl and the 5’-UTR sequence unique to ABCB5β  (see Appendix I). All TaqMan 
products were purchased from Life Technologies Ltd (UK). 
2.5 siRNAs 
The siRNAs used in this project are detailed in Table 2-4 
Name Target 
mRNA 
Target Sequence 
(5’ – 3’) 
Supplier Product Code Type 
siGLO Cyclophilin 
B 
GAGCCCAGAUC
AACCUUUA 
Dharmacon D-001610-01-05 PD 
GAPDH GAPDH proprietary Ambion 103855 PD 
CBX7 CBX7 GGGUAACACAC
ACCAAGAGT 
Ambion 137077 PD 
p16 p16 TACCGTAAATGT
CCATTTATA 
Qiagen SI02664403 PD 
PLK1 PLK1 proprietary pool Dharmacon L-003290-00-0005 PD 
KIF11 KIF11 GAGCCCAGAUC
AACCUUUA 
Dharmacon J-003317-13-0005 PD 
Ambion-1 ABCB5fl, 
α, β, γ 
CCACCAUCAGUA
ACAAUAUtt 
Ambion 
117801 
PD 
Ambion-2 ABCB5fl, 
α, β, γ 
CGAUGAGAUUA
AGACACUUtt 
Ambion 
117802 
PD 
Ambion-3 ABCB5fl, β GCAAAGGUCGG
ACUACAAUtt 
Ambion 
117803 
PD 
Beta-1 ABCB5β GCCUAAACCAAU
AAUUAUAtt 
Ambion 
298227 
CM 
Beta-2 ABCB5β CAUUCUUUCUU
ACCUAAUUtt 
Ambion 
298228 
CM 
Beta-3 ABCB5β CUAUUGUCUUU
CUUAUAUAtt 
Ambion 
298229 
CM 
Beta-4 ABCB5β CUCUAAUAUCUC
UCUGUGAtt 
Ambion 
446395 
CM 
Beta-5 ABCB5β AUAUAACUGCAG
AAAGAUAtt 
Ambion 
446396 
CM 
Beta-6 ABCB5β UGCAGAAAGAUA
AAUAUCAtt 
Ambion 
446398 
CM 
 
Table 2-5. siRNAs used in the investigation. 
PD – pre-designed by the manufacturer; CM – custom made. Custom made siRNAs were 
designed by Life Technologies Ltd (UK), to target the 5’-UTR sequence unique to 
ABCB5β  (see Appendix I). 
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2.6 miRNAs and anti-miRNAs 
The details of the miRNAs and anti-miRNAs (antimiRs) used in this investigation can 
be found in Table 2-6. 
Name Type Sequence Product 
Code 
miR-24 miRNA UGGCUCAGUUCAGCAGGAACAG HMI0410 
miR-140-3p miRNA UACCACAGGGUAGAACCACGG HMI0215 
miR-221 miRNA AGCUACAUUGUCUGCUGGGUUUC HMI0398 
miR-451 miRNA AAACCGUUACCAUUACUGAGUU HMI0583 
miR-574 miRNA UGAGUGUGUGUGUGUGAGUGUGU HMI0794 
Anti-24 anti-miRNA proprietary HSTUD0410 
Anti-140-3p anti-miRNA proprietary  HSTUD0215 
Anti-221 anti-miRNA proprietary HSTUD0397 
Anti-451 anti-miRNA proprietary HSTUD0583 
Anti-574 anti-miRNA proprietary  HSTUD0794 
Table 2-6. miRNAs and anti-miRNAs used in the investigation. 
All miRNAs used were purchased from Sigma Aldrich (UK).  
2.7 Bacterial cell culture 
Bacterial medium (LB (lysogeny broth) liquid medium and agar) was prepared by 
suspending 20 g of LB powder, Lennox (1% (w/v) NaCl, 1% (w/v) tryptone, 0.5% 
(w/v) yeast extract; Fisher Scientific Ltd, UK) in 1 L of sterile water. For LB-agar 
plates, the medium was supplemented with 1.5% (w/v) bacto agar (BD Biosciences, 
UK) prior to autoclaving for 15 min at 15 psi and 121°C. Where necessary, the medium 
was allowed to cool to 55°C before 100 µg mL-1 ampicillin (Sigma-Aldrich, UK) was 
added. LB-agar plates were prepared using aseptic techniques and stored at 4°C for up 
to one month. Prior to use, plates were dried and equlibriated at 37°C in an incubator 
(Sanyo, UK). 
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2.7.1 SOC rich medium 
SOC rich medium for bacterial transformations was prepared by adding 2% tryptone, 
0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 
mM glucose (Life Technologies Ltd, UK) to dH2O and autoclaving. 
2.8 Mammalian cell culture 
2.8.1 Culture conditions 
Cells were grown as monolayers on 75 cm2 tissue culture flasks (VWR, UK) and 
maintained by biweekly passage in 15 mL of the appropriate medium unless otherwise 
stated.  
 
Unless otherwise stated cells were split by washing the cells with 10 mL Dulbecco’s 
phosphate buffered saline (DPBS; PAA Laboratories, UK) without calcium and 
magnesium for 1 min at room temperature (RT) before treatment with 3 mL TrypLETM 
Express trypsin substitute (Life Technologes Ltd, UK) for 5 min at 37°C. TrypLETM 
Express was quenched by addition of 7 mL of the appropriate serum containing 
medium. The resuspended cells were transferred to a 15 mL sterile centrifuge tube 
(Fisher Scientific Ltd, UK) and pelleted by centrifugation at 600 x g for 4 min. Cells 
were resuspended in the appropriate medium, and then plated into a new 75 cm2 flask at 
the desired density. 
 
Cells were grown under 5% CO2 at 37°C with a water vapour saturated atmosphere 
(Galaxy 170S; New Brunswick Scientific, Edison, NJ). All manipulations were carried 
out in a sterile environment with disposable plasticware and glassware reserved 
specifically for the purpose. 
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2.8.1.1 HEK293T and A431 Culture 
Cells were grown in “DMEM medium” (Dulbecco’s Modified Eagle Medium (DMEM) 
with 4.5 mg L-1 glucose, 1 mM sodium pyruvate, 4 mM GlutaMAXTM and 40 nM 
phenol red, but not 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (HEPES; Life 
Technologies Ltd, UK). DMEM was supplemented with 10% (v/v) Fetal bovine serum 
(FBS; Sigma-Aldrich, UK) and 2mM L-glutamine (Life Technologies Ltd, UK). Prior 
to treatment with TrypLETM Express, A431 cells were washed with 6 mL Versene (Life 
Technologies Ltd, UK) at 37°C for 4 min. HEK293T cells were split at a ratio of 1:20 
into a new flask, A431 at 1:10 and HeLa at 1:10. 
2.8.1.2 WM1158, A375M, K562, Mel224 and Mel505 Culture 
Cells were grown in “RPMI medium” (Roswell Park Memorial Institute 1640 (RPMI 
1640), with 1 mM GlutaMAXTM, 40 nM phenol red and 25mM HEPES (Life 
Technologies Ltd, UK) supplemented with 10% (v/v) FBS, 2 mM L-glutamine and 1x 
Non-essential amino acids (PAA Laboratories Ltd, UK). K562 cells were grown in 
suspension in 75 mL “RPMI medium” and split 1:3 every seven days. WM1158 cells 
were split at a ratio of 1:8 into a new flask, A375M at 1:8, Mel224 at 1:6 and Mel505 at 
1:6. 
2.8.1.3 HMEC Culture 
Cells were grown in “M87A medium” (50% Mammary Epithelial Basal Medium 
(MEBM; Lonza Ltd, CH) supplemented with MEGM SingleQuot Kit Supplements and 
Growth Factors (excluding gentamycin; Lonza Ltd, CH), 5 µg/mL transferrin (Sigma-
Aldrich, UK), 5 µM isoproterenol (Sigma-Aldrich, UK), 2 mM L-glutamine; 50% 
DMEM: Nutrient Mixture F-12 (DMEM/F12), with 2 mM L-glutamine and 40 nM 
phenol red, but no HEPES (Life Technologies Ltd, UK) supplemented with 10 µg/mL 
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insulin, (Sigma-Aldrich, UK) 5% (v/v) FBS, 100 ng/mL hydrocortisone (Sigma-
Aldrich, UK), 10 nM 3,3’,5-triiodo-L-thyronine (Sigma-Aldrich, UK), 10 nM β-
estradiol (Sigma-Aldrich, UK) and 5 ng/mL epidermal growth factor (Life Technologies 
Ltd, UK); 0.1% (w/v) AlbuMAXTM I (Life Technolgies Ltd, UK) and 0.1 nM oxytocin 
(Bachem, CH). Cells were cultured from passage 4 (P4), seeded at a density of 5000    
cm-2, media changed every 1-2 days and split every four days. Cells were split by 
washing for 30 sec in DPBS at RT followed by incubation with 3 mL Trypsin-EDTA 
pre-warmed to 37°C for 7 min at 37°C. Trypsin-EDTA was quenched by addition of 7 
mL “M87A medium” and cells were centrifuged at 600 x g for 4 min. Cells were 
resuspended in medium and counted (NucleoCounter® NC-100TM; Chemometec, DM) 
before being plated into fresh 75 cm2 flasks. Cells were transfected with siRNA at 
passage 6 (P6; see Section 2.11.1). 
2.8.1.4 MDA-MB-468 Culture 
Cells were grown in “BLBC medium” (DMEM with 4.5 mg L-1 glucose, 1 mM sodium 
pyruvate, 4 mM GlutaMAXTM and 40 nM phenol red (but not HEPES), supplemented 
with 10% (v/v) FBS, 2 mM L-glutamine and 1 mM sodium pyruvate (Sigma-Aldrich, 
UK)). Prior to splitting, cells were washed with 6 mL Versene for 4 min at 37°C. cells 
were counted (NucleoCounter® NC-100TM; Chemometec, DM) and seeded at 10,000 cm-
2 into fresh 75 cm2 flasks.  
2.9 Bacterial (XL10-Gold® Ultracompetent E. coli) 
transformation 
XL10-Gold® Ultracompetent cells (Agilent Technologies, UK) were thawed on ice. For 
each sample to be transformed, 22.5 µL of bacteria were aliquoted into a 1.5 mL 
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Eppendorf microcentrifuge tube (Eppendorf, UK) prechilled on ice. The bacteria were 
treated with 1 µL XL10-Gold® β-mercaptoethanol mix, mixed gently, kept on ice for 10 
min and mixed gently every 2 min. Afterwards, 5 ng of plasmid DNA from each sample 
to be transformed was added to separate aliquots of the ultracompetent cells, mixed 
gently and incubated on ice for 30 min. The bacteria were heat-shocked for 30 sec at 
42°C and then incubated on ice for 2 min before 250 µL of preheated (42°C) SOC rich 
medium (see Section 2.7.1) was added to the tube. The cells were allowed to recover for 
1 h at 37°C with shaking at 250 rpm (Innova 4000 Benchtop Incubator Shaker; New 
Brunswick Scientific, NJ) before the entire transformation was plated onto a LB-agar 
plates containing 100 µg/mL ampicillin. Plates were subsequently incubated at 37°C for 
> 18 h. 
2.10 Mammalian cell plasmid transfection 
2.10.1 HEK293T 
2.10.1.1 For immunoblot analysis 
HEK293T cells were seeded as a monolayer at 30,000 cells cm-2 on 6 round-well plates 
(ThermoFisher Scientific, MA, USA) in 2.5 mL complete DMEM medium (see Section 
2.8.1.1) 24 h prior to transfection, to provide 60% - 70% confluency. For the 
transfection, 7.5 µg total plasmid DNA was added to 7.5 µL sterile water and 1 µL 5% 
(w/v) glucose in individual 1.5 mL Eppendorf microcentrifuge tubes (Eppendorf, UK). 
Subsequently, 1.5 µL polyethyleneimine (PEI) was added to each reaction and then 
incubated for 10 min at RT. During the 10 min incubation period, all medium was 
aspirated from each well and replaced with 1.5 mL fresh DMEM medium pre-warmed 
to 37°C. After the 10 min incubation, 1 mL of 37°C DMEM medium was added to each 
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tube and then applied to the cells. Cells were harvested 48 h post transfection for 
immunoblot analysis (see Section 2.23). 
2.10.1.2 For immunocytochemistry analysis 
HEK293T cells were seeded and transfected as in Section 2.10.1.1. 24 h post 
transfection, medium was aspirated from the wells and cells were washed with 1 mL 
DPBS. Cells were recovered from the wells by treatment with 500 µL TrypLETM 
Express for 5 min at 37°C and 2 mL of DMEM medium was subsequently added to 
quench the TrypLETM Express. Next, 1 mL of each cell suspension was added to a well 
of a new six round-well plate, each containing four sterile coverslips which had 
previously been treated with 100 µL 100 µg/ml-1 poly-L-lysine for 1 h at RT followed 
by three washes in 1 mL DPBS. Each well was topped up with 1.5 mL of fresh DMEM 
medium. The cells were cultured for a further 24 h in normal culture conditions and 
were fixed 48 h post transfection for immunocytochemistry analysis (see Section 
2.27.3).  
2.10.1.3 For cytotoxicity assay 
HEK293T cells were seeded as a monolayer at 3 x 104 cells cm-2 on 96-well flat bottom 
plates (ThermoFisher Scientific, MA, USA) in 250 µL complete DMEM medium (see 
Section 2.8.1.1) 24 h prior to transfection, to provide 60% - 70% confluency. For the 
transfection, 0.625 µg total plasmid DNA was added to 1.25 µL sterile water and 0.125 
µL 5% (w/v) glucose in individual 1.5 mL Eppendorf microcentrifuge tubes 
(Eppendorf, UK). Subsequently, 0.188 µL PEI was added to each reaction and then 
incubated for 10 min at RT. During the 10 min incubation period, all medium was 
aspirated from each well and replaced with 200 µL fresh DMEM medium pre-warmed 
to 37°C. After the 10 min incubation, 50 µL of 37°C DMEM medium was added to 
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each tube and then applied to the cells. Cells used 48 h post transfection for the 
cytotoxicity assay (see Section 2.26).  
2.11 Mammalian cell siRNA/miRNA transfection 
2.11.1 HMEC  
2.11.1.1 For immunocytochemistry 
HMECs were transfected with siRNA and miRNA in 384-well plates (ThermoFisher 
Scientific, MA, USA) at P6 using the reverse transfection method to replicate the 
conditions used in the previous study (Bishop et al., 2010).  All conditions were set up 
in sextuplicate.  
  
Wells for the transfection reagent only ‘HiPerFect Only’ condition were coated with 
MEGM (Lonza Ltd, CH) without supplements, plus 0.25 µL HiPerFect (QIAGEN, DE) 
in a total volume of 5 µL. Wells for conditions containing either siRNA or miRNA were 
coated with 5 µL HiPerFect containing supplement-free MEGM, plus 5 µL supplement-
free MEGM, containing either siRNA or miRNA to give a final concentration of 30, 60 
or 90 nM, depending on the experiments being carried out. The HiPerFect and 
si/miRNA mixtures were incubated for 90 mins at RT to allow transfection complexes 
to form. HMECs at P6 were plated at 10,000 cm-2 in 60 µL M87A medium (see Section 
2.8.1.3), to give each well a total volume of 70 µL. The transfection plate was media 
changed 48 h post transfection by the replacement of 50 µL, from each well with 80 µL 
fresh medium. The plate was fixed 120 h post transfection for immunocytochemistry 
analysis (see Section 2.27.2). 
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2.11.1.2 For RT-qPCR analysis 
HMECs for RT-qPCR analysis were reverse transfected in 6-well plates (Fisher 
Scientific Ltd, UK) at P6. For wells containing the transfection reagent only condition 
‘HiPerFect Only’, wells were coated with supplement-free MEGM (Lonza Ltd, CH) 
plus 6.9 µL HiPerFect (QIAGEN, DE) in a total volume of 188.6 µL supplement-free 
MEGM. For wells containing siRNA, the wells were coated with 48.27 µL of 1 µM 
siRNA in supplement-free MEGM, plus 6.9 µL HiPerFect in a total volume of 188.6 µL 
supplement-free MEGM. The transfection mixture was incubated for 90 mins at RT to 
allow transfection complexes to form. HMECs at P6 were plated at 10,000 cm-2 in 1.379 
mL M87A medium (see Section 2.8.1.3), to give each well a total volume of 1.6 mL 
and a final siRNA concentration of 30 nM. The transfection plate was harvested for RT-
qPCR analysis 48 h post transfection (see Section 2.13). 
2.11.2 MDA-MB-468 
MDA-MB-468s were transfected with siRNA and miRNA in 384-well plates 
(ThermoFisher Scientific, MA, USA) between passage 20 (P20) and passage 28 (P28) 
using the reverse transfection method, in order to reduce the chance of pipetting error, 
and to replicate the conditions used in the previous study (Overhoff et al., 2014).  All 
conditions were set up in sextuplicate.  
  
Wells for the transfection reagent only ‘HiPerFect Only’ condition were coated with 
DMEM without supplements, plus 0.2 µL HiPerFect (QIAGEN, DE) in a total volume 
of 5 µL. Wells for conditions containing either siRNA or miRNA were coated with 5 
µL HiPerFect containing supplement-free DMEM, plus 5 µL supplement-free DMEM 
(Sigma Aldrich, UK), containing either siRNA or miRNA to give a final concentration 
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of 60 or 90 nM. The HiPerFect and si/miRNA mixtures were incubated for 90 mins at 
RT to allow transfection complexes to form. MDA-MB-468s were plated at 30,000 cm-2 
in 60 µL BLBC medium (see Section 2.8.1.4), to give each well a total volume of 70 
µL. The transfection plate was media changed 48 h post transfection by the replacement 
of 50 µL, from each well with 80 µL fresh medium. The plate was fixed 120 h post 
transfection for immunocytochemistry analysis (see Section 2.27.2). 
2.12 Isolation of plasmid DNA from XL10-Gold® E. coli 
Small-scale (µg quantities) preparations of plasmid DNA were isolated from E. coli 
using the GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich, UK) as described by the 
manufacturer. Large-scale (mg quantities) preparations of plasmid DNA were isolated 
from E. coli using the QIAGEN Plasmid Mega Kit (QIAGEN, NL) as described by the 
manufacturer. Slight modifications to both protocols are included within the methods 
outlined below. 
2.12.1 Small-scale preparations 
A single bacterial colony from a freshly streaked plate was used to inoculate a small 
culture of 5 mL LB broth containing 100 µg/mL ampicillin (see Section 2.7), in a sterile 
50 mL Erlenmeyer flask and incubated overnight at 37°C with shaking at 250 rpm 
(Innova 4000 Benchtop Shaker; New Brunswick Scientific, Edison, NJ, USA). From 
the 5 mL culture, 2 mL was harvested by centrifugation for 2 min at 12,000 x g. The 
pellet was then resuspended in 200 µL Resuspension Solution, followed by 200 µL 
Lysis Buffer and the solution was mixed by inversion. The alkaline Lysis Buffer lyses 
the cells and causes the denaturation of nucleic acids and proteins within the lysate. 
After 5 min at RT, 350 µL Neutralization Solution was added, causing the aggregation 
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of insoluble genomic DNA and high molecular weight RNA, and the precipitation of 
protein-sodium dodecyl sulphate (SDS) complexes. The lysate was then centrifuged for 
10 min at 12,000 x g, during which time the GenElute HP Miniprep Binding Columns 
were primed by adding 500 µL Column Preparation Solution and centrifuging for 1 min 
at 12,000 x g. The supernatant from the cell lysate was then added to the columns and 
incubated for 1 min at RT, before being centrifuged at 12,000 x g for 1 min. With the 
plasmid DNA then bound to the column, the flow through was discarded. Each column 
was washed by adding 500 µL Wash Solution, before centrifuging for 1 min at 12,000 x 
g. Eluted wash solution was discarded and the columns were again centrifuged as before 
to remove any remaining traces of Wash Solution. Plasmid DNA was eluted by adding 
50 µL of 10 mM Tris buffer pH 8.8 to the column and incubating for 5 min at RT before 
being centrifuged at 12,000 x g for 1 min. The concentration and purity of the eluted 
plasmid DNA was determined by spectrophotometric analysis as described in Section 
2.14 and stored at -20°C. 
2.12.2 Large-scale preparations 
A single bacterial colony from a freshly streaked plate was used to inoculate a starter 
culture of 5 mL LB broth containing 100 µg/mL ampicillin (see Section 2.12.1), in a 
sterile 50 mL Erlenmeyer flask and incubated for 8 h at 37°C with shaking at 250 rpm. 
The starter culture was then diluted 1:500 in a 500mL LB broth containing 100 µg/mL 
ampicillin, in a sterile 2 L baffled Erlenmeyer flask and incubated at 37°C with shaking 
at 250 rpm for 16 h. The cells were harvested by transferring the culture to a 500 mL 
bottle and spinning in a superspeed centrifuge (Sorvall 5C Plus, Thermo-Sorvall, CT) at 
6,000 x g for 15 min at 4°C, before being resuspended in 50 mL Buffer P1. 50 mL of 
Buffer P2 was then added to lyse the cells and the bottle was vigorously inverted six 
times before being incubated at RT for 5 min. 50 mL of Buffer P3 (pre-chilled to 4°C) 
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was added and mixed through by six further vigorous inversions then the bottle was 
incubated on ice for 30 min. Following this the lysate was mixed briefly and centrifuged 
at 20,000 x g for 30 min at 4°C. Whilst the lysate was being centrifuged, a QIAGEN-
tip-2500 column was equilibrated by applying 35 mL Buffer QBT and letting the 
column empty by gravity flow. After centrifugation, the supernatant containing the 
plasmid DNA was promptly removed from the bottle, added to the equilibrated column 
and allowed to enter the resin by gravity flow. Subsequently, 200 mL of Buffer QC was 
applied to the QIAGEN-tip 2500 to wash the column and remove contaminants from 
the plasmid DNA. The plasmid DNA was eluted with 35 mL Buffer QF into a 50 mL 
centrifuge tube (Scientific Laboratory Supplies, UK) by gravity flow. DNA was 
precipitated by addition of 24.5 mL of isopropanol, mixed gently and immediately 
centrifuged at 15,000 x g for 30 min at 4°C before carefully removing the supernatant. 
The plasmid DNA pellet was washed with 7 mL 70% ethanol and centrifuged again at 
15,000 x g for 10 min. The supernatant was removed and the pellet air-dried for 10 – 20 
min, before redissolving the plasmid DNA in 500 µL 10 mM Tris buffer pH 8.8. The 
concentration and purity of the eluted plasmid DNA was determined by 
spectrophotometric analysis as described in Section 2.14 and stored at -20°C. 
2.13 Isolation of total RNA from human cells 
Small-scale (µg quantities) preparation of total RNA from human cells was carried out 
using the QIAGEN RNeasy® Mini Kit (QIAGEN, NL) as described by the 
manufacturer. Slight modifications to the protocol are detailed in the method below. 
 
Media was aspirated from the wells 48 h post transfection (see Section 2.11) and cells 
were washed with DPBS containing both magnesium and calcium (PAA Laboratories, 
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UK; H15-001). Cells were lysed by the addition of 600 µL Buffer RLT (supplemented 
with 1.0% β-mercaptoethanol) and a sterile, disposable cell scraper (Fisher Scientific 
Ltd, UK) was used to ensure that all cells were lysed. The lysate was removed to a 1.5 
mL Eppendorf microcentrifuge tube (Eppendorf, UK) and mixed by pipetting, before 
being homogenised by centrifuging through a QIAshredder spin column (QIAGEN, 
NL; 79654) for 2 min at 14,000 x g. One volume of 70% ethanol (Sigma-Aldrich) was 
added to the homogenised lysate and mixed by pipetting six times. The sample, 
including any precipitate formed, was transferred to an RNeasy spin column (in a 
supplied 2 mL collection tube) and was centrifuged for 15 sec at 8,000 x g, after which 
the flow-through was discarded. The column with bound RNA was subsequently 
washed with 700 µL Buffer RW1 by centrifuging for 15 sec at 8,000 x g followed by 
two further 500 µL washes with Buffer RPE using the same spin conditions. In each 
case the flow-through was discarded. The column was transferred to a fresh 2 mL 
collection tube and spun for a further 1 min at 14,000 x g to remove and residual Buffer 
RPE from the last wash. Subsequently, the column was transferred to a new 1.5 mL 
Eppendorf microcentrifuge tube and 50 µL RNase-free water was added directly to the 
spin column before being centrifuged for 1 min at 14,000 x g to elute the bound RNA. 
The concentration and purity of the eluted RNA was determined by spectrophotometric 
analysis as described in Section 2.14 and stored at -80°C. 
2.14 Determination of nucleic acid yield and quality 
DNA and RNA concentrations in nucleic acid preparations were determined by 
spectrophotometry by measuring the absorbance at 260 nm (A260) using the NanoDrop 
ND-1000 (ThermoFisher Scientific, MA, USA). The quality of nucleic is indicated by 
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the ratio between the absorbance at 260 and 280 nm. For pure DNA the A260/A280 ratio 
should be ~1.8 and for pure RNA the ratio should be ~2.0. Smaller ratios usually 
indicate contamination by protein or organic chemicals. As a secondary measure of 
nucleic acid purity, the A260/A230 ratio was also measured which should be in the range 
of 1.8 to 2.0 for DNA and 2.0 to 2.2 for RNA. Only nucleic acids that passed these 
criteria were used in downstream applications. 
2.15 Reverse-transcription of mRNA to cDNA 
cDNA synthesis was carried out using the GrandScript cDNA synthesis Kit (PCR 
Biosystems, UK) as per the manufacturer’s instructions. Briefly, 1 µg RNA (see Section 
2.13) was mixed with 4.0 µL 5x cDNA synthesis mix (proprietary) 1.0 µL reverse 
transcriptase (RTase; proprietary) and nuclease-free H2O to a total volume of 20 µL 
before incubation at 42°C for 30 min, followed by incubation at 70°C for 10 min to 
denature the RTase. cDNA was stored at -20°C for up to one week or used immediately 
for downstream applications.  
2.16 PCR of cDNA 
PCR was carried out using Taq DNA Polymerase and ThermoPol Buffer (New England 
Biolabs, UK) on previously generated cDNA (see Section 2.15).  Reactions were set up 
as described in Table 2-7 and run with the conditions detailed in Table 2-8. 
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Reagent Volume Final 
Concentration 
10x ThermoPol Reaction Buffer 5 µL 1x 
dNTPs (20 mM) 0.5 µL 200 µM  
Forward Primer (20 µM) 0.5 µL 0.2 µM  
Reverse Primer (20 µM) 0.5 µL 0.2 µM  
Template cDNA Variable 5 µg/µL 
Taq DNA Polymerase 0.25 µL 1.25 Units 
Nuclease-free water To 50 µL N/A 
Table 2-7. Reaction mix used for PCR of cDNA with Taq DNA Polymerase. 
10x ThermoPol Reaction Buffer and Taq DNA Polymerase – proprietary (New England 
Biolabs, UK); dNTPs – 5 mM dCTP, 5 mM dTTP, 5 mM dATP, 5 mM dGTP (Bioline, UK); 
Nuclease-free water was from Promega, UK. Forward and Reverse Primers used were 
dependent on the sequence to be amplified (see Section 2.3). 
 
Time (Sec) Temperature (°C) No. Of Cycles Step 
30 95 1 Initial denaturation 
20 95  Denaturation 
30 55 30 – 50 Primer binding 
60 per kb 68  Extension 
300 68 1 Final extension 
∞ 4 N/A Hold 
Table 2-8. Cycling conditions for Taq DNA Polymerase PCR. 
2.17 TaqMan qPCR of cDNA 
The TaqMan quantitative PCR (qPCR) system (Life Technologies Ltd, UK) uses two 
target-specific primers, which bind at opposite ends of the section of the template to be 
amplified, much like standard qPCR. Unlike standard qPCR, TaqMan qPCR also 
requires a third sequence-specific oligonucleotide probe which binds to the middle of 
the section to be amplified. This probe is different to the primers in two ways. Firstly, 
the probe cannot be extended by the Taq polymerase, as it has no free hydroxyl group. 
Secondly, the probe is covalently bound to two other molecules: a fluorescent Reporter 
molecule at the 5’ end, and a fluorescent Quencher molecule at the 3’ end. When not 
bound to DNA, the probe curls back on itself, so that the 5’ and 3’ ends of the molecule 
are in close proximity to each other, meaning that the Reporter and Quencher molecules 
are next to each other. When the Reporter is excited in this state, the energy is 
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transferred to the Quencher by fluorescence resonance energy transfer, and the Reporter 
does not produce a fluorescent signal. During the extension stage of the PCR reaction, 
the exonuclease activity of the Taq polymerase will cleave the nucleotides of the probe 
bound to the template, but only where both the primers and the probe are all bound to 
the same section of DNA. The hydrolysation of the probe will permanently separate the 
Reporter and Quencher molecules from each other, allowing the Reporter to fluoresce at 
a level detectable by the instrument when it is excited. As one Reporter molecule will 
be released from every new PCR amplicon created, the fluorescence in the reaction will 
increase proportionally with the amount of specific product in the reaction. 
 
cDNA from the reverse transcription of 1 µg mRNA extracted from cells (see Section 
2.15) was diluted 1:2 in RNase-free water and used in the reaction, as detailed in Table 
2-9. Each 20 µL reaction was transferred to a well of a 96-well reaction plate (Life 
Technologies Ltd, UK) and the plate was sealed using optical adhesive film (Life 
Technologies Ltd, UK). The plate was loaded onto the qPCR machine (Applied 
Biosystems 7500 Real –Time PCR System; Life Technologies Ltd, UK) and run with 
the conditions outlined in Table 2-10. 
 
PCR reaction mix component Volume per 20 µL reaction 
20x TaqMan Gene Expression Assay 1.0 µL 
2x TaqMan Gene Expression Master Mix 10.0 µL 
cDNA template 2.0 µL 
RNase-free water 7.0 µL 
Table 2-9. Reaction mix used for the TaqMan qPCR system (Life Technologies Ltd, UK). 
TaqMan Gene Expression Assay – contents dependent on gene to be analysed, see 
Table 2-4; TaqMan Gene Expression Master Mix – proprietary. 
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Time (sec) Temperature (°C) No. of Cycles Step 
120 50 1  
600 95 1 Initial denaturation 
15 95 40 Denaturation 
60 60  Extension 
Table 2-10. Cycling conditions for TaqMan qPCR. 
2.18 5’ RACE PCR 
5’ RACE PCR was carried out using the 5’ RACE System for Rapid Amplification of 
cDNA Ends, Version 2.0 kit (Life Technologies Ltd, UK). The reactions were carried 
out according to the manufacturer’s instructions apart from a few minor changes, 
detailed below.  
2.18.1 First strand cDNA synthesis 
mRNA isolated from P5 HMECs (See Section 2.13) was subjected to first strand cDNA 
synthesis. A total of 5 µg mRNA was used with 2.5 pmol RACE-GSP1 (see Table 2-3 
for details) in a volume of 15.5 µL. The mixture was incubated for 10 min at 70°C, 
followed by chilling on ice for 1 min. Subsequently, 2.5 µL 10x PCR buffer 
(proprietary), 2.5 µL 25 mM MgCl2, 1 µL 10 mM dNTP mix and 2.5 µL 100 mM DTT 
were added to the reaction and the mix was incubated for 1 min at 42°C. Finally, 1 µL 
SuperScriptTM II RT was added, followed by incubation for 30 min at 42°C and then 
70°C for 15 min to terminate the reaction. 
 
The mixture was placed at 37°C following a brief centrifugation and 1 µL RNase mix 
added and incubated for 30 min. Subsequently the reaction was collected by brief 
centrifugation and placed on ice. 
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2.18.2 Purification of cDNA 
Excess nucleotides and RACE-GSP1 were removed from the first strand product by 
purification using the provided S.N.A.P. columns. To the reaction containing the first 
strand product, 120 µL binding solution (6 M NaI) was added at RT; the resulting 
mixture was transferred to a S.N.A.P. column and centrifuged at 13,000 x g for 20 sec. 
The flowthrough from the centrifugation was discarded and the column was washed 
three times with 400 µL 4°C 1x wash buffer by centrifugation at 13,000 x g for 20 sec. 
The column was washed a further two times with 400 µL 4°C 70 % ethanol by 
centrifugation at 13,000 x g for 20 sec. After removing the flowthrough the membrane 
was dried by spinning the column for a further 1 min at 13,000 x g. The cDNA was 
recovered from the column by the addition of 50 µL RNase-free water pre-heated to 
65°C to the spin cartridge and centrifugation at 13,000 x g for 20 sec.  
2.18.3 TdT tailing of cDNA and amplification 
Terminal deoxynucleotidyl transferase (TdT) was used to an oligo-dC tail to the first 
strand cDNA generated in Section 2.18.1 and purified in Section 2.18.2. The TdT 
tailing reaction was set up as described in Table 2-11. 
 
Reagents Volume (µL) Final Concentration 
RNase-free water 4.5  N/A 
5x tailing buffer 5  1x 
2 mM dCTP 2.5  0.2 mM 
Purified cDNA sample 12  Unknown 
Table 2-11. Reaction mix used for TdT tailing reaction (Life Technologies Ltd, UK). 
5x tailing buffer – proprietary. 
The reaction mixture was incubated for 2 min at 94°C and then 1 min on ice, followed 
by the addition of 1 µL TdT. The sample was incubated at 37°C for 10 min for the 
reaction to occur and subsequently at 65°C for 10 min to inactivate the TdT. The 
contents of the reaction was collected by brief centrifugation and placed on ice.  
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2.18.4 Amplification of dC-tailed cDNA 
dC-tailed cDNA obtained from 2.18.3 was amplified directly by PCR using the reagents 
detailed in Table 2-12 and the conditions found in Table 2-13. 
Reagent Volume (µL) Final Concentration 
RNase-free water 31.5 N/A 
10x PCR buffer 5 1x 
MgCl2 (25 mM) 3 1.5 mM 
dNTP mix (10 mM) 1 200 µM  
RACE-GSP2 (10 µM) 2 200 nM 
Abridged Anchor Primer (10 µM) 2 200 nM 
  dC-tailed cDNA 5 Unknown 
Taq DNA polymerase 0.5 2.5 U 
Table 2-12. Reaction mix used for PCR of dC-tailed cDNA. 
10x PCR buffer – 200 mM Tris-HCl (pH 8.4), 500 mM KCl. 
 
Time (sec) Temp (°C) Cycles Step 
60 95 1 Initial Denaturation 
30 95  Denaturation 
45 55 35 Annealing 
60 72  Extension 
420 72 1 Final Extension 
Table 2-13. Cycling conditions for PCR of dC-tailed cDNA. 
 
2.18.5 Nested amplification of dC-tailed cDNA 
Following the first amplification of dC-tailed cDNA, not enough product was generated 
to undertake direct sequencing. To produce additional cDNA, the products from the 
original PCR were diluted and then re-amplified using the nested gene-specific primer 
RACE-GSP3 (See Table 2-3) and the provided abridged universal amplification primer. 
The PCR products from Section 2.18.4 were diluted by the addition of 495 µL TE 
buffer (10 mM Tris-HCl (pH 8.0), 1 mM EDTA) to 5 µL of the products. The reaction 
was then set up using the reagents detailed in Table 2-14, and ran with the conditions 
outlined in Table 2-15. 
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Reagent Volume (µL) Final Concentration 
RNase-free water 33.5 N/A 
10x PCR buffer 5.0 1x 
MgCl2 (25 mM) 3.0 1.5 mM 
dNTP mix (10 mM) 1.0 200 µM  
RACE-GSP3 (10 µM) 1.0 200 nM 
Abridged universal anchor primer (10 µM ) 1.0 200 nM 
Dilution of PCR product 5.0 Unknown 
Taq DNA polymerase 0.5 2.5 U 
Table 2-14. Reaction mix used for nested amplification of dC-tailed cDNA. 
10x PCR buffer – 200 mM Tris-HCl (pH 8.4), 500 mM KCl. 
Time (sec) Temp (°C) Cycles Step 
60 95 1 Initial Denaturation 
30 95  Denaturation 
45 55 35 Annealing 
60 72  Extension 
420 72 1 Final Extension 
Table 2-15. Cycling conditions for nested amplification of dC-tailed cDNA. 
2.19 Agarose gel electrophoresis of DNA 
Agarose gels [2% (w/v)], were prepared by melting the required amount of powdered 
agarose (DNA grade; Life Technologies Ltd, UK) in TAE buffer (40 mM Tris-acetate, 
1 mM EDTA) by heating in a microwave oven (Sharp, UK) until dissolved. The melted 
solution was allowed to cool to 55°C before GelRedTM (Biotium, CA, USA; 41002) was 
added to 1x. The gel was then poured into the appropriate mould (Owl Separation 
Systems; Thermo Fisher Scientific, UK) and allowed to set. DNA fragments were 
separated by electrophoresis through a gel submerged in TAE buffer. Before loading 
onto the gel, the samples were mixed with the appropriate volume of 6x gel-loading 
buffer (2.5% Ficoll® 400, 11 mM EDTA, 3.3 mM Tris-HCl pH 8.0, 0.017% SDS, 
0.15% Orange G; New England Biolabs, UK). The samples were loaded into the wells 
alongside a 100 bp DNA ladder (HyperLadder IV; Bioline, UK) and electrophoresed at 
10 V cm-1 until the required resolution was achieved. The DNA was visualised using an 
ultraviolet (UV) transilluminator and images recorded using the MultiImageTM Light 
Cabinet (Alpha Innotech Corporation, CA, USA). 
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2.20 Site-directed mutagenesis 
Oligonucleotide-directed mutations were introduced into both the V5-6His and EGFP 
tagged forms of pcDNA3.1-ABCB5fl-wt and pcDNA3.1-ABCB5β-wt (see Table 2-2) 
using the QuikChange II XL site-directed mutagenesis kit (Agilent Technologies, UK). 
2.20.1 Mutagenic primer design 
Mutagenic oligonucleotides were designed using the web-based QuickChange Primer 
Design Program available at http://www.stratagene.com/qcprimerdesign and purchased 
from Sigma-Aldrich (Table 2-3). 
2.20.2 Mutant strand synthesis 
Template plasmid DNA was amplified by PCR using a pair of mutagenic primers. The 
primer pairs are complementary to opposite strands of the template and span the site to 
be mutated, causing the PCR reaction to generate mutant DNA. Following 
amplification, Dpn I endonuclease digestion of methylated and hemi-methylated DNA 
is carried out by addition of 1 µL 10 U mL-1 Dpn I and incubation for 1 h at 37°C. 
Because the template plasmid DNA is generated in a dam+ E. coli strain and therefore 
methylated, whereas the newly synthesised DNA is unmethylated, only the template 
DNA is susceptible to DpnI digestion. This enables selection of the newly synthesised 
DNA containing the desired mutation to occur. The resulting plasmid DNA can 
subsequently be used to transform XL10-Gold® Ultracompetent Cells as described in 
Section 2.9.  
 
Thermal cycling reactions were set up in thin-walled PCR tubes (Sigma-Aldrich, UK), 
to maximise temperature-cycling performance. Each reaction was set up as listed in 
Table 2-16 and cycled using the parameters outlined in Table 2-17. 
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QuickChange® Reaction Reagents Volume  Concentration 
Reaction Buffer (10x) 5 µL 1x 
dsDNA Template 1 µL 0.2 ng/µL 
Primer #1 1 µL  2.5 ng/µL 
Primer #2 1 µL 2.5 ng/µL 
dNTP Mix 1 µL proprietary  
QuikSolution 3 µL proprietary 
ddH2O To 50 µL 
final volume 
 
PfuTurbo DNA Polymerase (2.5 U/µL) 1 µL 2.5 Units 
Table 2-16. Protocol for the QuickChange® XL site-directed mutagenesis kit (Stratagene, 
UK). 
This protocol was used to introduce the required mutations to pcDNA3.1-ABCB5fl-wt and 
pcDNA3.1-ABCB5β-wt vectors expressing both V5-6His and EGFP tagged protein. 
Reaction buffer (1x): 200 mM Tris-HCl (pH 8.8), 20 mM MgSO4, 100 mM KCl, 100 mM 
(NH4)2SO4, 1% Triton® X-100, 1 mg/mL nuclease free bovine serum albumin; dNTP mix 
and QuikSolution composition: proprietary (Agilent Technologies, UK). 
 
Time (sec) Temperature (°C) No. Of Cycles Step 
60 95 1 Initial 
denaturation 
50 95  Denaturation 
50 60 18 Annealing 
540 68  Extension 
420 68 1 Final extension 
Table 2-17. PCR programme used to mutate ABCB5fl and ABCB5β .  
 
The sequence of the entire mutant cDNA insert was confirmed as described in Section 
2.21. 
2.21 DNA Sequencing 
2.21.1 Automated sequencing 
Automated DNA sequencing was out-sourced and performed by LifeSciences (Source 
BioScience, UK). 
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2.21.2 In-house sequencing 
In-house Sanger sequencing of DNA was carried out using BigDye® Terminator v3.1 
Cycle Sequencing Kit (Life Technologies Ltd, UK). 
2.21.2.1 Cycle sequencing of plasmid DNA 
The BigDye® Terminator v3.1 Cycle Sequencing Kit provides the required reagents 
components for the sequencing reaction in a pre-mixed format. These reagents were  
used  for performing fluorescence-based cycle sequencing reactions on single-stranded 
or double-stranded DNA templates and on PCR fragments. 
 
Each reaction mixture was prepared as shown in Table 2-18. 
 
Reagent Volume Concentration 
Oligonucleotide 1.0 µL 320 fmol/µL 
BigDye® Terminator Buffer (5x) 2.0 µL 1x 
DNA Template variable 0.1 µg/µL 
Ready Reaction Premix (2.5x) 4 µL 1x 
Nuclease-free water To 10 µL final volume  
Table 2-18. Reaction mixture preparation for DNA sequencing. 
BigDye® Terminator Buffer and Ready Reaction Premix composition: proprietary (Life 
Technologies Ltd, UK) 
 
Cycle sequencing was performed in the Touchgene Gradient Thermal Cycler (Techne 
Ltd, UK) using the protocol outlined in Table 2-19.  
Time (Sec) Temperature (°C) No. Of 
Cycles 
Step 
60 96 1 Initial denaturation 
10 96  Denaturation 
5 50 25 Annealing 
240 60  Extension 
∞ 10 ∞ Final Extension 
Table 2-19. Thermocycling conditions for plasmid DNA sequencing. 
 
 99 
2.21.2.2 Ethanol/EDTA precipitation of DNA 
To ensure optimum results, unincorporated dye terminators (which can cause high 
levels of background fluorescent signal) were completely removed before 
electrophoresis.  
 
Tubes containing the amplified products (in 10 µL volumes) were briefly spun to collect 
the sample before adding 2.5 µL of 125 mM EDTA (25 mM final; Sigma-Aldrich, UK) 
followed by 30 µL of 100% ethanol (Sigma-Aldrich, UK). The tubes were sealed, 
mixed by inverting four times, incubated at RT for 15 min and spun for 20 min at 17000 
x g at 4°C in a fixed rotor centrifuge (Heraeus Fresco 17; ThermoFisher Scientific, MA, 
USA). The supernatant was discarded and 30 µL of 70% ethanol was added to each 
sample. Tubes were spun for 10 min at 17,000 x g at 4°C and the supernatant was 
discarded. Samples were allowed to air-dry for 30 min in the dark, resuspended in 10 
µL Hi-DiTM Formamide (Applied Biosystems, UK) and loaded onto a MicroAmp® 
Optical 96-Well Reaction Plate (Life Technologies Ltd, UK). 
2.21.2.3 Sample Electrophoresis 
Before electrophoresis, the 96-well reaction plate was sealed and the samples were 
heated for 5 min at 96°C on a hot block (DRI Block® DB1.M; Techne Ltd, UK) to 
denature the DNA, then cooled rapidly for 1 min on ice.  
 
Automated sample electrophoresis and sequencing analysis were performed using the 
instrument protocol “sequencing_600bp_POP7” and analysis protocol “3130 
POP7_BDTU3-KB_DENOVO_V.5.2” on ABI Prism® 3130xl Genetic Analyser 
(Applied Biosystems, UK). 
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2.21.2.4 Sequencing data analysis 
Analysis of the electropherograms was performed using the Sequence Scanner V1.0 
(Applied Biosystems, UK). 
2.22 Plasmid constructs 
2.22.1 pcDNA3.1-ABCB5fl-wt and pcDNA3.1-ABCB5β-wt 
plasmids 
Plasmids encoding human ABCB5fl or ABCB5β with either a C-terminal enhanced 
green fluorescent protein (EGFP) tag (pcDNA3.1-ABCB5fl-wt_EGFP and pcDNA3.1-
ABCB5β-wt_EGFP, respectively) or a C-terminal 6-histidine (V5-6His) tag 
(pcDNA3.1-ABCB5fl-wt_V5-6His and pcDNA3.1-ABCB5β-wt_V5-6His, 
respectively) were kindly provided by Prof. Michael Gottesman (Bethesda, MD, USA). 
2.22.2 Site directed mutagenesis 
All ABCB5fl and ABCB5β mutants were derived from the appropriate WT plasmid 
using the QuikChange II XL site directed mutagenesis kit (see Section 2.20). The 
primers used to derive each mutant were: ABCB5fl_E550Q-F (c.1885G>C), 
ABCB5fl_E1181Q-F (c.3778G>C), ABCB5β_E736Q-F (c.2752G>C) and their reverse 
complements (see Table 2-3).  Colonies from the mutagenesis reaction were picked and 
incubated overnight in 5 mL LB-amp liquid medium at 37°C with shaking at 250 rpm. 
Plasmid DNA was isolated from the cultures as described in Section 2.12.1. 
2.22.3 Confirming veracity of mutagenesis 
Each successful mutagenesis was confirmed either by automated DNA sequencing (see 
Section 2.21.1; Source BioScience, UK) or in-house sequencing (see Section 2.21.2). 
The primers used for sequencing were designed to cover the whole ABCB5fl or 
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ABCB5β cDNA. For ABCB5fl these were: ABCB5_42F, ABCB5_601F, 
ABCB5_1041F, ABCB5_1603F, ABCB5_2177F, ABCB5_2742F, ABCB5_3268F, 
ABCB5_3706F and ABCB5_161R. For ABCB5β these were: ABCB5_1603F, 
ABCB5_2177F, ABCB5_2742F, ABCB5_3268F, ABCB5_3706F and ABCB5_1781R 
(see Table 2-3). 
2.22.4 pcDNA3.1-CD36_Venus plasmid 
The pcDNA3.1-CD36_Venus plasmid encoding the human plasma membrane, 
scavenger receptor CD36 with a C-terminal fluorescent Venus protein (an improved 
version of yellow fluorescent protein, with reduced chloride sensitivity, faster 
maturation and increased brightness) tag was kindly provided by Dr. Marjolein Snippe 
(London, UK). 
2.23 Preparation of whole-cell protein content 
Total-cell extracts from mammalian cells for immunoblot analysis were prepared 48 h 
post plasmid transfection (see Section 2.10) or 120 h post siRNA transfection (see 
Section 2.11). Prior to lysis, cells were washed twice with DPBS containing both 
magnesium and calcium (PAA Laboratories, UK) and lysed in the cell culture dish on 
ice in 300 µL lysis buffer (150 mM NaCl, 1% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris pH 8.0 (Sigma-Aldrich, UK; R0278), 150 mM 
NaCl, 10 mM HEPES, 25 U/µL Benzonase® Endonuclease (Merck Millipore, DE) and 
2x cOmpleteTM Protease Inhibitor Cocktail (Roche, UK). Cells were treated with lysis 
buffer for 5 min on ice before samples were collected from the dish by vigorous cell 
scraping using a sterile, disposable cell scraper (Fisher Scientific Ltd, UK) and pipetting 
into a 1.5 mL Eppendorf microcentrifuge tubes (Eppendorf, UK). Samples were 
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centrifuged at 17,000 x g for 5 min at 4°C to remove any insoluble material, the 
supernatant was removed to fresh tubes and stored at -20°C.  
2.24 Protein quantitation 
Protein concentration of whole-cell extracts was determined using the Bio-Rad DC 
Protein Assay (Bio-Rad, UK). The Assay is based on the Lowry method (Lowry et al., 
1951) and was carried out following the manufacturer’s instructions. The reactions were 
performed in triplicate in 96-well microplates (ThermoFisher Scientific, MA, USA) and 
a range of bovine serum albumen (BSA) concentrations (0, 0.25, 0.5, 0.75, 1.0, 2.0, 3, 4. 
6, 8 and 10 mg mL-1) were used to produce a standard curve. 
2.25 Analysis of protein expression 
2.25.1 General reagents and buffers 
The buffers used in this investigation for western blotting are detailed below in  
Table 2-20. 
Buffer Reagent Concentration 
SDS gel-loading buffer (6x) Tris-HCl (pH 6.8) 350 mM 
 DTT 250 mM 
 Glycerol 60% (w/v) 
 SDS 12% (w/v) 
 Bromophenol blue 0.12% (v/v) 
Running buffer (5x) Tris 250 mM 
 Glycine 250 mM 
 SDS 1.0% (w/v) 
Transfer buffer (10x) Tris 195 mM  
 Glycine 250 mM  
 SDS 0.185% (w/v) 
TBS (10x) Tris-HCl (pH 7.6) 200 mM 
 NaCl 1.4 M 
Stripping buffer (1x) PBS adjusted to pH 
2.0 with HCl 
1x 
 SDS 1.0% 
 
Table 2-20. List of buffers used for western blotting in the investigation. 
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DTT – dithiothreitol; PBS – phosphate buffered saline; SDS – sodium dodecyl sulphate. 
All reagents were supplied by Sigma-Aldrich, UK. 
 
Running buffer, transfer buffer and TBS were all diluted to 1x with dH2O. Transfer 
buffer was supplemented with 20% (v/v) methanol; both transfer and running buffer 
were only used once; TBS was supplemented with 0.2% (v/v) Tween-20 (Sigma-
Aldrich, UK) to make TBS-T. 
2.25.2 Antibodies 
The antibodies used in this investigation for western blotting are detailed below in 
Table 2-21. 
Antibody Working 
Dilution 
Species Clonality Source 
Anti-ABCB5 (Atlas) 1:2,000 Rabbit Polyclonal Atlas Antibodies AB, SE 
Anti-ABCB5 (Rockland) 1:500 Rabbit Polyclonal Rockland Inc. PA, USA 
Anti-ABCB5 (Sigma) 1:500 Rabbit Polyclonal Sigma-Aldrich, UK 
Anti-β-tubulin 1:100,000 Mouse Monoclonal EnoGene Biotech Ltd, NY, USA 
HRP Anti-Rabbit  1:5,000 Goat Polyclonal Life Technologies Ltd, UK 
HRP Anti-Mouse 1:1,000 Goat Polyclonal DAKO, UK 
Table 2-21. List of antibodies used for western blotting in the investigation. 
HRP – horseradish peroxidase. 
2.25.3 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Gels were prepared using the discontinuous buffer system devised by Davis (1964), 
Ornstein (1964), and Laemmli (1970) in which the buffer in the sample and stacking gel 
contain Tris-Cl (pH 6.8), and the resolving gel contains Tris-Cl (pH 8.8).  
 
All SDS-PAGE was performed using the Mini-PROTEAN® electrophoresis system 
from Bio-Rad (CA, USA) and Tris-glycine running buffer (see Section 2.25.1). Proteins 
were diluted in 6x SDS sample buffer (see Section 2.25.1) and denatured briefly (5 min 
at 95°C) before loading on a freshly made SDS-polyacrylamide resolving gel (7.5% 
when resolving for ABCB5 isoforms or 15% when resolving for p16 protein) with a 4% 
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stacking gel. For each sample, 0.5 µg of total protein extract (protein concentration was 
determined as described in Section 2.24) was loaded in each lane. A lane containing 10 
µl of standard molecular weight marker (Precision Plus Protein All Blue Standards; 
Bio-Rad, UK) was loaded onto each gel to enable the subsequent determination of 
protein molecular weights. Proteins were initially separated using a constant voltage of 
80 V until the molecular weight marker separation became evident. The voltage was 
then increased to 110 V, and the separation was continued until the dye-front reached 
the base of the gel.  
2.25.4 Immunoblot analysis 
Western blotting was originally devised by Towbin (1979) and Burnette (1981) and 
involves the transfer of electrophoretically separated proteins from an SDS gel to a solid 
support (nitrocellulose membrane) and probing with antibodies specific for particular 
amino acids sequences. The bound (primary) antibody is then detected by a secondary 
(horseradish peroxidase (HRP)-conjugated) antibody via chemiluminescence. 
Following separation by SDS-PAGE, proteins were transferred onto a nitrocellulose 
membrane (Amersham Hybond ECL Nitrocellulose; GE Healthcare, NJ). The transfer 
was carried out for 1 h at 400 mA when probing for ABCB5 isoforms, and at 350 m A 
when probing for p16. After electroblotting, the nitrocellulose membrane was washed in 
the appropriate TBS-T (see Section 1 and blocked in 5% (w/v) milk (Marvel, UK) in the 
same TBS-T for 1 h at RT on a rocking platform. The membrane was probed overnight 
with the primary antibody in 10 mL 5% (w/v) milk in the appropriate TBS-T inside a 50 
mL centrifuge tube (Scientific Laboratory Supplies, UK) at 4°C on a roller (Denley 
Spiramix 5; Thermo Denley, UK). The membrane was washed eight times for 5 min 
each with TBS-T before incubation (1 h at RT in a 50 mL centrifuge tube on a roller) 
with the appropriate secondary HRP-conjugated antibody in 10 mL 5% (w/v) milk in 
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the appropriate TBS-T. Following a further eight 5 min washes in the appropriate TBS-
T, bound antibodies were visualised by chemiluminescence (Immobilon Western 
Chemiluminescent HRP Substrate; Millipore, UK) and exposed to Hyperfilm ECL (GE 
Healthcare, NJ, USA). 
2.25.5 Densitometric analysis of western blotting 
Western blots generated using the technique described in Section 2.25.4 were subjected 
to densitometric analysis in order to assess relative protein levels. Western blots were 
scanned at 800 dpi and the resulting images were loaded into ImageJ (Schneider et al., 
2012) for analysis using the densitometry tool. The highest molecular weight bands for 
ABCB5fl and ABCB5β were studied, so that lower molecular weight degradation 
products were not included. The area under the intensity peak for each band was 
calculated relative to background intensity and plotted for statistical analysis (see 
Section 2.29).  
2.26 Lactate dehydrogenase cytotoxicity assay 
Cytotoxicity in HEK293T cells following plasmid transfection was measured as a 
function of lactate dehydrogenase (LDH) activity, carried out using the CytoTox 96® 
Non-Radioactive Cytotoxicity Assay kit (Promega, WI, USA). The assay was carried 
out according to the manufacturer’s instructions, with minor alterations included within 
the method below.  
 
HEK293T cells in 96-well format were transfected in triplicate 48 h prior to lysis by the 
addition of 25 µL Lysis Solution (10x; 9 % (v/v) Triton X-100) and incubation for 1 h 
at 37°C. Subsequently, 50 µL of the supernatant from each well was removed to a fresh 
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96-well plate, followed by the addition of 50 µL Substrate Mix (proprietary) and an 
incubation for 30 min at RT in the dark. To stop the reaction, 50 µL Stop Solution (1 M 
acetic acid) was added to each well of the plate. The absorbance across the plate was 
read at 490 nm.  
2.27 Immunocytochemistry 
2.27.1 Antibodies and cell stains 
The antibodies and fluorescent stains used to stain cells by immunocytochemistry are 
detailed in Table 2-22. 
 
Antibody Or 
Stain 
Conjugate Working 
Dilution 
Species Clonality Source 
Anti-p16 N/A 1:1,000 Mouse Monoclonal J. Koh, Duke 
University, NC, 
USA 
Anti-KDEL N/A 1:100 Mouse Monoclonal Merck Millipore, 
MA, USA 
Anti-Mouse 488 Alexa Fluor® 
488 
1:500 Goat Polyclonal Life Technologies 
Ltd, UK 
Anti-Mouse 555 Alexa Fluor® 
555 
1:500 Goat Polyclonal Life Technologies 
Ltd, UK 
HCS Cell Mask 
Deep Red 
N/A 1:2,500 N/A N/A Life Technologies 
Ltd, UK 
DAPI N/A 1:1,000 N/A N/A Life Technologies 
Ltd, UK 
Table 2-22. Antibodies and cell stains used for fluorescence microscopy in the 
investigation. 
 
2.27.2  Staining cells for high-content fluorescence microscopy 
120 h post-transfection, all medium was pipetted from the wells and cells were washed 
with 75 µl DPBS containing both magnesium and calcium (PAA Laboratories, UK) and 
then fixed with 4% (w/v) paraformaldehyde (PFA) and 5% (w/v) sucrose in PBS (all 
from Sigma-Aldrich, UK), for 15 min at RT. Cells were washed with PBS before being 
permeablised with 0.1% (v/v) Triton X-100 (Sigma-Aldrich, UK) in PBS for 15 min at 
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RT. Cells were again washed with PBS and blocked in “blocking solution” [0.25% 
(w/v) BSA (Sigma-Aldrich, UK) in PBS] for 30 min at RT. After blocking, the cells 
were incubated with the primary antibody (anti-p16, JC2; see Section 2.27.1) for 2 h at 
RT in “blocking solution”, and subsequently washed with “blocking solution” for 30 
min at RT. Cells were then incubated with the second antibody conjugated to a 
fluorescent-dye, DAPI and HCS Cell Mask Deep Red in “blocking solution” for 2 h at 
RT in the dark. After incubation with the secondary antibody and stains, the cells were 
washed three times with “blocking solution” and then twice with PBS. Plates were 
stored with 80 µL PBS in each well at 4°C, and imaged as detailed in Section 2.28.2. 
2.27.3 Staining cells for confocal microscopy 
Cells on coverslips 140 µm ± 15 µm thick were fixed 48 h post-transfection by 
aspirating all media from the wells, washing cells twice with 2.5 mL DPBS containing 
both magnesium and calcium (PAA Laboratories, UK) and subsequently fixing with 4% 
(w/v) PFA and 5% (w/v) sucrose in PBS (all Sigma-Aldrich, UK), for 15 min at RT. 
Following two washes in PBS, the cells were permeablised using 0.1% (v/v) Triton X-
100 (Sigma-Aldrich, UK) in PBS for 15 min at RT and subsequently washed in PBS. 
Cells were blocked for 1 h at RT in 5% (w/v) BSA (Sigma-Aldrich, UK) in PBS.  After 
blocking, coverslips were removed from wells onto a sheet of Parafilm M (Pechiney 
Plastic Packaging Company, IL, USA) and incubated with 100 µL of the primary 
antibody (see Section 2.27.1) in 1% (w/v) BSA in PBS for 1 h at RT. Following 
incubation with primary antibody, the coverslips were returned to a fresh 6 round-well 
plate (ThermoFisher Scientific, MA, USA) before washing three times with 1 mL PBS. 
Coverslips were again removed onto a sheet of Parafilm M and probed with the 
appropriate secondary antibody conjugated to fluorescent-dye, and DAPI in 1% (w/v) 
BSA in PBS for 1 h at RT in the dark. Subsequently, coverslips were again returned to a 
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fresh 6 round-well plate and washed 3x in 2 mL PBS, before mounting onto microscope 
slides using FluorSaveTM Reagent (Merck Millipore, DE). Slides were stored at 4°C in 
the dark. Cells were viewed using a Zeiss LSM710 confocal laser scanning microscope 
based on an Axiovert inverted microscope (Carl Ziess, DE) with a 20x air, 40x oil 
immersion or 63x oil immersion objective with numerical apertures of 1.3, 1.4 and 1.4, 
respectively. Laser lines 405 nm, 488 nm and 555 nm were used to excite DAPI, Alexa 
Fluor® 488 and Alexa Fluor® 555, respectively. The pinhole was set to 5 airy units for 
all experiments. Images were acquired with sequential scanning to allow cross-talk free 
DAPI, Alexa Fluor® 488 and Alexa Fluor® 555 images to be collected. 
2.28 High-content fluorescence microscopy 
2.28.1 System. 
All high-content fluorescence microscopy images were captured using the IN Cell 1000 
automated microscope (GE Healthcare, UK) at 10x magnification and analysed using 
Developer Toolbox 1.7 (GE Healthcare, UK). 
2.28.2 Imaging 
Cells in 384-well plates at 48 h post transfection (see Section 2.11.1.1) were imaged for 
Brightfield (150 ms exposure) and siGLO (535 nm excitation; 1500 ms exposure) at 10x 
magnification, with two images taken per well.  
 
Cells fixed and stained in 384-well plates for high-content analysis were imaged for 
DAPI (360 nm excitation; 500 ms exposure), Alexa Fluor® 488 (475 nm excitation; 500  
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Figure 2-1. In Cell analysis protocol for transfected cells. 
A. Nuclei stained with DAPI (blue) are selected by intensity, then counted and measured 
by the software (Developer Toolbox 1.7). Cyan overlay marks counted and measured 
nuclei. B. Cell Mask (red) staining is detected by the software and split into individual 
cells using the DAPI stain as a guide; the area of each cell was subsequently measured. 
Cyan overlay mark cells measured by the software. C. p16 intensity was measured in 
each nuclei is measured using the guide previously created using the DAPI staining. 
Yellow and cyan outlines represent previously marked nuclei and cells, respectively.  
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ms exposure) and HCS Cell Mask Deep Red (620 nm excitation; 10 ms exposure) at 
10x magnification, with nine images acquired per well.  
 
2.28.3 Analysis 
Images taken for high-content analysis were examined using a protocol designed to 
examine multiple variables within the cell, namely: cell number; cell area; nuclear area; 
and nuclear green fluorescence (anti-p16 antibody) intensity.  
 
Both cell number and nuclear area were measured using the DAPI staining of nuclei 
(Figure 2-1 panel A). The protocol was programmed to recognise the whole of each 
nuclei, whilst disregarding any background fluorescence, allowing the nuclei to be 
counted and measured at the same time.  
 
The cellular area of each cell was measured using the HCS Cell Mask Deep Red, which 
stained all nucleic acid in each cell, allowing the area of each cell to be easily visualised 
against the background (Figure 2-1 panel B). However, as many of the cells were in 
contact, there was a requirement for the individual cells to be isolated, so the area of 
each could be accurately measured. To achieve this, the protocol was programmed to 
use the nuclei previously identified as markers for individual cells, and split the cell 
areas accordingly, so that each ‘cell’ contained a single nuclei.  
 
Finally, the relative fluorescence intensity of p16 was measured in the nuclei of each 
cell (Figure 2-1 panel C). In order to carry out this measurement, the protocol was 
programmed to measure the relative green fluorescence within each area previously 
defined as a nuclei.  
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2.29 Statistical analysis of results 
All experiments in this investigation were completed in triplicate unless otherwise 
stated in the text. All statistical analysis was performed using Prism v5.0d (GraphPad 
Software Inc, CA, USA). 
2.29.1 Welch’s t test 
The unpaired two-tailed t test was used when the means of only two samples (with 
unequal variances) were to be compared.  
2.29.2 One-way ANOVA 
Performing multiple t-tests on a set of more than two samples can result in a ‘statistical 
test theory type 1 error’ (a false positive), where a hypothesis that should have been 
rejected, is in fact accepted. Therefore, the one-way analysis of variance (ANOVA) was 
used to statistically analyse data where three or more means had to be tested.  
 
In many cases throughout this study, a Dunnett’s multiple comparison follow up test 
was also used to compare individual conditions within an experiment to a control 
condition.  
 
One problem with the ANOVA, is that it is impossible for the statistics software being 
used (Prism 5.0d; GraphPad Software Inc, CA) to calculate exact p values for this 
statistical test. Statistical significance is only accurately calculated as an arbitrary ‘q 
value’, which has no real meaning outside of the program. Approximate p values are 
however reported in the form, p < 0.05 or p < 0.001 etc. More information about this 
issue can be found at http://www.graphpad.com/support/faqid/189/ (accessed October 
2013).  
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Chapter Three 
 
3  Characterisation of 
ABCB5 isoforms at the 
protein level 
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3.1 Introduction 
The ABCB5 gene is predicted to encode an integral, dodecaspan membrane protein of 
the ABC superfamily of transport proteins. Members of the ABCB family of 
transporters are reported to efflux a wide variety of substrates across cellular 
membranes, ranging from chemotherapeutic agents (ABCB1) and peptides (ABCB2 
and ABCB3), to lipids such as phosphatidylcholine (ABCB4; (Szakács et al., 2006). Of 
the four ABCB5 isoforms described (ABCB5fl, ABCB5α, ABCB5β and ABCB5γ), 
only the two longest isoforms, ABCB5fl and ABCB5β, are thought to encode active 
efflux transporters (Frank et al., 2005, Kawanobe et al., 2012). As neither ABCB5α nor 
ABCB5γ contain a TMD, and as both only have a partial NBD, they are highly unlikely 
to be able to act as transporters. It has been previously postulated, however, that the 
ABCB5α peptide could be involved in the regulation of transport, and that the ABCB5α 
mRNA could reduce expression of the ABCB5 gene, or increase message stability of 
ABCB5fl or ABCB5β (Gottesman, 2004, Chen et al., 2005a).  
 
Shortly after it was first described, ABCB5β was proposed to have a role in progenitor 
cell fusion (Frank et al., 2003), although this result has not been studied any further or 
reported since. More recently it has been reported that ABCB5β is highly expressed in 
the cancer stem cell-like malignant melanoma initiating cells (MMICs; (Frank et al., 
2003, Schatton et al., 2008). As such, the majority of the research carried out since this 
discovery has been concerned with using antibodies – both commercially available, and 
in-house generated – purportedly against ABCB5β to mark MMICs (Ma et al., 2010, 
Schatton et al., 2010, Frank et al., 2011, Ramgolam et al., 2011, Wilson et al., 2011, 
Linley et al., 2012, Aldaz et al., 2013, Mathieu et al., 2014). 
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As a consequence, the other isoforms of ABCB5 are relatively uncharacterised both in 
terms of their structure and function. The limited research on characterisation has 
revolved around the postulation that ABCB5fl and ABCB5β would be able to transport 
chemotherapeutic drugs, due to their sequence similarity with ABCB1. The first 
published experiments to test this were carried out by the Frank Group (Harvard, MA, 
USA) in cells with endogenous ABCB5β expression, but no ABCB5fl expression 
(evaluated by antibody binding), and the authors reported that this truncated protein 
could transport both rhodamine-123 and doxorubicin (Frank et al., 2003, Frank et al., 
2005). Subsequently, a separate group using exogenously expressed ABCB5β or 
ABCB5fl, reported that ABCB5β was unable to transport the previously reported 
substrates (Chen et al., 2009). ABCB5fl expression was, however, found to effectively 
confer drug resistance to multiple chemotherapeutic drugs including anthracycline, 
mitoxantrone, and epipodophyllotoxin (Gillet et al., 2009, Chen et al., 2009). In support 
of this latter finding, another group also found that ABCB5fl could confer resistance to 
anthracyclines and taxanes when stably expressed in HEK293 cells (Kawanobe et al., 
2012).  
 
When ABCB5β was reported to have a role in progenitor cell fusion, the protein was 
proposed to localise to the plasma membrane, due to flow cytometry analysis of 
antibody binding (Frank et al., 2003). This same paper, however, also showed clear 
intracellular staining using the same antibody when permeablised cells are examined by 
immunofluorescence microscopy, which suggested that the vast majority, if not all, of 
the protein is actually retained intracellularly (Frank et al., 2003). Intracellular 
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localisation of ABCB5β has also been observed by others (Linley et al., 2012, Mathieu 
et al., 2014).  
3.1.1 Aims 
The overall hypothesis for the work detailed within this chapter was that ABCB5fl and 
ABCB5β are plasma membrane proteins that can be expressed effectively in a variety of 
cell types, conferring resistance to a variety of toxic xenobiotic compounds. The 
hypothesis of this project was studied by transiently expressing the two largest isoforms 
of ABCB5, ABCB5fl and ABCB5β, in a naive cell type, and to using this platform to 
further characterise the proteins. Specifically, the aims were to: 
• Express EGFP- or His-tagged ABCB5fl and ABCB5β in a mammalian cell line, 
and confirm protein expression by western blotting and confocal microscopy; 
• Evaluate the sub-cellular localisation of ABCB5fl and ABCB5β using EGFP-
tagged proteins; 
• Create point mutations to prevent ATP catalysis by ABCB5fl and ABCB5β, and 
investigate the effect on expression, localisation and transport function; 
• Generate TaqMan primer/probe sets against ABCB5fl and ABCB5β to 
distinguish between the two isoforms at the mRNA level; and 
• Utilise RT-qPCR and western blotting to characterise endogenous ABCB5fl and 
ABCB5β expression at the mRNA and protein level in cell lines for further 
study. 
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3.2 Results 
3.2.1 ABCB5fl and ABCB5β  protein expression in HEK293T 
cells 
In order to study ABCB5fl and ABCB5β protein expression effectively, a transient 
expression system in HEK293T cells was chosen, which allowed for changes in the 
protein to be easily made via point mutation of the plasmid. A similar approach has 
been used previously to study other ABCB family transporters with great success 
(Zolnerciks et al., 2007, Groen et al., 2011).  
 
Plasmids encoding ABCB5fl or ABCB5β with either a C-terminal V5 and 6-histidine 
(V5-6His) tag or a C-terminal enhanced green fluorescent protein (EGFP) tag were 
obtained. These plasmids encoding ABCB5fl (pcDNA3.1-ABCB5fl-wt_V5-6His, 
pcDNA3.1-ABCB5fl-wt_EGFP), and ABCB5β (pcDNA3.1-ABCB5β-wt_V5-6His, 
pcDNA3.1-ABCB5β-wt_EGFP), were kindly provided by Prof. Michael Gottesman 
(NIH, Maryland, MD, USA; Table 2-2).  
 
The plasmids were transfected into HEK293T cells in 6-well plates using PEI 
conditions previously optimised for expression of ABCB1 (Zolnerciks et al., 2007), and 
successfully used with a variety genes such as ABCB1, ABCB4, CDC50, ATP8B1, 
CD36 and FATP4 (see Section 2.10), along with the appropriate control plasmid, which 
lacked any inserted gene (pcDNA3.1-EGFP or pcDNA3.1-V5-6His). 
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3.2.1.1 Immunoblot analysis of ABCB5fl and ABCB5β  transiently 
expressed in HEK293T cells 
In order to assess the transfection efficiency of the HEK293T cells, and the expression 
of the two ABCB5 isoforms, three commercially available antibodies were purchased, 
each reported to recognise both ABCB5fl and ABCB5β (Table 2-21). Whole cell 
lysates were prepared from HEK293Ts 48 h after transfection and 0.5 µg of total 
protein from each sample was separated by electrophoresis through a 7.5% SDS-PAGE 
gel. The samples were transferred onto a nitrocellulose membrane and blocked before 
incubation with the appropriate antibodies. 
 
The anti ABCB5 antibody purchased from Atlas Antibodies AB (Atlas) was found to 
recognise specific proteins migrating as 140 kDa and 90 kDa species in samples 
prepared from HEK293T cells transfected with plasmids encoding ABCB5fl and 
ABCB5β proteins, respectively (Figure 3-1 panel A). These bands correspond 
accurately to the predicted molecular weights of ABCB5fl (138 kDa) and ABCB5β (89 
kDa). In addition to the proteins at the predicted molecular weights, further smaller 
molecular weight species were observed on the western blot. As the Atlas antibody 
detected no protein in either of the control samples (untransfected HEK293T cells, or 
cells transfected with an empty vector), it was hypothesised that these are degradation 
products of ABCB5fl and ABCB5β that retain the Atlas antibody epitope, and were not 
due to non-specific binding. This result also demonstrated that there was no (or 
undetectable levels of) ABCB5fl or ABCB5β protein expressed endogenously in 
HEK239T cells.  
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Figure 3-1. Western blot analysis of ABCB5 expression in transfected HEK293T cells 
using three commercially available antibodies.  
Lysates prepared from untransfected HEK293T cells, and HEK293T cells transfected 
with empty vector (pcDNA3.1-V5-6His), a plasmid encoding ABCB5fl (pcDNA3.1-ABCB5fl-
wt_V5-6His), or a plasmid encoding ABCB5β  (pcDNA3.1-ABCB5β-wt_V5-6His) were 
probed using three commercially available antibodies. A. Anti-ABCB5 (Atlas) detected 
proteins at the expected molecular weights for ABCB5fl (140 kDa) and ABCB5β  (90 kDa) 
in the appropriate samples. B. Anti-ABCB5 (Rockland) detected multiple proteins 
migrating with apparent molecular weights of less than ABCB5fl and ABCB5β . C. Anti-
ABCB5 (Sigma) failed to detect any protein. Protein loading was controlled in all western 
blots using an anti-β-tubulin antibody at different exposures, to ensure a strong signal. 
Arrows show the predicted molecular weights of ABCB5fl (red) and ABCB5β  (blue). n = 2 
biological repeats. 
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In addition to the Atlas antibody, two others that have previously been used in 
published studies were purchased from Sigma Aldrich Ltd (Sigma) (Linley et al., 2012, 
Grimm et al., 2012), and Rockland Inc. (Rockland) (Wilson et al., 2011, Ramgolam et 
al., 2011). When these two antibodies were used to probe blots generated from 
transfected HEK293T cell lysates, no bands corresponding to the predicted molecular 
weights of ABCB5fl or ABCB5β were detected (Figure 3-1 panels B and C).  
 
]The Rockland antibody recognised proteins in all samples prepared from transfected 
HEK293T cells, including the negative controls. Two proteins were detected in each 
sample, of approximately 70 kDa and 55 kDa. A larger protein was also present in each 
of the samples prepared from transfected HEK293T cells, which migrated with an 
apparent molecular weight of approximately 75 kDa. None of the observed protein 
species correlated with the predicted size of either ABCB5fl or ABCB5β, suggesting 
that the antibody does not detect either isoform under the conditions tested. The three 
proteins detected are most likely due to non-specific antibody binding to cellular 
unrelated to either ABCB5fl or ABCB5β.  
 
The Sigma antibody failed to detect any proteins by western blotting in any of the 
samples tested, also suggesting that in the conditions utilised, this antibody is 
ineffective at detecting either ABCB5fl or ABCB5β protein.  
 
These western blots show that the Atlas antibody for ABCB5 is the most suitable for 
further use in this study. It is curious that the other two antibodies tested could not 
detect ABCB5fl or ABCB5β as both of these have previously been used in published 
studies to report ABCB5fl and ABCB5β expression. 
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3.2.1.2 Expression of EGFP-tagged ABCB5fl and ABCB5β  
In addition to the analysis of transient ABCB5fl and ABCB5β expression in HEK239T 
cells by western blot, both expression and localisation were studied by confocal 
microscopy of HEK293T cells transfected with plasmids encoding EGFP-tagged 
ABCB5fl or ABCB5β. As ABCB5β has previously been reported to be present at the 
plasma membrane of melanoma cells (Frank et al., 2003), this was the expected 
subcellular location of both ABCB5fl and ABCB5β.  
 
Confocal analysis of transfected HEK293T cells showed a high transfection efficiency, 
with around 80% of cells exhibiting green fluorescence when transfected with the 
CD36_Venus positive control plasmid pcDNA3.1-CD36_Venus (Figure 3-2). Low 
transfection efficiency was observed with both the ABCB5fl and ABCB5β expressing 
plasmids, with approximately 5% of cells found to express either protein isoform. Of 
the cells expressing either ABCB5fl or ABCB5β, the majority of cells express the 
proteins at low levels, but small numbers of cells display very high levels of expression. 
None of the ABCB5 expressing cells were found to have fluorescently tagged ABCB5 
protein at the plasma membrane, with all observed fluorescence seen intracellularly, as 
opposed to the plasma membrane localisation observed with CD36_Venus expression.  
 
As the protein was not found to localise to the plasma membrane, the opportunity to 
carry out informative functional studies of ABCB5fl and ABCB5β is greatly reduced. It 
should be noted that although ABCB5β was proposed to be present at the plasma 
membrane, the reporting paper clearly showed intracellular staining of ABCB5β in  
 
 
Figure 3-2. Immunofluorescence analysis of ABCB5fl and ABCB5β  expression in HEK293T cells. 
Representative images show untransfected HEK293T cells, or cells transfected with pcDNA3.1-EGFP, pcDNA3.1-ABCB5fl-wt_EGFP, 
pcDNA3.1ABCB5β-wt_EGFP, or pcDNA3.1-CD36_Venus. Fluorescently tagged ABCB5fl, ABCB5β  and CD36 protein (green) and DAPI staining of 
nuclei (blue) were observed 48 h post transfection at 40x magnification. n = 4 biological repeats.  
melanoma cells with a non-commercially available antibody (Frank et al., 2003). This 
localisation was also published in both Linley et al., (2012) and Mathieu et al., (2014) 
supporting the findings reported here (see Section 3.3.2). 
3.2.1.3 ABCB5fl-EGFP and ABCB5β-EGFP localise to the  
endoplasmic reticulum in HEK293T cells 
To further study the localisation of ABCB5fl-EGFP and ABCB5β−EGFP in HEK293T 
cells, the cells were fixed, permeablised and co-stained with an antibody against the 
carboxy-terminal ER retention sequence KDEL, and an appropriate secondary antibody 
(Figure 3-3 panel A).  
 
In cells expressing either ABCB5fl-EGFP or ABCB5β-EGFP, co-localisationI of the 
EGFP tag and the ER KDEL marker is apparent, strongly suggesting that the EGFP-
tagged ABCB5 isoforms do not traffic beyond the ER. In order to confirm co-
localisation, line scans were performed on the images (Figure 3-3 panel B). These 
revealed that the vast majority of green fluorescence from EGFP tagged ABCB5fl 
(93.3%) or ABCB5β (94.8%) was found within regions of high red fluorescence, 
supporting the hypothesis that both ABCB5fl and ABCB5β are retained intracellularly.   
 
No fluorescence was visualised in the plasma membrane of any cells expressing the 
proteins, disputing earlier claims that this is the primary location of ABCB5β   
 
                                                
 
I Due to the limitations of the objectives of confocal microscope being used, the maximum resolution that can be 
achieved is 240 nm. Therefore, co-localisation is defined in this study as being when two fluorophores are within 240 
nm of each other. 
Figure 3-3. Subcellular localisation of ABCB5fl and ABCB5β  in HEK293T cells. 
A. Representative images show untransfected HEK293T cells, or cells transfected with pcDNA3.1-EGFP, pcDNA3.1-ABCB5fl-wt_EGFP, or 
pcDNA3.1ABCB5β-wt_EGFP. Fluorescently tagged ABCB5fl and ABCB5β  protein (green), fluorescently labelled KDEL (red), and DAPI staining of 
nuclei (blue) were observed 48 h post transfection at 40x magnification. n = 4 biological repeats. 
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Figure 3-3. (continued) Subcellular localisation of ABCB5fl and ABCB5β  in HEK293T cells. 
B. Representative images show untransfected HEK293T cells, or cells transfected with pcDNA3.1-EGFP, pcDNA3.1-ABCB5fl-wt_EGFP, or 
pcDNA3.1ABCB5β-wt_EGFP. Fluorescently tagged ABCB5fl and ABCB5β  protein (green), fluorescently labelled KDEL (red), and DAPI staining of 
nuclei (blue) were observed 48 h post transfection at 63x magnification. White boxes represent magnified area in the subsequent image. Line 
graphs show KDEL (red) and EGFP (green) fluorescence along the white arrow in each magnified image. Areas of the EGFP fluorescence within 
areas of KDEL fluorescence are filled in green. This area is represented as a percentage of total EGFP fluorescence in each figure legend. n = 4 
biological repeats. 
(Frank et al., 2003), and supporting visual evidence of an intracellular localisation of 
ABCB5β (Linley et al., 2012, Mathieu et al., 2014). 
3.2.2 Cytotoxicity and mutation of ABCB5fl and ABCB5β  
In a previous study, the closely related ABC transporter, ABCB4, was found to have a 
cytotoxic effect when over-expressed in HEK293T cells (Groen et al., 2011). It was 
therefore hypothesised that the low expression of ABCB5fl and ABCB5β observed may 
be due to a similar cytotoxic effect in these transfected cells. In order to test this 
hypothesis, two approaches were used: an LDH assay to measure the release of a 
cytosolic enzyme, and the generation of ‘inactive’ ABCB5 isoforms to examine whether 
these are better tolerated. 
3.2.2.1 ABCB5fl and ABCB5β  are not cytotoxic in HEK293T cells 
The LDH assay measures the activity of the stable cytosolic LDH enzyme in the culture 
supernate, where higher activity denotes more LDH release due to cell lysis, and 
therefore higher levels of cytotoxicity. The level of LDH release from untransfected 
cells was compared to that of cells transfected with an empty vector, or transfected with 
a vector expressing ABCB5fl or ABCB5β. 
 
The previously published study (Groen et al., 2011), found that expression of ABCB4 in 
HEK293T cells caused a 3-fold increase in LDH release from cells compared to a 
vector only control (Figure 3-4 panel A). In contrast to this, no significant changes in 
LDH release were observed upon transfection of plasmids containing ABCB5fl or 
ABCB5β into HEK293T cells (Figure 3-4 panel B), when compared to the empty 
control plasmids. These results suggested that neither ABCB5fl nor ABCB5β were 
cytotoxic to HEK293T cells. 
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Figure 3-4. ABCB5fl and ABCB5β  expression in HEK293T cells do not cause cell death. 
A. Expression of ABCB4 in HEK239T cells causes cytotoxicity as measured by increased 
LDH release (Groen et al., 2011)I. B. Introduction of vectors encoding ABCB5fl or 
ABCB5β  into HEK293T cells caused no significant change in cell cytotoxicity compared 
to the introduction of empty vectors, as measured by percentage LDH release 48 h post 
transfection. Error bars represent 1 SD, n = 3 biological repeats.  
3.2.2.2 Generation of ‘non-functional’ ABCB5fl and ABCB5β  mutants 
To confirm that ABCB5fl and ABCB5β are not cytotoxic to cells, and to rule out that 
the primary active function of the isoforms was not responsible for the low level of 
expression, mutations were made in the Walker B motifs of ABCB5fl and ABCB5β to 
prevent ATP hydrolysis. The consensus sequence of the Walker B motif is hhhhDE 
(where h is any hydrophobic amino acid), with the glutamate residue being essential for 
ATP hydrolysis (Hanson and Whiteheart, 2005). This glutamate residue was therefore 
mutated to encode a glutamine, by site-directed mutagenesis of the two Walker B motifs 
in NBD1 and NBD2 of ABCB5fl (E550 in NBD1 and E1181 NBD2), and the single  
 
                                                
 
I Reproduced and adapted from: Groen et al., (2011) Complementary Functions of the Flippase ATP8B1 and the 
Floppase ABCB4 in Maintaining Canalicular Membrane Integrity, Figure 1 panel D; with permission of the publisher 
(Gastroenterology). License number 3371380502686.  
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Figure 3-5. Mutation of the conserved Walker B glutamate residues in ABCB5fl and 
ABCB5β . 
A. The predicted structure of ABCB5fl as generated by the I-TASSER prediction server, 
based on the mouse Abcb1 structure (see Section 1.5.1). NBDs are shown in blue and 
TMDs are shown in red. The black arrow on the left image signifies the viewpoint of the 
right hand image, in which the TMD sequences are also removed for clarity. Conserved 
glutamate residues (green) are shown at the NBD:NBD interface. B. The Walker B motif 
(purple) in the NBD1 is conserved across multiple ABC transporters. The essential 
glutamate residue (green) was mutated to a glutamine with a CAG > GAG codon 
mutation. C. The Walker B motif (purple) in the NBD2 is conserved across multiple full 
ABC transporters; ABCD1 and ABCB6 are both half transporters and lack NBD2. The 
essential glutamate residue (green) was mutated to a glutamine with a CAG > GAG 
codon mutation. 
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Walker B motif in ABCB5β (E736 in NBD2, equivalent to E1181 in ABCB5fl; Figure 
3-5 panel A). 
 
NBD1 of ABCB5fl was mutated by site-directed mutagenesis using the mutagenic 
primers described in Table 2-3, to make an 1885G>C alteration in the cDNA sequence 
(Figure 3-5 panel B). NBD2 of both ABCB5fl and ABCB5β were mutated to 3778G>C 
and 2752G>C, respectively (Figure 3-5 panel C). As a result of the mutation 
experiments, plasmids encoding EGFP- and V5-6His- tagged mutants of ABCB5fl and 
ABCB5β were generated at follows: ABCB5fl NBD1 mutant (pcDNA3.1-ABCB5fl-
E550Q_EGFP or _V5-6His); ABCB5fl NBD2 mutant (pcDNA3.1-ABCB5-
E1181Q_EGFP or _V5-6His); ABCB5fl NBD1 and NBD2 double mutant (pcDNA3.1-
ABCB5fl-E550/1181Q_EGFP or _V5-6His); and ABCB5β NBD2 mutant (pcDNA3.1-
ABCB5β-E736Q_EGFP or _V5-6His). 
3.2.2.3 Expression of ABCB5fl and ABCB5β  Walker B mutants in 
HEK293T cells 
The predicted non-functional mutants of ABCB5fl and ABCB5β were transfected into 
HEK293Ts as before so that any effect on expression and localisation could be 
evaluated.  
 
Western blotting of the ABCB5fl mutant showed small variations in the amount of total 
protein, and relative sizes of each band for each individual mutation (Figure 3-6 panel 
A).  Fluctuations in total protein were observed with expression of both the single 
Walker B mutants (NBD1 mutant – pcDNA3.1-ABCB5fl-E550Q_V5-6His; NBD2  
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Figure 3-6. Expression of ABCB5 Walker B mutants in HEK293T cells. 
A. Western blotting of whole cell lysates from HEK293Ts transfected with wild type and 
mutant ABCB5fl or ABCB5β  show small variations in expression. Arrows show the 
predicted molecular weights of ABCB5fl (red) and ABCB5β  (blue). B. Quantitation of 
western blotting by densitometry, normalised to β-tubulin expression, shows no 
significant changes in protein expression between wild type and mutant forms of 
ABCB5fl and ABCB5β . n = 3 biological repeats.  
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mutant – pcDNA3.1-ABCB5fl-E1181Q_V5-6His), and the double mutant of ABCB5fl 
(pcDNA3.1-ABCB5fl-E550/1181Q_V5-6His). Small changes in the protein level of the 
ABCB5β mutant (pcDNA3.1-ABCB5β-E736Q_V5-6His) were also observed when 
compared to the β-tubulin loading control. Densitometric analysis of the western 
blotting results showed no significant changes in expression, of the highest molecular 
weight species, between the ABCB5fl and ABCB5β mutant and wild type proteins, 
when compared to β-tubulin (Figure 3-6 panel B). The lower molecular weight proteins 
detected on the western blot were not included in the densitometric analysis, as these 
most likely represent partially degraded protein species, and may not accurately 
represent the protein they are derived from.  
 
This data suggests that the ability of ABCB5fl and ABCB5β to hydrolyse ATP is not 
related to the low level of expression observed for these proteins. It is possible that the 
protein does not require ATP to function, however, this is unlikely as ATP-independent 
function has not been previously been reported for any human ABC transporters.  
 
In addition to western blot analysis of the mutants, -EGFP tagged ABCB5fl and 
ABCB5β mutants were expressed in HEK293T cells, fixed, and stained with DAPI and 
KDEL as previously described, in order to assess whether any changes in protein 
localisation had occurred in response to mutation.  
 
Low expression levels of mutant ABCB5fl and ABCB5β protein were observed, 
resembling the levels previously seen for wild type protein (Figure 3-7 panel A). Co-
localisation of fluorescently tagged mutant ABCB5fl and ABCB5β was seen with the  
Figure 3-7. Subcellular localisation of ABCB5fl and ABCB5β  Walker B mutants in HEK293T cells. 
Representative images showing HEK293T cells transfected with wild type or mutant ABCB5fl or ABCB5β . Fluorescently tagged ABCB5fl and 
ABCB5β  (green), fluorescently labelled KDEL (red), and DAPI staining of nuclei (blue) were observed 48 h post transfection at 40x and 63x 
magnification. White boxes represent magnified areas in the panels B and C. n = 4 biological repeats. 
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Figure 3-7. (Continued) Subcellular localisation of ABCB5fl and ABCB5β  Walker B mutants in HEK293T cells. 
Representative images showing HEK293T cells transfected with wild type or mutant ABCB5fl or ABCB5β . Fluorescently tagged ABCB5fl and 
ABCB5β  (green), fluorescently labelled KDEL (red), and DAPI staining of nuclei (blue) were observed 48 h post transfection at 63x magnification 
(zoomed to 126x). Line graphs show KDEL (red) and EGFP (green) fluorescence along the white arrow in each magnified image. Areas of the 
EGFP fluorescence within areas of KDEL fluorescence are filled in green. This area is represented as a percentage of total EGFP fluorescence in 
each figure legend. n = 4 biological repeats. 
 133 
Figure 3-7. (Continued) Subcellular localisation of ABCB5fl and ABCB5β  Walker B mutants in HEK293T cells. 
Representative images showing HEK293T cells transfected with wild type or mutant ABCB5fl or ABCB5β . Fluorescently tagged ABCB5fl and 
ABCB5β  (green), fluorescently labelled KDEL (red), and DAPI staining of nuclei (blue) were observed 48 h post transfection at 63x magnification 
(zoomed to 126x). Line graphs show KDEL (red) and EGFP (green) fluorescence along the white arrow in each magnified image. Areas of the 
EGFP fluorescence within areas of KDEL fluorescence are filled in green. This area is represented as a percentage of total EGFP fluorescence in 
each figure legend. n = 4 biological repeats. 
ER marker KDEL, mirroring earlier results (Figure 3-7 panels B and C). Line scans of 
cells exhibiting co-localisation of EGFP and KDEL confirmed these findings, with the 
majority of green fluorescence marking ABCB5fl and ABCB5β locations found within 
areas of red fluorescence marking the ER.  
 
Together, these data show that the single and double Walker B mutations of ABCB5fl 
and ABCB5β did not have any effect on their expression and localisation. Although 
there is a possibility that the hydrolysis of ATP is not required for protein function, it is 
more probable that the activity of the proteins has no bearing on their localisation within 
the cell.  In fact, as earlier suggested, the localisation seen in these experiments could be 
correct, as all previous studies claiming a plasma membrane localisation have been 
carried out using antibodies, and not tagged protein.  
3.2.3 Primers for ABCB5 isoforms 
3.2.3.1 TaqMan primer/probe generation 
The success of the transient transfection experiments allowed conditions for RT-qPCR 
to be optimised for both ABCB5fl and ABCB5β using mRNA extracted from 
untransfected and transfected HEK293T cells. 
 
TaqMan primer/probe sets were purchased to amplify ABCB5fl and ABCB5β cDNA 
(Table 2-4). A pre-designed primer/probe set (tmABCB5) was purchased from Life 
Technologies Ltd (UK), to amplify a sequence common to both ABCB5fl and 
ABCB5β (Figure 3-8). Two additional primer/probe sets were designed, and purchased, 
to distinguish between ABCB5fl (tmABCB5flonly; using the 5’ mRNA sequence unique 
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to this isoform), and ABCB5β (tmABCB5βonly using the, 197 nucleotide, retained 
intronic sequence in the 5’-UTR; Appendix I). 
 
Figure 3-8. TaqMan target sites within the ABCB5 cDNA sequence. 
Cartoon illustrating the positions of the qPCR primer and probe binding sites within the 
mature mRNAs of ABCB5β  and ABCB5fl. Binding sites of the primer/probe sets 
tmABCB5, tmABCB5flonly and tmABCB5βonly and are shown in red, purple and blue 
respectively.  
Although primer/pair tmABCB5βonly has the possibility of targeting ABCB5α and 
ABCB5γ in addition to ABCB5β, this is the only region of the gene that can be targeted 
to distinguish between ABCB5fl and ABCB5β.  
 
3.2.3.2 Primer/probe validation using transiently-transfected 
HEK239T 
The generated primer/probe sets were validated using cDNA generated from HEK293T 
cells transfected with the ABCB5fl and ABCB5β encoding plasmids pcDNA3.1-
ABCB5fl-wt_EGFP and pcDNA3.1-ABCB5β-wt_EGFP, and the control plasmid 
pcDNA3.1-EGFP. The data were normalised against the expression of GAPDH 
(primer/probe set tmGAPDH) for each of the samples (Figure 3-9 panels A and B). 
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Figure 3-9. TaqMan primer/probe validation in transfected HEK293T cells. 
Validation of TaqMan primer/probe sets for ABCB5fl (tmABCB5 (red) and tmABCB5flonly 
(purple)) and ABCB5β  (tmABCB5 and tmABCB5βonly (blue)) was performed on cDNA 
derived from HEK293T cells transiently transfected with pcDNA3.1-EGFP, pcDNA3.1-
ABCB5fl-wt_EGFP or pcDNA3.1-ABCB5β-wt_EGFP. A. The presence of ABCB5fl was 
detected by both tmABCB5 and tmABCB5flonly. The presence of ABCB5β  was only 
detected by tmABCB5 B. qPCR cT values show that in conditions where no expression 
was observed, the signal was completely undetected. Error bars represent 1 SD from the 
triplicate mean. n = 3 biological repeats. 
No endogenous expression of ABCB5fl or ABCB5β was detected in HEK293Ts at the 
mRNA level, making them an ideal cell line to validate the specificity of the TaqMan 
primer/probe sets. Primer/probe set tmABCB5 detected expression in cells transfected 
with the plasmids encoding either ABCB5fl or ABCB5β, but not in cells transfected 
with the empty vector, showing that this primer/probe set can amplify both ABCB5fl 
and ABCB5β specifically. tmABCB5flonly was specific for ABCB5fl, as product was 
only detected in cDNA prepared from cells transfected with pcDNA3.1-ABCB5fl-
wt_EGFP. Primer/probe set tmABCB5βonly did not amplify cDNA produced from any 
of the transfected cells, including the cells transfected with the pcDNA3.1-ABCB5β-
wt_EGFP plasmid, indicating that this primer/probe set is not effective at detecting 
expression of ABCB5β. 
 
For all subsequent qPCR experiments, the tmABCB5 and tmABCB5flonly 
primer/probe sets were used. The combined data from these allowed the expression of 
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both ABCB5fl and ABCB5β to be estimated even in the absence of a primer/probe set to 
specifically amplify ABCB5β. For example, in a sample where a high level of 
expression is observed with tmABCB5, but a low level of expression is seen with 
tmABCB5flonly, it can be deduced that the product amplified is from ABCB5β. 
3.2.4 Measuring the endogenous expression levels of ABCB5fl and 
ABCB5β  mRNA and protein in cell lines 
In order to discover cell lines with endogenous expression of ABCB5fl or ABCB5β, 
which could potentially be utilised for future study of the proteins, both RT-qPCR and 
western blotting were used to examine mRNA and whole cell lysate from six cell lines. 
The chronic myelogenous leukaemia (CML) cell line, K562, and the squamous cell 
carcinoma (SCC) cell line, A431, were used as positive controls, as endogenous 
expression of ABCB5β had previously been reported in both (Lehne et al., 2009). The 
melanoma cell lines A375M, WM1158, Mel224 and Mel505 were tested for expression 
of ABCB5fl and ABCB5β, as high expression ABCB5β is frequently reported in this 
type of cancer. 
 
Expression of ABCB5fl and ABCB5β was studied relative to the expression of the 
housekeeping gene GAPDH in each of the cell lines. Expression of ABCB5fl mRNA 
was only detected in the K562 (2.89 x 10-3% ± 0.56 x 10-3%) and A431 (1.44 x 10-3% ± 
0.36 x 10-3%) cell lines (Figure 3-10 panel A). Expression of ABCB5β mRNA was 
observed in cDNA generated from both of the control cell lines K562 (0.115% ± 
0.010%) and A431 (0.060% ± 0.005%), as well as the melanoma cell lines Mel224 
(0.027% ± 0.002%) and Mel505 (0.012% ± 0.003%). In total ABCB5fl mRNA 
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expression was found at much lower levels compared to ABCB5β (40 fold lower 
in K562, and 42 fold lower in A431) in expressing cells.  
 
Figure 3-10. Endogenous expression of ABCB5 in multiple cancer cell lines. 
A. qPCR was carried out on cDNA derived from a CML (K562), SCC (A431) and four 
melanoma (A375M, WM1158, Mel224 and Mel505) cell lines. ABCB5 expression (red) was 
detected in four (K562, A431, Mel224 and Mel505) of the six cell lines. ABCB5fl 
expression (purple) was detected at low levels in two (K562 and A431) of the cell lines. 
B. Low levels of ABCB5β  protein were detected by western blotting of whole cell lysates 
in four (K562, A431, Mel224 and Mel505) of the six evaluated cell lines. Arrows show the 
predicted molecular weights of ABCB5fl (red) and ABCB5β  (blue). 
 
Western blotting of whole cell lysates using the Atlas antibody for ABCB5 showed 
low-level expression of ABCB5β (89 kDa) in K562, A431, Mel224, and Mel505 cells 
(Figure 3-10 panel B). Although ABCB5fl mRNA was detected in both the K562 and 
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A431 cell lines, ABCB5fl (138 kDa) protein was not detected in either of these, or any 
of the other cell lines tested.  
 
Together, these data suggest that the K562, A431, Mel224 and Mel505 cell lines could 
be used to investigate the endogenous expression and function of ABCB5β, with the 
K562 line being the prime candidate, as it was found to have the highest protein 
expression level of the four.  
3.3 Discussion 
3.3.1 Summary of the findings 
A HEK293T-based transient expression system was chosen in which to study ABCB5fl 
and ABCB5β, as the same approach had already been used to study other ABCB family 
transporters with success (Zolnerciks et al., 2007, Groen et al., 2011).  PEI transfection 
of HEK293T cells was carried out using plasmids encoding ABCB5fl or ABCB5β, each 
with either a V5-6His or EGFP tag, and were analysed by western blotting or 
fluorescence microscopy, respectively.  
 
Western blotting was carried out using three commercially available antibodies, two of 
which have previously been included in published studies using endogenously 
expressed protein (Ramgolam et al., 2011, Wilson et al., 2011, Grimm et al., 2012, 
Linley et al., 2012). Western blot analysis carried out on cell lysates from untransfected 
HEK293Ts, and HEK293Ts transfected with either the empty V5-6His plasmid, or the 
plasmid encoding ABCB5fl or ABCB5β, showed that only one of the three antibodies 
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tested (Atlas) could specifically recognise both ABCB5fl and ABCB5β, where as the 
other two (previously published) antibodies (Rockland and Sigma) could not. 
 
Confocal analysis of HEK293Ts transfected with EGFP-tagged ABCB5fl and ABCB5β 
revealed poor transfection efficiency and low level expression compared to the positive 
control plasmid encoding Venus tagged CD36. The fluorescently labelled ABCB5fl and 
ABCB5β did not traffic to the plasma membrane as previously reported (Frank et al., 
2003), as all green fluorescence was observed in an intracellular localisation. Co-
localisation of both ABCB5fl and ABCB5β was observed with the ER marker KDEL, 
confirming the intracellular localisation of the proteins.  
 
The hypothesis that ABCB5fl and ABCB5β may be detrimental to HEK293Ts, thereby 
preventing proper expression and localisation, was investigated by an LDH activity 
assay and protein mutation. The LDH activity assay showed that no cytotoxicity was 
associated with transfection of plasmids containing ABCB5fl or ABCB5β compared to 
empty control plasmids. Predicted non-functional mutants of both ABCB5fl and 
ABCB5β were produced to investigate whether functional activity had any impact on 
expression and localisation. No significant changes in expression or localisation were 
observed upon transfection of any mutant protein into HEK293T cells, when compared 
to the wild type proteins. 
 
TaqMan primer/probe sets were generated in order to study ABCB5fl and ABCB5β 
mRNA levels. Primer/probe sets targeting either ABCB5fl or ABCB5β, and one 
targeting both were tested for specificity. The tmABCB5βonly was found to be 
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ineffective at detecting either transcript, and thus was not used any further. tmABCB5 
was able to detect both ABCB5fl and ABCB5β, and tmABCB5flonly was found to only 
detect ABCB5fl. A combination of the primer/probe sets tmABCB5 and 
tmABCB5flonly were used for all future RT-qPCR experiments so that the expression 
of ABCB5fl and ABCB5β could be delineated. 
 
Finally, the expression levels of endogenous ABCB5fl and ABCB5β mRNA and protein 
were tested in six cell lines. Expression of ABCB5β was detected in four of the cell lines 
at both the mRNA and protein level (K562, A431, Mel224, Mel505). ABCB5fl mRNA 
was only detected in two of the cell lines (K562, A431), with the protein undetectable in 
all samples.  
3.3.2 Discussion  
Antibodies against ABCB5β have previously been used in multiple published studies to 
identify endogenously expressing cells, and more commonly MMICs (Ma et al., 2010, 
Schatton et al., 2010, Frank et al., 2011, Ramgolam et al., 2011, Wilson et al., 2011, 
Linley et al., 2012, Aldaz et al., 2013, Mathieu et al., 2014). This investigation found 
that two of the commercially available antibodies used in previous studies for targeting 
ABCB5β are ineffective.  
 
The three antibodies evaluated in this study (Atlas, Rockland and Sigma) were used to 
target HEK293T cells that were untransfected, transfected with an empty vector, or 
transfected with a vector encoding either ABCB5fl or ABCB5β. The only antibody 
found to produce bands of the expected molecular weight for both ABCB5fl and 
ABCB5β (Atlas), only did so in protein samples taken from HEK293Ts transfected with 
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the relevant transcript, and not in either of the negative control samples. This signified 
that the Atlas antibody against ABCB5 is specific, and could be used for the further 
study of cells with endogenous ABCB5fl and ABCB5β expression. Multiple bands with 
lower molecular weights than those of ABCB5fl and ABCB5β were also observed with 
the antibody in each of the relevant samples. The most likely possibility is that these 
bands are seen due to ABCB5fl or ABCB5β protein degradation, resulting in smaller 
protein fragments containing the antibody binding epitope migrating down the gel along 
with the full size protein. It should also be noted that the pattern of bands in the 
ABCB5β expression HEK293T cells was very similar to that of the endogenously 
expressing K562, A431, Mel224 and Mel505 cell lines also tested for protein 
expression. This may suggest that the protein degradation which results in this banding 
pattern may have occured during or after the cell lysis step of protein recovery, although 
protease inhibitors were used, and at twice the manufacturer’s recommended 
concentration.   
 
Two antibodies used in previously published studies (Rockland and Sigma) were also 
tested (Ramgolam et al., 2011, Wilson et al., 2011, Linley et al., 2012, Grimm et al., 
2012), but were not found to produce any bands at the expected molecular weights in 
the same samples used to test the Atlas antibody. The Rockland antibody produced 
bands in all samples tested, including the sample taken from untransfected HEK293Ts, 
which do not endogenously express ABCB5fl or ABCB5β as suggested by the results 
obtained the Atlas antibody, and confirmed by RT-qPCR. The bands produced by the 
Rockland antibody were all below the expected molecular weight of ABCB5β (89 kDa), 
with two major bands present in all samples, and three bands present in the cells 
transfected with the empty vector, or the vector encoding ABCB5fl or ABCB5β. These 
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bands are unlikely to be due to unspecific antibody binding, due to the stringent washes 
used during the western blotting protocol, but are probably due to a contamination of 
the polyclonal antibody with antibodies which are not specific to ABCB5 and are in fact 
targeted to a different epitope than the one desired. The Sigma antibody failed to detect 
ABCB5fl or ABCB5β, or indeed any other protein in any of the samples tested, 
suggesting that is ineffective at detecting either of these isoforms of ABCB5.  
 
Overall expression of both ABCB5fl and ABCB5β was found to be relatively low when 
compared to cells transfected with the CD36 encoding control plasmid. This issue was 
not rectified by the mutation of the proteins, which was previously found to resolve this 
issue for ABCB4 (Groen et al., 2011). High expression of both ABCB5fl and ABCB5β 
mRNA was detected by RT-qPCR, suggesting that the low levels of protein observed 
are likely to be due to either inefficient translation or high turnover of the isoforms. 
Indeed, the band pattern observed on the western blots of transfected HEK293T lysates 
may be indicative of a high protein turnover due to ubiquitin mediated degradation by 
the 26S proteasome.  
 
One possible reason for a low translation efficiency is that the mRNA may contain one 
or more rare codons in its sequence, leading to longer than normal pauses within the 
translation mechanism as rare tRNAs (transfer RNAs) are needed to continue extending 
the peptide sequence. These longer than normal pauses in translation have been linked 
to both changes in protein stability (Tsai et al., 2008, Fung et al., 2014), and substrate 
specificity in ABCB1 (Fung et al., 2014, Kimchi-Sarfaty et al., 2007). It is, therefore, 
possible that the inclusion or rare codons within the ABCB5fl and ABCB5β mRNA may 
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cause a pause in translation which either stops translation altogether, or causes the 
protein to misfold, resulting in a protein which is targeted by the cell for degradation.  
 
Although ABCB5β has been described as having a plasma membrane localisation 
(Frank et al., 2003), papers have consistently included images which show ABCB5β as 
having an intracellular localisation (Figure 3-11) (Frank et al., 2003, Mathieu et al., 
2014, Linley et al., 2012). Although it should be noted that these papers only show 
ABCB5 targeted antibody binding and not tagged protein, this localisation is consistent 
with the results seen within this study where EGFP-tagged ABCB5fl and ABCB5β 
failed to reach the plasma membrane in all cells where it was overexpressed.  In 
addition, the predicted non-functional mutants of ABCB5fl and ABCB5β were also 
found in the same intracellular localisation as their wild type counterparts, suggesting 
that the function of these proteins has no effect on their localisation within the cell. It 
should also be noted that both ABCB2 (TAP1) and ABCB3 (TAP2) are localised within 
the ER (Kleijmeer et al., 1992), and ABCB6 is localised to the outer mitochondrial 
membrane (Krishnamurthy et al., 2006b), and as such, the intracellular localisation of 
ABCB family proteins is not without precedent. 
 
One of the supporting arguments that ABCB5β is present at the plasma membrane is 
that expression of the protein is reported to extrude doxorubicin from endogenously 
expressing cells (Frank et al., 2005). This data may be inaccurate, however, as ABCB5β 
expression was confirmed via antibody staining, which as previously stated here, may 
not be able to accurately determine the presence of ABCB5β. Additionally, the presence 
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Figure 3-11. Subcellular localisation of ABCB5 in previous studies. 
HEK293T were cells transfected with pcDNA3.1-ABCB5fl-wt_EGFP or pcDNA3.1ABCB5β-
wt_EGFP. Fluorescently tagged ABCB5fl and ABCB5β  (green) and DAPI staining of 
nuclei (blue). Immunofluorescent staining of ABCB5β  (green) and DAPI staining on 
nuclei (blue) in HEM (human epidermal melanocytes) and FM82 (human melanoma) cells 
was previously publishedI by Frank et al., (2003), and Linley et al., (2012). 
 
of other ABC transporters, such as ABCC1 and ABCG2, which are known to extrude 
doxorubicin (Calcagno et al., 2008, Jungsuwadee et al., 2012), was not properly ruled 
out. Therefore, it is likely these or other ABC proteins are responsible for the removal 
of doxorubicin from the cells as it is doubtful that ABCB5β is a functional protein. 
 
                                                
 
I Reproduced and adapted from: Frank et al., (2003) Regulation of Progenitor Cell Fusion by ABCB5 P-glycoprotein, 
a Novel Human ATP-binding Cassette Transporter, Figure 3 panel C; and Linley et al., (2012) The Helicase HAGE 
Expressed by Malignant Melanoma-Initiating Cells Is Required for Tumor Cell Proliferation in vivo, Figure 5 panel 
B; with permission of the publisher (The Journal of Biological Chemistry). 
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Expression of ABCB5fl has been linked to drug resistance in another study using 
exogenously expressed protein (Kawanobe et al., 2012), although the cellular 
localisation of the protein was not reported. It is possible that ABCB5fl could have both 
a drug resistance role and an intracellular localisation, as it has previously been shown 
that ABCB1 can confer drug resistance to expressing cells by actively transporting 
doxorubicin into lysosomes (Yamagishi et al., 2013). A similar mechanism for 
ABCB5fl would allow the previous observations of drug resistance properties, and the 
subcellular localisation seen previously, and within this study, to be reconciled. 
3.3.3 Future work 
This study has been concerned with exogenously expressing both ABCB5fl and 
ABCB5β protein. Through the use of confocal microscopy, and fluorescently tagged 
protein, the localisation of both isoforms has been called into question with respect to 
previously published data. In order to accurately determine which subcellular organelle 
the two isoforms localise to, differential centrifugation should be performed on 
HEK293T cells transfected with vectors encoding both wild type and mutant ABCB5fl 
and ABCB5β. The centrifugation should be carried out in such a way that the internal 
organelles (ER, Golgi apparatus, mitochondria lysosomes etc.) are separated, as these 
are the likely areas of ABCB5fl and ABCB5β localisation, with the ER identified in this 
study as site of strong ABCB5-related fluorescence. This technique, and the subsequent 
western blotting of the separated samples for both ABCB5 and additional proteins – 
used to mark organelles – would allow for the precise intracellular location of both the 
wild type and mutant forms of each isoform to be determined. This technique could 
subsequently be carried out to determine whether the localisation of ABCB5fl and 
ABCB5β is any different in cells with endogenous expression, such as the A431 and 
K562 cell lines identified in this study.  
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There is a possibility that within these experiments the presence of an EGFP tag upon 
the C-terminus of ABCB5fl and ABCB5β may have adversely effected proteins 
localisation, has EGFP tagging of proteins has previously been shown to alter 
localisation in some cases (Palmer and Freeman, 2004, Zhu et al., 2013a). This is 
unlikely however, as the images taken agree with ones previously published, but if it 
were the case, the localisation data presented here could be erroneous. This possibility 
could be eliminated however by carrying out the previously described differential 
centrifugation with protein extracted from HEK239T cells transfected with both -EGFP, 
or -V5-6His tagged ABCB5fl/ABCB5β. If the -EGFP tagged protein was found to 
reside within the same organelles as the -V5-6His tagged protein, the ABCB5fl and 
ABCB5β protein localisation findings reported in this study could be confirmed as 
accurate. 
 
Glycosylation of the proteins may also have an effect on their localisation, as previously 
reported for a wide array of membrane proteins (Graf et al., 2004, Hoosdally et al., 
2009, Haga et al., 2011, Moharir et al., 2013). Both ABCB5fl and ABCB5β contain 
potential glycosylation sites, although only ABCB5fl has sites that are predicted to be in 
a region where glycosylation could take place (see Section 1.5.1.2). In order to examine 
whether glycosylation can effect localisation in these proteins, lysates taken from 
HEK293T cells transfected with ABCB5fl and ABCB5β should be subjected to PNGase 
F treatment in order to remove any bound glycans. Western blotting of these samples 
could then be used to visualise any changes in the motility of the ABCB5 species during 
SDS-PAGE as a result of deglycosylation. If changes in motility are seen with either 
ABCB5fl or ABCB5β point mutations could then be made in the protein coding 
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sequence, in order to remove the glycan binding sites. Expression of these mutants in 
HEK293T cells would then allow any change in subcellular localisation due to the 
prevention of glycan formation to be studied. 
 
In order to enhance the expression of ABCB5fl and ABCB5β, multiple small molecules 
previously shown to enhance the expression of other ABC transporters could be tested 
for efficacy. Although not strictly enhancing expression, the proteasome inhibitor 
MG132 has previously been shown to increase ABC protein abundance due to a 
reduction in degradation (Fukuda et al., 2011). The histone deacetylase (HDAC) 
inhibitors sodium butyrate and 4-phenyl butyrate could also be tested, as they are both 
reported to increase expression of a wide array of genes, some involved in transcription 
and translation, by preventing the tight wrapping of DNA around deacetylated histones 
(Gorman et al., 1983). In addition to these, it has been shown in other ABC transporters 
that treatment of cells with their substrates allows better ABC transporter expression, 
presumably due to the stabilisation of protein folding in an environment where the 
transporter can fold around its substrate (Loo and Clarke, 1997).  
 
The possibility of rare codons being present within the ABCB5fl and ABCB5β mRNA 
coding sequences should also be addressed. In order to investigate this, the coding 
sequences of both isoforms should be checked against a list of the most and least 
common codons in human cells. Two avenues of approach could then be taken; the first 
involving the identification of particularly rare codons, and the mutation of them into 
more common ones; the second approach would be to codon optimise the entirety of 
both ABCB5fl and ABCB5β, and to have them synthesised. Both of these methods 
would provide a coding sequence with a reduced chance of translation termination or 
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misfolding. If either of these issues were a problem for the cell in the expression of 
ABCB5fl and ABCB5β, an increased level of protein, and possibly an alternative 
subcellular localisation, would be expected in subsequent experiments. 
 
In this study, multiple Walker B mutants of ABCB5fl and ABCB5β were generated, 
which were predicted to be non-functional. A recent study of SNPs within the ABCB5 
gene identified one causing a non-synonymous mutation of K115E in ABCB5β (K560E 
in ABCB5fl; 10 amino acids away from the first Walker B mutation made in this study 
– E550Q) (Lin et al., 2013). K115 is an amino acid residue found between the D-loop 
and H-loop of NBD1, and the lysine to glutamate change was reported to be associated 
with decreased melanoma risk and reduced transport activity. The same mutation could 
be carried out in both the ABCB5fl and ABCB5β vectors described previously, and 
transfected into HEK293T cells to allow any changes in either the expression or 
localisation to be visualised when compared to the wild type proteins.  
 
An informative avenue of future study would be to create stably expressing cell lines 
with the wild type or mutant ABCB5fl and ABCB5β as previously carried out by 
Kawanobe et al., (2012), who used their cell lines to study transport activity, and 
measure the related kinetics. The stable expression of the proteins will allow for the cell 
clones with the highest expression of ABCB5fl or ABCB5β to be selected for further 
study. The resulting cell lines could subsequently be utilised, together with the 
endogenously expressing cell lines identified in this study, for more in depth studies 
using flow cytometry to study both transport activity, and the destination of the 
transport substrates – such as anthracyclines or taxanes – within the cell. 
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Together, the experiments proposed here would provide a further insight into the 
function and activities of ABCB5fl and ABCB5β and corroborate or call into question 
large amounts of the previously published literature on these proteins. 
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Chapter Four 
 
4  Investigating the 
relationship between 
ABCB5 and the tumour 
suppressor p16 
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4.1 Introduction 
p16, encoded by CDKN2A, is an important regulator of the normal cell cycle, 
controlling the cell’s passage through the r-point of the cell cycle – the main checkpoint 
of the G1/S phase transition – via its interaction with CDK4/6 (Serrano et al., 1993, Gil 
and Peters, 2006). p16 expression increases with age in vivo, causing cells to lose their 
proliferative capability and enter senescence. This, and the linkage of the INK4A/ARF 
locus by GWAS to many age-related diseases (Krishnamurthy et al., 2006a, McPherson 
et al., 2007, Matheu et al., 2009), makes p16 an attractive target for modulation in 
relation to treating these diseases. Either reducing the expression of p16 or clearing p16-
expressing senescent cells from the body could potentially relieve the symptoms of age-
related disease. This idea is given more weight by a recent study which showed that in 
the transgenic INK-ATTAC mice selective clearance of the marked p16-positive 
senescent cells by drug-induced caspase activity could either delay the onset of age-
related disorders (with lifelong drug treatment), or attenuate the progression of already 
established disorders (with drug treatment in later life) (Baker et al., 2011). Any therapy 
involving modulation of p16 in humans, however, would have to be carefully monitored 
due to the strong link between lack of p16 expression and cancer in humans (Kamb et 
al., 1994), although this is normally due to promoter methylation or mutation.  
 
Expression of p16 is commonly reduced in human tumours, where the INK4A/ARF 
locus may be deleted, mutated or epigenetically down regulated (Esteller et al., 2001, 
Forbes et al., 2006). p16 was initially discovered in melanoma (Serrano et al., 1993), 
where expression of ABCB5β and ABCB5α are reported to be frequently up-regulated 
(Chen et al., 2005a, Frank et al., 2005, Fukunaga-Kalabis et al., 2010, Gazzaniga et al., 
2010). 
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The ABCB5 gene is predicted to encode an integral, dodecaspan membrane protein of 
the ABC superfamily of transport proteins. Members of the B family of these 
transporters have been found to efflux a wide variety of substrates from the cell, ranging 
from chemotherapeutic agents (ABCB1), to lipids such as phosphatidylcholine 
(ABCB4; (Szakács et al., 2006). Four isoforms of ABCB5 have been described 
(ABCB5fl, ABCB5α, ABCB5β and ABCB5γ), and the two longest isoforms ABCB5fl 
and ABCB5β have been reported to be encode active efflux transporters, which are 
capable of extruding chemotherapeutic drugs – specifically doxorubicin – from 
melanoma cells (Frank et al., 2005, Kawanobe et al., 2012). Not long after it was first 
described, ABCB5β was proposed to also have a role in progenitor cell fusion, and 
more recently it has been suggested that it is highly expressed in a sub-population of 
melanoma cells, namely the cancer stem cell-like MMICs (Frank et al., 2003, Schatton 
et al., 2008). 
 
Recently, a genome-wide siRNA screen identified novel modulators of p16 in normal 
HMECs (Bishop et al., 2010), which have a finite lifespan with well-documented p16-
mediated senescence resulting from normal serial passage (Garbe et al., 2009). This 
screen suggested that siRNA-mediated knockdown of ABCB5 expression caused a 
concomitant reduction in the level of p16 protein, combined with an increase in cellular 
proliferation and decrease in cell and nuclear size (Bishop et al., 2010). Both ABCB5fl 
and ABCB5β are predicted and reported to be plasma membrane proteins, and as such, 
are potentially accessible targets via which to modulate p16.  
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4.1.1 High-content-fluorescent microscopy 
Fluorescence microscopy is a powerful tool to study biological processes. The 
fluorescent labelling of proteins (by antibody staining or conjugation to a fluorescent 
protein, such as EGFP) and nucleic acids (by using fluorescent molecules which 
intercalate into DNA or RNA) has made the labelling of virtually any structure in the 
cell possible, even in live cells (Giepmans et al., 2006, Conrad and Gerlich, 2010). With 
a wide variety of fluorescent biosensors and imaging modalities available it has become 
possible to detect post-translational modifications, protein-protein interactions, small 
molecules and measure steady state protein dynamics (Lippincott-Schwartz et al., 2003, 
Giepmans et al., 2006). Early difficulties in systematic and quantitative analyses limited 
imaging-based assays to manual, low-throughput experiments, capable of studying just 
a few candidate genes. However, due to developments in the automation of microscope 
control and image analysis, it is now possible to evaluate large numbers of candidate 
genes in a single study (Conrad et al., 2004, Pepperkok and Ellenberg, 2006).  
 
The main readout used in this study is also one of the most basic that high-content 
microscope systems can perform, fluorescence intensity. This readout is often used to 
score protein abundance (Müller et al., 2005, Loo et al., 2007), but can also be used for 
many other types of study, including: cellular DNA content (Kittler et al., 2007); 
lipoprotein uptake (Bartz et al., 2009); mitochondrial Ca2+ transport (Jiang et al., 2009); 
or the entry of viruses into cells (Brass et al., 2008). 
 
It is also possible to study the morphology of cells by staining the cytoskeleton, 
chromatin and nucleic acids enabling the measurement of different aspects of cell 
morphology including nuclear area (by staining DNA) and whole cell area (by staining 
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all nucleic acids (Bishop et al., 2010)). Utilising these measurements, analysis software 
can be ‘taught’ to identify individual cells, allowing cell number to be calculated, and 
information to be collected on a well-by-well and cell-by-cell basis. 
4.1.2 Aims 
The hypothesis for the work carried out in this chapter was that cellular levels of 
ABCB5 and are linked to p16 expression, and that understanding the pathway by which 
this occurs may provide reveal potential therapeutic targets for age-related disorders 
associated with p16 expression. The aim of this project was to understand and 
characterise the relationship between the ATP-binding cassette transporter family 
member ABCB5 and the tumour suppressor p16. Specifically, to: 
• Confirm the results reported by Bishop et al. (2010), in which siRNAs targeting 
ABCB5 mRNA caused morphological and proliferative changes, with a 
concomitant reduction of p16 in HMEC; 
• Validate the knockdown phenotype at the mRNA level by RT-qPCR and protein 
level by western blotting of ABCB5; 
• Identify the relevant isoform of ABCB5 involved in p16 reduction by: 
o RT-qPCR to determine which isoforms of ABCB5 are expressed in 
HMECs, and 
o The use of siRNAs to target specific ABCB5 isoforms and determine the 
effect on p16 expression; 
• Investigate ABCB5 expression at the mRNA and protein levels in early to late 
passage HMECs and evaluate its relationship to p16 expression. 
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4.2 Results 
4.2.1 Optimisation of HMEC transfection 
4.2.1.1 HMEC characteristics 
HMECs undergo p16-mediated senescence in cell culture (Brenner et al., 1998, Garbe et 
al., 2009), making them a suitable model to study the effects of modulating senescence 
and p16 expression using siRNA-mediated gene knockdown. With serial passaging, the  
 
Figure 4-1. Population doublings and p16 expression in serially passaged HMECs. 
A. Population doublings of HMECs in culture from passage 4 (P4) to passage 14 (P4). B. 
Immunofluorescence images of HMEC fixed at P6 and P11 showing DAPI staining of 
nuclei (blue) and antibody staining of p16 (green). C. The percentage of p16 expressing 
cells at P6 (21.5 ± 1.4) and P11 (96.5 ± 0.6), quantified using the Developer Toolbox 1.7 
(GE Healthcare, UK). Error bars represent one SD. n = 3 biological repeats. 
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expression of p16 gradually increases throughout the population, triggering senescence 
and reducing the overall proliferative capacity of the culture (Figure 4-1 panel A). The 
expression of p16 in cells was visualised by antibody staining at passage 6 (P6) and 
passage 11 (P11; Figure 4-1 panel B; see Section 2.28). When p16 staining was 
quantified, 21.5% (± 1.4%) of cells were found to express p16 at P6, where as at P11, 
96.5% (± 0.6%) were found to express the protein (Figure 4-1 panel C; see Section 
2.28). 
4.2.2 siRNA knockdown of ABCB5 
4.2.2.1 Controlling for phenotypic changes 
Three siRNAs targeting Cyclophilin B, CBX7 and p16 were used alongside the ABCB5-
targeting siRNAs to be examined in order to control for both induction and reduction in 
cellular p16 levels. siRNA targeting Cyclophilin B (siGLO; Dharmacon, DE), 
conjugated to a fluorescent tag (Pierce NuLightTM DY-547), was used to track cellular 
uptake of siRNA-transfection reagent complexes. siGLO also functions as a negative 
siRNA control, as knockdown of this gene causes no phenotypic changes in p16 
expression or senescence (Bishop et al., 2010). siRNA targeting the polycomb group 
(PcG) protein, CBX7, was used as a positive control (see Section 1.14.3). Loss of CBX7 
induces senescence by removing the epigenetic repression of p16, thereby reducing cell 
proliferation and increasing cell area. The opposite effect is observed for the control 
siRNA targeting p16, which knocks down expression of the protein product and 
therefore increases cell proliferation and decreases cell area. 
 
 
 
 158 
Figure 4-2. The effect of p16 and CBX7 targeting siRNAs on proliferation, cell area and 
p16 levels. 
A. Quantitated cell number and cell area. Significant changes in both cell number and 
cell area were observed (p < 0.001 for all) when cells were transfected with siRNA 
targeting CBX7 (orange) or p16 (purple) compared to the siGLO negative control (grey). 
B. Immunofluorescence images of HMECs 120 h post transfection with 30 nM siGLO, 
CBX7 or p16 siRNAs. Antibody staining of p16 is shown in green and DAPI staining of 
nuclei is shown in blue. C. Control siRNAs targeting CBX7 (orange) or p16 (purple) show 
a respective increase and reduction in p16 intensity (AU), relative to the siGLO negative 
control (grey). Median p16 intensity values (AU) are shown by the dotted lines. The solid 
black line represents fluorescence intensity from control staining with the secondary 
antibody alone. All error bars represent one SD,  ** p < 0.01, *** p < 0.001, n = 4 biological 
repeats. 
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To confirm that the positive control siRNAs targeting CBX7 and p16 affected cell 
number and cell morphology via modulation of p16 protein level, HMECs were 
transfected with siRNA targeting p16, CBX7 and the negative control siRNA (siGLO) at 
the previously optimised conditions (see Appendix II) and analysed for p16 protein 
intensity. High content analysis using the IN Cell system was performed 120 h post 
transfection as described (see Section 0) to quantify changes in cell number, cell area 
and p16 intensity (Figure 4-2). This multi-parameter analysis allowed the cellular 
phenotypes caused by positive control siRNAs targeting CBX7 (induction of 
senescence) or p16 (increased proliferation) to be distinguished accurately and in an 
unbiased manner.  
 
Targeting of CBX7 caused a significant decrease in cell number (p < 0.001), together 
with significant increases in cell area (p < 0.001) and p16 intensity (p = 0.0005), 
establishing CBX7 knockdown as an effective positive control for p16 activation and 
cellular senescence (Figure 4-2). By contrast, targeting of p16 directly caused a 
significant increase in cell number (p < 0.001) and significant decreases in cell area (p < 
0.001) and p16 intensity (p = 0.0325), confirming that the measures effectively 
quantitate the phenotype resulting from a reduction in cellular p16. As both the siRNAs 
targeting CBX7 and p16 showed strong phenotypic changes compared to siGLO, in line 
with what was predicted, they were used as positive controls for all subsequent 
transfections in HMECs. 
4.2.2.2 Ambion siRNAs 
Following transfection optimisation of HMECs, the first aim of the project was to 
confirm the data generated previously (Bishop et al., 2010), in which siRNAs targeting 
of ABCB5 reduced the level of p16. 
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In order to validate the findings of Bishop et al. (2010), the three siRNAs targeting 
ABCB5 (Table 2-5) used in the study were purchased from Ambion (Ambion-1, 
Ambion-2 and Ambion-3). The pool of these three siRNAs (Ambion-P) had previously 
been shown to significantly reduce the expression of p16, causing an increase in cell 
number and decrease in cell area. The region of the ABCB5 mRNA targeted by the each 
of these three siRNAs is shown in Figure 4-3. 
 
Figure 4-3. Ambion siRNA target sites within the mRNA sequence of the four ABCB5 
isoforms. 
Cartoon illustrating the positions of the three Ambion siRNAs within the mature mRNA 
of the ABCB5 isoforms. Red lines represent siRNA binding sites. 
 
The optimised protocol for transfecting HMECs in 384-well plates (see Section 4.2.1) 
was used to introduce the three siRNAs targeting ABCB5 into the cells, both 
individually and as a pool (by addition of equal amounts of each individual siRNA to 
give a final, total concentration of 30 nM per well). A decrease in p16 intensity was 
observed for all three Ambion siRNAs and the pool, similar to cells which have 
undergone p16 knockdown (Figure 4-4 panels A and B). Transfection with two siRNAs  
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Figure 4-4. Ambion siRNAs targeting ABCB5 reduce p16 and induce a proliferative 
phenotype in HMECs. 
A. Control siRNAs targeting CBX7 (orange) or p16 (purple) increased and decreased p16 
intensity (AU) respectively compared to the siGLO control (grey). Median p16 intensity 
values are shown by the dotted lines. B. Transfection with individual Ambion siRNAs 
(red) and the pool of all three siRNAs targeting ABCB5 (red) reduced p16 intensity 
relative to the siGLO control. Representative images show antibody staining of p16 
(green) and DAPI staining of nuclei (blue) 120 h post transfection. Median p16 intensity 
values (AU) are shown by the dotted lines C. An increase in cell number and decrease in 
cell area were observed upon transfection of all Ambion siRNAs and the pool of all three 
compared to the siGLO control. All error bars represent one SD. *** p < 0.001. n = 4 
biological repeats. 
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(Ambion-2, Ambion-3) and the pool were found to cause a decrease that was 
statistically significant (p < 0.001). These siRNAs were also found to cause a significant 
increase in cell number (p < 0.001), suggesting that siRNA-mediated loss of ABCB5 
caused an increase in proliferation (Figure 4-4 panel C). Each Ambion siRNA and the 
pool were also found to cause a significant reduction in cellular area (p < 0.001).  
 
Together, these data strongly suggest that transfection of the HMECs with siRNA 
targeting ABCB5 causes reduction in cellular p16, and therefore an increase in 
proliferation, mirroring the findings previously reported by Bishop et al., (2010). The 
efficacy of Ambion-3 implies that transcripts ABCB5α and ABCB5γ are irrelevant in the 
regulation of senescence, and that the phenotype is dependent on either the ABCB5fl or 
the ABCB5β transcript. 
4.2.3 ABCB5 isoform expression in HMEC 
To validate knockdown of ABCB5 mRNA by the Ambion siRNAs TaqMan RT-qPCR 
was used (described in Section 3.2.3). First, the primer/probe sets tmABCB5 and 
tmABCB5flonly (Table 2-4) were used to elucidate which isoforms of ABCB5 were 
expressed in the HMECs (Figure 4-5 panel A). As discussed previously, tmABCB5 will 
detect both ABCB5fl and ABCB5β, where as tmABCB5flonly will detect only 
ABCB5fl (see Section 3.2.3).  
 
In order to test the efficacy of these primer/probe sets with very low levels of cDNA, 
qPCR was carried out using tmABCB5flonly and tmABCB5 on serially diluted plasmid 
DNA containing the cDNA sequence of ABCB5fl (pcDNA3.1-ABCB5fl-wt_EGFP; 
Figure 4-5 panel B) and ABCB5β (pcDNA3.1-ABCB5β-wt_EGFP; Figure 4-5 panel 
C). 500 ng plasmid DNA was serially diluted from 10 fold to 100,000 fold. This 
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experiment showed that both primer/probe sets were able to detect very low levels of 
DNA (cT values of 38.58 for tmABCB5flonly, and 38.11 for tmABCB5), whilst still 
being in the linear range.  
 
mRNA extracted from HMECs at P6 and analysed by RT-qPCR using primer/probe set 
tmABCB5flonly consistently failed to detect expression of ABCB5fl, suggesting that 
HMECs do not express this isoform (Figure 4-5 panels D and E). qPCR was 
subsequently carried out on the same cDNA using primer/probe set tmABCB5 which 
can amplify both ABCB5fl and ABCB5β. qPCR using tmABCB5 demonstrated 
expression of ABCB5β, although at very low levels (cT = 36.92 ± 0.07) compared to 
GAPDH (cT = 19.13 ± 0.10). 
 
To determine whether there is a total absence of ABCB5fl mRNA in the HMECs, a high 
cycle end point RT-PCR technique was used. cDNA generated from HMEC P6 mRNA 
was amplified by PCR using primer set ABCB5-EP (Table 2-3; Figure 4-5 panel A) 
over 50 cycles in an effort to detect low level expression. cDNA generated from 
HEK239T cells transfected with the pcDNA3.1-ABCB5fl-wt_EGFP vector (Table 2-2; 
see Section 2.10.1) acted as a positive control (Figure 4-5 panel F). PCR product was 
detected in cDNA prepared from the transfected HEK293T mRNA, but no ABCB5fl 
was detected in cDNA prepared from HMECs. It was therefore concluded that HMECs 
do not express ABCB5fl. However, as primer/probe set tmABCB5 successfully detected 
expression, it was concluded that HMECs do express ABCB5β.  
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Figure 4-5. HMECs at P6 express ABCB5β  but lack ABCB5fl mRNA and ABCB5 protein at 
all passages. 
A. Cartoon illustrating the positions of the PCR primer and probe binding sites within the 
mature mRNAs of the ABCB5 isoforms. Binding sites of the primer set ABCB5-EP, and 
the primer/probe sets tmABCB5flonly and tmABCB5 are shown in yellow, purple and 
red, respectively. B and C. qPCR of serially diluted plasmids (500 ng plasmid DNA 
diluted 10 to 100,000 fold) encoding ABCB5fl (pcDNA3.1-ABCB5fl-wt_EGFP) and ABCB5β  
(pcDNA3.1-ABCB5β-wt_EGFP) using primer/probe sets tmABCB5 (red) and 
tmABCB5flonly (purple) shows detection of the appropriate sequences even at high cT 
values. D. qPCR of HMEC derived cDNA shows low level expression of either ABCB5fl or 
ABCB5β , primers specifically targeting ABCB5fl could not detect any expression. E. cT 
values from qPCR of HMEC derived cDNA show low-level expression of either ABCB5fl 
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or ABCB5β  relative to GAPDH and p16 using tmABCB5. tmABCB5flonly specifically 
targeting ABCB5fl failed to detect any expression. F. No expression of ABCB5fl mRNA 
was observed in the HMECs but a product of the predicted size (248 bp) was amplified 
from the transiently transfected HEK293T positive control. G. Western blotting of lysates 
prepared from HMECs at P5 to P11 failed to detect either ABCB5β  or ABCB5fl protein. 
Arrows show the predicted molecular weights of ABCB5fl (red) and ABCB5β  (purple). 
Error bars represent one SD. n = 3 biological repeats. 
In order to study ABCB5 protein levels, HMEC lysates were generated from cells at P5 
to P11 (see Section 2.23). Protein levels were determined as described in Section 2.24; 
from each passage number, 30 µg of protein was electrophoresed on an SDS-PAGE gel, 
alongside 1 µg of protein taken from HEK293T cells transfected with either pcDNA3.1-
ABCB5fl-wt_V5-6His or pcDNA3.1-ABCB5β-wt_V5-6His to act as positive controls, 
and subjected to western blotting for ABCB5 (see Section 2.25). Figure 4-5 panel G 
shows neither ABCB5fl nor ABCB5β protein was detected at any passage number 
tested, even with the high amount of protein loaded. As a result, it must be presumed 
that any observed effect of ABCB5β knockdown on p16 levels is as a result of a 
reduction in ABCB5β mRNA and not as a reduction in ABCB5β protein. 
4.2.4 Validation of siRNA knockdown of ABCB5 by RT-qPCR  
It is important to validate the knockdown of ABCB5 mRNA by the Ambion siRNAs to 
ensure that the proliferative phenotype is due to knockdown of ABCB5 and not the 
result of off-target effects. The TaqMan primer/probe set tmABCB5 (see Section 3.2.3; 
Table 2-4; Figure 4-5 panel A) was therefore used for RT-qPCR analysis of siRNA 
transfected HMECs. The expression of ABCB5fl could not be detected in the HMECs 
used for the siRNA knockdown experiments, therefore any amplified product will 
reflect the abundance of the ABCB5β transcript. 
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RT-qPCR was carried out on mRNA prepared from HMECs transfected with siRNAs 
targeting ABCB5, siGLO, CBX7 and p16 in 6-well format (see Section 2.11.1.2) and 
normalised to GAPDH expression, as assessed using tmGAPDH. All Ambion siRNAs 
against ABCB5 were found to give a significant knockdown of ABCB5β mRNA relative 
to the siGLO negative control (p < 0.001; Figure 4-6 panel A). Ambion-3 and Ambion-
P gave the largest knockdown in mRNA with a respective 82% (± 3.7%) and 79% (± 
1.8%) reduction. Ambion-2 produced a 52% (± 5.5%) reduction in ABCB5β mRNA, 
and Ambion-1 showed a 21% (± 6.0%) reduction.  
 
RT-qPCR of the same mRNA using the TaqMan primer/probe set tmp16 (Table 2-4) 
targeting p16 showed an 85% (± 7.5%) increase in p16 expression following 
transfection with the CBX7 siRNA (p < 0.001), and a 75% (± 8.3%) decrease in p16 
mRNA levels upon transfection with siRNA targeting p16 directly (p < 0.001), as 
compared to the siGLO negative control (Figure 4-6 panel B).  Importantly, decreases in 
p16 mRNA levels were detected with transfection of Ambion-1 (8% ± 7.6% decrease), 
Ambion-2 (19% ± 4.6% decrease), Ambion-3 (39% ± 7.2% decrease) and Ambion-P 
(37% ± 3.9% decrease), with Ambion-2, Ambion-3 and Ambion-P all giving significant 
decrease (p < 0.001), suggesting that the effect of ABCB5β knockdown is upstream of 
p16 mRNA generation. 
 
When both the phenotypic analysis and validation results of the ABCB5 knockdown are 
taken together, they show that the ABCB5 targeting siRNAs, which cause a significant 
knockdown of ABCB5 mRNA (p < 0.001), also cause a significant decrease in p16 
intensity, p16 mRNA levels and cell area, and a significant increase in cell number.  
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Figure 4-6. Knockdown of ABCB5β  mRNA by Ambion siRNAs in HMECs. 
A. qPCR carried out using the tmABCB5 primer pair on cDNA generated from HMEC 
mRNA isolated 48 h post transfection shows all Ambion siRNAs (red) generated a 
significant reduction in ABCB5β  message following transfection. Error bars represent 
one SD. *** p < 0.001. B. qPCR carried out using tmp16 shows a significant reduction in 
p16 mRNA following transfection with Ambion-2, Ambion-3 and Ambion-P. n = 3 
biological repeats.  
 
With qPCR and PCR data suggesting that HMECs do not express the full-length 
isoform of ABCB5, and with only siRNA Ambion-1 targeting the alpha and gamma 
isoforms, knockdown of ABCB5β is likely responsible for the p16 reduction phenotype.  
If either the alpha or gamma isoforms were responsible, only siRNA Ambion-1 would 
be predicted to produce a p16 reduction phenotype in the HMECs. 
 
With the knockdown of ABCB5β by multiple, different siRNAs mirroring the level of 
phenotypic changes observed in the cells, it is highly likely that the phenotype is due to 
ABCB5β knockdown, and not due to off-target effects of the siRNA transfection. 
Additionally, as no change was seen in the levels of ABCB5β mRNA upon transfection 
with siRNAs targeting either CBX7 or p16, a reciprocal effect of p16 acting on ABCB5β 
is unlikely, indicating that the effect on p16 and cell cycle control is downstream of 
ABCB5β.  
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4.2.5 Targeting the ABCB5β  mRNA with specific siRNA 
4.2.5.1 Generating siRNAs that target the ABCB5β  isoform but not 
ABCB5fl 
One of the aims of this investigation was to determine which isoform of ABCB5 was 
responsible for the effect on p16. The siRNAs and RT-qPCR experiments above 
implicate ABCB5β as the relevant transcript. In an attempt to confirm this, siRNAs that 
specifically target ABCB5β but not ABCB5fl were designed.  
 
 
Figure 4-7. ABCB5β-specific siRNA target sites within the ABCB5 mRNA sequence. 
A cartoon illustrating the positions of the siRNAs targeting ABCB5β  within the mature 
mRNA of the ABCB5 isoforms. Blue lines represent siRNA binding sites for Beta-1, Beta-
2 and Beta-3. 
ABCB5β is reported to include a short but unique 5’-UTR that is absent from the full-
length transcript. siRNAs targeting the 5’-UTR of ABCB5β were custom made by 
submitting the 5’-UTR sequence to the GeneAssistTM Custom siRNA BuilderI (Life 
Technologies, UK; Table 2-2). The siRNAs (Beta-1, Beta-2 and Beta-3) – designated 
set one – were designed to target a 197-nucleotide retained-intronic section of the 
                                                
 
I Available at http://www5.invitrogen.com/custom-genomic-products/tools/sirna/ 
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ABCB5β mRNA 5’-UTR (Appendix I; Figure 4-7). These siRNAs should target 
ABCB5β without targeting ABCB5fl. The siRNAs would also target both the ABCB5α 
and ABCB5γ isoforms, but these have previously been shown to be irrelevant to the p16 
phenotype (see Section 4.2.2).  
 
4.2.5.2 Transfection of HMECs with ABCB5β  siRNA set one 
In an attempt to knockdown ABCB5β specifically, the set one siRNAs designed to 
target the isoform were transfected into HMECs (see Section 4.2.5.1). Beta-1, Beta-2 
and Beta-3 and a pool of all three siRNAs (Beta-P1) were transfected into HMECs at P6 
alongside the three control siRNAs, as described previously. 
 
CBX7 and p16 control siRNAs significantly changed p16 intensity following 
transfection into the HMECs, compared to the siGLO control, as described previously 
(p < 0.001; Figure 4-8 panel A). Very slight variations in p16 intensity were observed in 
cells transfected with Beta-1, Beta-2, Beta-3 and the Beta-pool, however, none of these 
were found to be significant (Figure 4-8 panel B). Furthermore, no significant 
phenotypic changes in cell number or cell area were apparent after transfection with any 
of the ABCB5β siRNAs targeting the 5’-UTR (Figure 4-8 panel C). Together, the data 
report no significant changes in cell phenotype when the cells are transfected with any 
of the set one siRNAs designed to specifically target ABCB5β. 
 
 170 
Figure 4-8. ABCB5β-targeted siRNAs show no p16 reduction phenotype in HMECs. 
A. Control siRNAs targeting CBX7 (orange) or p16 (purple) show an increase in p16 
intensity and a reduction in p16 intensity, respectively when compared to the siGLO 
control (grey). Median p16 intensity values (AU) are shown by the dotted lines. B. 
Transfection with set one siRNAs targeting the 5’-UTR of ABCB5β  (blue) showed no 
significant change in p16 intensity compared to siGLO control (grey). Representative 
images show antibody staining of p16 (green) and DAPI staining of nuclei (blue) 120 h 
post transfection. C. No change in cell number or cell area was observed in cells 
transfected with siRNAs targeting the 5’-UTR of ABCB5β  at 120 h time point. All error 
bars represent one SD. *** p < 0.001. n = 4 biological repeats. 
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4.2.5.3 RT-qPCR quantitation of ABCB5β  knockdown by Beta-1, 
Beta-2 and Beta-3 
To assess whether the beta isoform-specific siRNAs knocked down ABCB5β mRNA, 
cDNA generated from the transfected HMECs was analysed by qPCR as before (Figure 
4-9 panel A), by normalising ABCB5β levels to GAPDH. None of the three siRNAs, or 
the Beta pool, caused a significant knockdown of the ABCB5β mRNA, consistent with 
the lack of phenotypic change in cell proliferation, cell morphology and p16 abundance.  
 
When the expression of p16 was evaluated in the same samples by qPCR, the control 
siRNAs targeting CBX7 and p16 caused a significant increase and decrease in levels of 
mRNA, respectively (p < 0.001; Figure 4-9 panel B). None of the siRNAs targeting 
ABCB5β caused any significant change in the levels of p16 expression, as predicted 
given the lack of efficacy in their ability to knockdown ABCB5β. 
 
 
Figure 4-9. Knockdown of ABCB5β  by siRNAs in HMECs. 
A. qPCR carried out using tmABCB5 on cDNA generated from HMEC mRNA isolated 48 h 
post transfection showed no significant change with any control siRNAs; siGLO (grey), 
CBX7 (orange) and p16 (purple). All three siRNAs targeted to ABCB5β  (blue), and the 
pool, also showed no significant reduction in ABCB5β  message. B. qPCR carried out 
using tmp16 also shows no significant change in levels of p16 mRNA following 
transfection with any siRNAs targeting ABCB5β . Error bars represent one SD. *** p < 
0.001. n = 3 biological repeats. 
 172 
4.2.5.4 Transfection of HMEC with ABCB5β  5’-UTR-specific siRNAs 
Beta-4, Beta-5 and Beta-6 
Due to the lack of efficacy of the first three ABCB5β 5’-UTR-specific siRNAs, a 
further set targeting ABCB5β were generated (Beta-4, Beta-5, Beta-6 and the pool of all 
three, Beta-P2; designated set two; Figure 4-10). These siRNAs, targeting different 
sequences within the short 5’-UTR of the ABCB5β transcript, were transfected into the 
HMECs, but again no significant changes were seen for p16 intensity or cell area 
(Figure 4-11). Unexpectedly, siRNA Beta-5 did, however, cause a small but significant 
reduction in cell number (p < 0.01). This siRNA only affected cell number and not cell 
area or p16 intensity, and as a consequence, the effect on cell number is most likely due 
to an off-target effect, causing cell death and not cellular senescence. 
 
 
Figure 4-10. Additional ABCB5β  specific siRNA target sites within the ABCB5 mRNA 
sequence. 
A cartoon illustrating the positions of the siRNAs targeting ABCB5β  within the mature 
mRNA of the ABCB5 isoforms. Blue lines represent siRNA binding sites. 
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Figure 4-11. siRNAs Beta-4, 5, 6 or Beta-P2 targeting ABCB5β  show no p16 reduction 
phenotype in HMEC. 
A. Control siRNAs targeting CBX7 (orange) or p16 (purple) show an increase in p16 
intensity and a reduction in p16 intensity, respectively when compared to the siGLO 
control (grey). Median p16 intensity values (AU) are shown by the dotted lines. B. 
Transfection with siRNAs targeting the ABCB5β  5’-UTR (blue) showed no significant 
change in p16 intensity with compared to the siGLO control (grey). Representative 
images show antibody staining of p16 (green) and DAPI staining of nuclei (blue) 120 h 
post transfection. C. No significant change in cell number or cell area was observed in 
cells transfected with siRNAs targeting ABCB5β , apart from a small but statistically 
significant reduction in cell number with Beta-5. All error bars represent one SD. * p < 
0.05, ** p < 0.01, *** p < 0.001. n = 3 biological repeats. 
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4.2.5.5 Test of ABCB5β  5’-UTR-specific siRNAs Beta-4, Beta-5 and 
Beta-6 efficacy by RT-qPCR 
The failure of siRNAs Beta-4, Beta-5, Beta-6 or Beta-P2 to induce a p16-reduction 
phenotype in the cells prompted experiments to validate knockdown of ABCB5β at the 
mRNA level. qPCR was performed using the tmABCB5 primers on cDNA prepared  
 
Figure 4-12. Further knockdown of ABCB5β  by siRNAs in HMECs. 
A. qPCR carried out using tmABCB5 on cDNA generated from HMECs transfected with 
the control siRNAs siGLO (grey), CBX7 (orange) and p16 (purple) showed no significant 
change in ABCB5β  mRNA levels. siRNAs Beta-4, Beta-5 and Beta-6 targeting the 
ABCB5β  5’-UTR (blue), and the pooled siRNA Beta-P2, also caused no significant 
reduction in ABCB5β  mRNA. Error bars represent one SD. B. qPCR carried out using 
tmp16 showed no significant change in p16 mRNA following transfection with any 
siRNAs targeting ABCB5β . *** p < 0.001. n = 3 biological repeats. 
 
from HMECs as described previously (Figure 4-12 panel A), and normalised to 
GAPDH expression levels. The results show that these further siRNAs had no effect on 
the endogenous ABCB5β mRNA, explaining the lack of proliferative phenotype 
observed after transfection. Additionally, levels of p16 mRNA assessed by RT-qPCR 
using the tmp16 primer/probe set also showed no significant change upon transfection 
with any of the siRNAs targeting the 5’-UTR of ABCB5β (Figure 4-12 panel B).   
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4.2.6 Sequencing the ABCB5β  5’-UTR endogenous to HMECs 
Due to the lack of efficacy of all six siRNAs targeting the ABCB5β 5’-UTR, it was 
hypothesised that the NCBI consensus sequence (NM_178559.5), used to design the 
siRNAs, could be different to the sequence found in HMECs. To investigate this, the 5’-
UTR of ABCB5β in HMECs was sequenced from cDNA amplified using a 5’ Rapid 
Amplification of cDNA Ends (RACE) PCR (Figure 4-13; see Section 2.18). 
 
RACE PCR is a technique employed to amplify a nucleic acid sequence from a mRNA 
template between a defined internal site and an unknown sequence at either the 3’ or the 
5’-end of the mRNA (Frohman et al., 1988). Normally, PCR amplification requires two 
sequence-specific primers that flank the region to be amplified; not knowing the 
sequence of one end of the region provides a severe limitation (Loh et al., 1989).  3’ and 
5’ RACE approaches can solve this problem.  
 
5’ RACE allows the isolation and characterisation of 5’-ends from low-copy messages 
and was carried out as follows. First strand cDNA synthesis was primed using a gene-
specific antisense oligonucleotide (GSP1), which allowed the conversion of a specific 
mRNA to cDNA, and maximised potential for complete extension to the 5’-end of the 
message. After the cDNA was synthesised, the product was purified from 
unincorporated dNTPs and GSP1, and treated with terminal deoxynucleotidyl 
transferase (TdT), which added a homopolymeric tail to the 3’-ends of the cDNA. 
 
Amplification of the target sequence was then carried out using a nested gene-specific 
primer (GSP2), which anneals 3’ to GSP1, and a complementary homopolymer- 
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Figure 4-13. Overview of 5’ RACE procedure. 
mRNA isolated from cells is reverse-transcribed to cDNA using a gene-specific primer 
(GSP1) and SuperScript II. The mRNA is degraded using RNase and the remaining cDNA 
is purified using a S.N.A.P. column. Purified cDNA is tailed with dCTP by the activity of 
terminal deoxynucleotidyl transferase. The resulting dC-tailed cDNA is amplified by PCR 
using the Abridged Anchor Primer (AAP) – which binds to the dC-tail – and another gene 
specific primer (GSP2), nested from the location of GSP1. The PCR product is then re-
amplified using the Abridged Universal Anchor Primer – which binds to the anchor site 
created by the AAP – and another nested gene-specific primer (GSP3).  
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··
·
· ·
· ·
CCC----CCC
· ·
CCC----CCC
GGG----GGG· ·
· ·
CCC----CCC
GGG----GGG·
GSP2
Abridged Anchor Primer
· ·
CCC----CCC
GGG----GGG· ·
Abridged Universal
Anchor Primer
GSP3
First strand primer, GSP1
annealed to mRNA
mRNA copied into cDNA by
SuperScript II RT
mRNA degraded using
RNase Mix
cDNA purified using
S.N.A.P. column
Tail of purified cDNA tailed
with dCTP and terminal
deoxynucleotidyl transferase
dC-tailed cDNA amplified by
PCR using the Abdridged
Anchor Primer and nested GSP2
Primary PCR product re-amplified
using the Abridged Universal
Anchor Primer and nested GSP3
PCR product ready to use in
downstream applications 
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Figure 4-14. The ABCB5β  5’-UTR sequenced from HMECs is identical to the NCBI 
consensus sequence. 
The 5’-UTR of ABCB5β  expressed in HMECs was amplified using a 5’ RACE 
methodology and sequenced. The sequenced 5’-UTR (HMEC) was aligned to the NCBI 
consensus sequence (NCBI; NM_178559.5) using ClustalW2 (Larkin et al., 2007). The two 
sequences were identical apart from the poly-G tail added during the 5’ RACE reaction.  * 
denotes that the two bases are identical, orange text marks the retained intronic 
sequence of ABCB5β , black text marks the 5’-UTR and blue text marks the potential 
protein coding sequence. 
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containing anchor primer, which allowed amplification of the homopolymeric cDNA 
tail. This permitted amplification of the unknown sequence between the GSP2 and the 
5’-end of the mRNA. After an additional nested PCR, the product was sequenced 
directly (Innis et al., 1990). 
 
The sequenced 5’-UTR of ABCB5β was aligned against the NCBI consensus sequence 
using ClustalW2 (Figure 4-14). No differences between the two sequences were found, 
confirming the expression of the ABCB5β isoform in HMECs and the veracity of the 
published sequence. The lack of knockdown by the specific ABCB5β-targeting siRNAs 
was, therefore, not due to incorrect sequence targeting, but possibly due to steric 
hindrance at the target site due to mRNA secondary structure or bound proteins.  
4.2.7 Prediction of ABCB5β  5’-UTR secondary structure 
Sequencing of the ABCB5β 5’-UTR did not show any differences between the NCBI 
consensus sequence and the endogenous message in HMECs, therefore it was 
hypothesised that the binding sites for the six ABCB5β targeting siRNAs may be 
inaccessible in stable RNA secondary structures. This could prevent the binding of 
siRISC and the subsequent degradation of target mRNA (Luo and Chang, 2004, 
Overhoff et al., 2005, Schubert et al., 2005).  
 
In an attempt to test this hypothesis the secondary structure of the 5’ end of the ABCB5β 
message was modelled using the mfold web server I  (Zuker, 2003). The mRNA 
sequence was submitted to the web server in 500-nucleotide sections covering the 
                                                
 
I The mfold web server can be found at: http://mfold.rna.albany.edu/?q=mfold/rna-folding-form 
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binding sites of siRNAs Beta-1 to Beta-6 (Bases 1 – 500), Ambion-1 and Ambion-2 
(1601 – 2100), and Ambion-3 (2501 – 3000; see Appendix III). The binding sites for 
the Ambion siRNAs (which knocked down the mRNA) were included as a comparison 
for the Beta siRNAs (which failed to knockdown the message).  
 
The mRNA folding software predicted that the 5’-UTR containing the binding sites for 
siRNAs Beta-1 to Beta-6 contains a highly structured mix of stem, hairpin and loop 
sections (Figure 4-15 panel A). The binding sites for siRNAs Beta-1 to 6 are mostly in 
energetically stable stem and hairpin structures, although Beta-2 targets a relatively 
open conformation. mRNA secondary structure has previously been reported to hinder 
siRISC binding, however, the secondary structure predicted for the target sequences of 
Ambion-1, Ambion-2 and Ambion-3 are not dissimilar (Figure 4-15 panels B, C and D). 
 
The similarities between the secondary structure in these regions, but the differences in 
the knockdown produced by the siRNAs targeting them, suggests that either the 
predicted conformations are not physiologically relevant, or that they have little effect 
on siRNA binding. If the predicted secondary structures generated here are accurate and 
did predict siRNA-binding efficiency, it would be probable that the Ambion siRNAs 
would also have failed to knockdown ABCB5β mRNA in the cells.  
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Figure 4-15. Predicted mRNA secondary structure in regions targeted by the siRNAs 
used in the investigation. 
mRNA secondary structure was predicted by uploading 500 nt sections of the ABCB5β  
mRNA to the mfold web server (Zuker, 2003). siRNA binding sites are represented by 
coloured dots. Numbers indicate every 20 nucleotides. A. The binding sites of siRNAs 
Beta-1 to Beta-6. Circles with half colours represent bases targeted by two different 
siRNAs. 
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Figure 4-17. (Continued) Predicted mRNA secondary structure in regions targeted by 
siRNAs used in the investigation. 
mRNA secondary structure was predicted by uploading 500 nt sections of the ABCB5β  
mRNA to the mfold web server (Zuker, 2003). siRNA binding sites are represented by 
coloured dots. Numbers indicate every 20 nucleotides. B-D. The binding sites of siRNAs 
Ambion-1 (B), Ambion-2 (C) and Ambion-3 (D). 
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4.2.8 ABCB5β  and p16 expression in HMEC with increasing 
passage 
To further investigate the relationship between the expression of p16 and ABCB5β in 
HMECs, the relative abundance of each of the transcripts was assessed by RT-qPCR of 
mRNA isolated from early (P5) to late (P10) passage cells (Figure 4-16).  
 
Data for the expression of both p16 (using primer/probe set tmp16; Table 2-4) and 
ABCB5β (tmABCB5) show a step-wise increase in mRNA expression with increasing 
passage number. The expression of ABCB5β is significantly increased at P8 (p < 0.05) 
compared to P5, and its expression at P10 is 2.1 (± 0.2; p < 0.001) fold higher than P5. 
The expression of p16 increases with passage in HMECs as has been previously 
reported (Garbe et al., 2009), with the increase in expression becoming significant at P7 
(p < 0.001). At P10 the expression of p16 is 1.7 (± 0.1; p < 0.001) fold higher than at  
 
Figure 4-16. RT-qPCR analysis of p16 and ABCB5 expression in HMECs with passage. 
mRNA was subjected to RT-qPCR analysis and normalised to a GAPDH housekeeping 
control. Results show significant increases in both the expression of p16 (using 
primer/probe set tmp16) and ABCB5 (using primer probe set tmABCB5) with increasing 
passage number compared to their expression at passage 5 (P5). ABCB5fl expression 
could not be detected using primer/probe set tmABCB5flonly at any passage number. 
Error bars represent one SD. * p < 0.05; ** p < 0.01; *** p < 0.001. n = 3 biological repeats.  
P5 P6 P7 P8 P9 P1
0
0.0
0.5
1.0
1.5
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P5. As previously noted in this study (see Section 4.2.3), the expression of ABCB5fl 
could not be detected at any passage number tested.  
 
All data concerning expression of ABCB5β and p16 show that both increase with 
passage. It is possible that this is due to an effect of one on the other, and in light of the 
data discussed here it could be due to a downstream effect of ABCB5β mRNA on p16. 
4.3 Discussion 
4.3.1 Summary of the findings 
HMECs were chosen as the model cell type in which to study the effect ABCB5 
knockdown on p16, as they undergo a well characterised p16-mediated senescence 
response in cell culture (Brenner et al., 1998, Garbe et al., 2009), making them an ideal 
system to study p16 and senescence in vitro (see Section 4.2.1.1). The cells were 
optimised for transfection with 30 nM siRNA, by finding both the optimum seeding 
density (10,000 cm-2; see Appendix II) and optimum volume of transfection reagent per 
well (0.25 µL well-1), to provide the greatest target gene knockdown, with the lowest 
toxicity possible.  
 
Control siRNAs targeting CBX7 and p16 were tested as positive controls for modulation 
of senescence. siRNA targeting CBX7 was found to cause a significant increase in p16 
intensity and cell area, with a significant decrease in cell number making CBX7 siRNA 
a robust positive control for increase in p16 expression and cellular senescence. The p16 
targeting siRNA was found to cause significant decreases in p16 intensity and cell area, 
 184 
and a significant increase in cell number establishing direct knockdown of p16 as an 
effective positive control for a reduction in cellular p16.  
 
Three siRNAs (Ambion-1, Ambion-2 and Ambion-3) and their pool (Ambion-P) that 
target ABCB5 were then used to determine the effect of loss of ABCB5 in HMECs (see 
Section 4.2.2.2). All three siRNAs and the pool decreased p16 intensity and caused a 
statistically significant reduction in cell area. Ambion-2, Ambion-3 and Ambion-P 
caused a significant, concomitant increase in cell number.  
 
RT-qPCR using two TaqMan primer/probe sets, one targeting ABCB5fl only 
(tmABCB5flonly), and the other targeting both ABCB5fl and ABCB5β (tmABCB5; see 
Section 4.2.3), and high-cycle endpoint RT-PCR using the primer set ABCB5-EP 
established that HMECs lack detectable levels of ABCB5fl expression but must express 
ABCB5β. siRNA knockdown was validated using the tmABCB5 primer/probe set to 
amplify ABCB5β in all subsequent experiments (see Section 4.2.4). All three Ambion 
siRNAs targeting ABCB5 significantly knocked down ABCB5β mRNA, compared to 
the negative control. Ambion-3 and Ambion-P gave the largest knockdown of the target 
mRNA. No changes in the levels of ABCB5β were observed upon transfection of the 
cells with siRNAs targeting CBX7 or p16. The p16 mRNA level was reduced following 
transfection with all Ambion siRNAs and the pool, with Ambion-2, Ambion-3 and 
Ambion-P generating a statistically significant decrease. Together these data strongly 
suggest that knockdown of ABCB5β is causative in the reduction of p16 observed in 
transfected HMECs. 
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Western blotting showed that neither ABCB5fl (as expected) nor ABCB5β were 
detectable at the mid to late passages numbers tested even with heavily overloaded 
samples. While it is impossible to rule out a role for ABCB5 protein, expression that is 
below the detectable threshold suggests that it is unlikely ABCB5 acts at the protein 
level to influence proliferative phenotype and regulation of p16. 
 
These experiments implicate ABCB5β as the relevant transcript in the regulation of p16. 
siRNAs were therefore designed to specifically target ABCB5β, utilising the 5’-UTR of 
the transcript that is not present in ABCB5fl (see Section 4.2.5.1). None of the six 
ABCB5β-specific siRNAs, or their respective pools caused significant changes in p16 
intensity, cell size or cell number. Neither was there any significant change in the level 
of ABCB5β mRNA, strongly suggesting that these siRNAs did not knockdown their 
intended target. The 5’-UTR of ABCB5β in HMECs was therefore amplified by 5’ 
RACE PCR, and sequenced. The sequence was identical to the NCBI consensus 
sequence, ruling out the possibility that the published sequence used to design the 
ABCB5β specific siRNAs was incorrect. These data also provided direct evidence that 
ABCB5β was expressed in HMECs. 
 
Finally, the expression of p16 and ABCB5β in HMECs was measured by RT-qPCR in 
early (P5) to late (P10) passage cells (see Section 4.2.8). The expression of both p16 
and ABCB5β was found to increase step-wise and in parallel with increasing passage 
number.  
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4.3.2 Discussion 
Multiple individual siRNAs targeting ABCB5 were found to reduce p16, HMEC cell 
size, and cause an increase in cell number, suggesting, that loss of ABCB5 drives the 
culture into a more proliferative state, away from the p16-positive senescent phenotype 
associated with ageing. Through a process of elimination, ABCB5β was established as 
the relevant isoform.  
 
Western blotting failed to show detectable ABCB5β protein in samples taken from P5 
to P11. Given that expression of ABCB5β mRNA was confirmed by RT-qPCR in both 
young and old cells, this is a curious result. It is possible that the low levels of ABCB5β 
mRNA observed give rise to a protein level that is too low to detect with the Atlas 
antibody, despite significant protein loading. It is also possible that either the cells 
rapidly degrade the small amount of protein being produced, or that the mRNA is 
inefficiently translated as suggested previously for expression in HEK293T cells (see 
Section 3.2). However, it may be possible that the p16-reduction phenotype observed 
following ABCB5β knockdown is a direct consequence of a reduction in ABCB5β 
mRNA, and not reduction in ABCB5β protein.  
 
Concomitant reduction in both p16 mRNA and protein was observed upon ABCB5β 
knockdown, therefore it is hypothesised that transfection with the ABCB5β targeting 
siRNAs leads to a reduction in the transcription of p16, or causes an increase in p16 
mRNA degradation. Direct reduction or increase in the levels of p16 by either 
transfection with siRNA targeting p16 or CBX7, respectively, did not cause an increase 
in ABCB5β mRNA, making it likely that the reduction of p16 is a downstream result of 
ABCB5β knockdown. The lack of a reciprocal change in ABCB5β mRNA levels 
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following transfection with siRNA targeting p16 or CBX7 rules out the possibility of a 
feedback loop in which the modulation of p16 levels affects the level of ABCB5β.   
 
None of the six siRNAs designed to specifically target ABCB5β caused any reduction in 
the mRNA upon transfection. It seems likely that the siRISC complex if formed in the 
cell with these siRNAs might not degrade the mRNA for one of several reasons. It is 
possible that the siRISC complex does not recognise the heteroduplex due to steric 
hindrance, from either stable RNA secondary structure formed within the region (Luo 
and Chang, 2004, Overhoff et al., 2005, Schubert et al., 2005), or because other proteins 
are already bound to the message. Computer modelling of the ABCB5β mRNA 
secondary structure found no obvious differences between binding sites of siRNA with 
high and low knockdown efficacies, but in silico modelling of RNA structure may not 
be particularly reliable, and would require direct investigation to confirm. The 
possibility of RNA-binding proteins (RBPs) occluding the RISC binding sites should 
also be investigated. 
 
A further possibility is that the 197 base region of mRNA is simply not a ‘good’ region 
for siRNAs to be designed against. Although siRNAs have been in use for nearly 15 
years, the algorithms used for their design are imperfect and knockdown of the intended 
target in never ensured (Liu et al., 2014). It is possible that this inexact method of 
siRNA sequence prediction, coupled with the small size of the submitted sequence 
(submitted sequences are usually at least 1000 bases in length), may provide the 
prediction software with too little information to produce a reliable siRNA sequence.    
 
 
 188 
The most pressing question arising from these results is how the knockdown of 
ABCB5β mRNA causes a reduction in p16 mRNA and protein within the HMECs. If the 
ABCB5β protein product was translated, theoretically it would be possible that it could 
secrete a molecule that promotes p16-induced senescence from the cytosol. This seems 
unlikely, however, as the ABCB5β protein was undetectable in the HMECs, and, in any 
case, the truncated protein encoded by the transcript would be unlikely to function as an 
ABC transporter (Chen et al., 2009).  
 
A remaining possibility is that ABCB5β mRNA acts as an lncRNA (see Section 1.20). 
lncRNAs are functional RNA molecules, not just intermediates, and as such are more 
likely to be found in complexes than mRNA, often bound to proteins or other nucleic 
acids (Geisler and Coller, 2013). If ABCB5β acted as an lncRNA, it may help to explain 
some of the more perplexing results reported here. If the RNA was bound to other 
proteins (not involved in translation), it may explain both why the ABCB5β protein is 
poorly translated, and why some of the siRNAs failed to knockdown the transcribed 
product. There is no precedent for an RNA transcript to have a duel role as both mRNA 
and lncRNA, however it is theoretically possible for ABCB5β, given the results here 
described.  
 
At present, no direct link between ABCB5β and cellular senescence or the cell cycle has 
been described in the literature. The only connection between ABCB5β and the cell 
cycle currently reported is the observation that in ABCB5β+ MMICs the DEAD box 
polypeptide 43 (HAGE) is up-regulated, leading to down-regulation of promyelocytic 
leukaemia protein (PML) isoforms II and III (PML-II/III; Linely et al., 2012). The cause 
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of the increased expression of HAGE in these cells was not identified, although it could 
result from ABCB5β expression. Increased expression of HAGE is known to induce 
suppressor of cytokine signalling 1 (SOCS1), which ubiquitinates janus kinase 2 
(JAK2) and targets it for degradation (Mathieu et al., 2014). Degradation of JAK2 
blocks signal transduction and the downstream expression of PML in these cells. PML 
has previously been shown to bind hypophosphorylated pRB, preventing its 
phosphorylation, and subsequent release of the E2F transcription factors (Figure 4-17 
section 2; (Alcalay et al., 1998). This lead Linley et al. to conclude that the proliferation 
of ABCB5+ MMICs resulted from reduced PML expression, due to increased HAGE 
expression (Linley et al., 2012, Mathieu et al., 2014).  
 
The increase in HAGE expression removes an anti-proliferative signal by reducing pRB 
phosphorylation inhibition, therefore, it is possible that this event constitutes cellular 
stress that results in increased p16 expression. Accordingly, it is therefore possible that 
ABCB5β knockdown reduces expression of HAGE, causing up-regulation of PML-II/III 
to restore the repression of pRB phosphorylation. As this layer of cell-cycle control is 
restored it may relieve cell stress, leading to a reduction in p16 expression. Intriguingly, 
expression of another isoform of PML, PML-IV, has previously been linked to 
premature senescence in fibroblasts, through the phosphorylation and acetylation of p53 
(Pearson and Pelicci, 2001). 
 
Another possible explanation linking the knockdown of ABCB5β to down-regulation of 
p16, is that ABCB5β mRNA may cause a cell stress phenotype in response to yet 
unknown mechanism (Figure 4-17 section 3). As previously discussed, lncRNAs have a  
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Figure 4-17. Possible mechanisms describing the relationship of ABCB5β  and p16. 
1. ABCB5β  transcription may be controlled by a number of transcription factors with 
binding sites within the ABCB5 promoter region, or due to PXR and RXR, which are 
known to activate transcription of other ABC family transporters in the presence of 
cytotoxic drugs (see Section 6.1). 2. ABCB5β+ MMICs are reported to have increased 
HAGE expression, leading to hyperphosphorylation of pRB due to a reduction in PML 
expression. This growth signal could be viewed as ‘cellular stress’, leading to induction 
of p16 expression. 3. ABCB5β  may act through another, currently unknown, route to 
produce cellular stress leading to induction of p16 expression. 4. ABCB5β  may act as a 
repressor of PRC1/2, or reduce expression of essential complex components. Solid lines 
signify reported interactions, where as dotted lines signify proposed interactions. Red 
lines represent epigenetic silencing.  
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wide array of possible actions, and therefore ABCB5β could effect the expression of 
multiple genes and proteins in many different ways. It is possible that ABCB5β RNA 
may be involved in the up-regulation, or activation, of a gene or protein that increases 
the level of cellular stress in HMECs. Knockdown of ABCB5β may therefore lead to a 
reduction of p16 expression as the stress on the cell is relieved. 
 
It is also hypothesised that ABCB5β may act by reducing the expression of certain PcG 
proteins which are known to be involved in the negative regulation of p16 expression 
(Figure 4-17 section 4) (Bracken et al., 2007). If this were the case, knockdown of 
ABCB5β may lead to increased repression of the INK/ARF locus, and so decreased p16 
expression. Alternatively, ABCB5β may be directly involved in the regulation of 
PRC1/2 by association with proteins that form the complex. ANRIL, the lncRNA 
encoded by the antisense strand of the INK/ARF locus, is already known to associate 
with both PRC1 and PRC2, acting as a scaffold for complex formation (Yap et al., 
2010). Although ANRIL positively regulates the actions of PRC1/2, it sets a precedent 
for the binding of lncRNA to the component proteins. 
4.3.3 Future Work 
Although the link between ABCB5β knockdown and p16 reduction in HMECs has been 
established, many questions remain unanswered. For example, the consequence of 
overexpression of ABCB5β in HMECs has not been studied. Elevated levels of both 
ABCB5β and p16 were seen with increasing passage number, associating them with 
cellular senescence. The transfection of HMECs with a plasmid encoding ABCB5β, 
such as the one used in this study (see Chapter 3), could be an avenue of future 
investigation. Overexpression of ABCB5β may cause an increase in p16 expression and 
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induce premature senescence in HMECs, if this is the case, it would strengthen the 
hypothesis that ABCB5β causes an increase in p16 via a stress-induced senescence 
manner. If the addition of ABCB5β was not found to cause an increase in p16-mediated 
senescence, it would suggest either that the low levels of mRNA expressed within the 
HMECs are sufficient to fully effect p16 expression, or that increased levels of ABCB5β 
do not drive an increase in p16 expression. Additionally, the transfection of HMECs 
with plasmids encoding ABCB5fl, could be carried out within this experiments, to assess 
whether this isoform can produce the same effects observed upon introduction of 
ABCB5β.  
 
The long-term effects of ABCB5β knockdown are also currently unknown. To 
investigate this, lentiviral particles carrying short hairpin RNA (shRNA) targeted to 
ABCB5β could be introduced into the HMECs, resulting in a consistent, stable 
knockdown of the mRNA. Culturing HMECs with a stable ABCB5β knockdown would 
generate more information about the relationship between ABCB5β and p16. One 
intriguing question is whether a long-term knockdown of ABCB5β would either delay, 
or indeed stop the onset of the p16 induced senescence phenotype observed in these 
cells. If p16 induced senescence is bypassed, cell growth may be subsequently arrested 
by telomere shortening, as previously reported in p16_ HMECs (Yaswen and Stampfer, 
2002). If this is not the case, the reason for this should be investigated, primarily by 
studying the expression of hTERT within the stably transduced HMECs. Within these 
experiments, a double stable knockdown of ABCB5β and p16 should be performed, so 
that any differences between the double and single knockdowns can be assessed. These 
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experiments may give rise to data either confirming or rejecting the hypothesis that 
ABCB5β expression is an important factor in the p16-mediated senescence of HMECs. 
 
The hypothesis that ABCB5β may function as an lncRNA should also be explored in 
detail. As lncRNAs have a wide array of functions within the cells, with over 15 
different modes of action currently known (Geisler and Coller, 2013), elucidating the 
function of a particular lncRNA can be a challenge. Most commonly, lncRNAs perform 
their functions whilst bound to RBPs. In order to test this possibility, endogenous 
ABCB5β from HMECs could be analysed for bound RBPs using a modified RBP 
immunoprecipitation (RIP) technique. RIP can be viewed as the RNA equivalent of the 
well-known chromatin immunoprecipitation (ChIP) technique. Where ChIP identifies 
proteins bound to DNA, RIP can be used to identify specific RNA molecules bound to 
RBPs. RIP is performed by immunoprecipitation of endogenous RBP complexes, and 
the co-isolation of RNAs associated with the precipitated complex. Once performed, 
RNA probes could be used to pull out the ABCB5β transcript and any associated RBPs, 
which can then be used for further investigations into the function of ABCB5β.  
 
An important avenue of future study should be the investigation of how the level of 
ABCB5β mRNA is linked to p16 expression. At present, the link between HAGE and 
ABCB5β is restricted to the increased expression of HAGE in ABCB5β+ MMICs. In 
order to expand the knowledge around this possible interaction, the expression of 
HAGE in HMECs subjected to ABCB5β knockdown should be investigated; in 
particular, the relative levels of HAGE, SOCS1 and PML expression should be studied, 
as these genes were previously identified as having altered expression in ABCB5β+ 
MMICs (Linley et al., 2012, Mathieu et al., 2014). Changes in the relative expression 
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levels of these genes in response to ABCB5β knockdown would bolster the hypothesis 
that HAGE is up regulated in response to an increase in ABCB5β expression. 
Additionally, the relative expression of these genes should be studied in HMECs of 
increasing passage number. Increased levels of HAGE in samples taken from cells with 
a higher passage number may be further indication of ABCB5β playing an important 
role in the induction of p16-mediated senescence in HMECs, and strengthen the 
hypothesis that ABCB5β acts on p16 via HAGE, SOCS1 and PML.  
 
It was hypothesised within Section 4.3.2 that ABCB5β may act to negatively regulate 
PRC1/2, either through a direct interaction, or via down regulation of constituent 
components of the complexes. To investigate this further, RT-qPCR should be 
performed on mRNA extracted from both control cells, and cells transfected with 
siRNA targeting ABCB5β, in order to analyse any changes in the expression levels of 
PcG proteins essential for p16 repression, such as CBX7, CBX8, EZH2, BMI1 and 
SUZ12 (Bracken et al., 2007). If any of these genes are found to exhibit altered 
expression patterns in cells transfected with ABCB5β targeting siRNA, any array of 
additional PcG proteins, and their regulators, could also be studied to gain a further 
insight. Another approach to this possible mechanism would be to investigate whether 
any changes occur in both the PcG proteins, and histone modifications found at the 
INK/ARF locus, after transfection of HMECs with ABCB5β targeting siRNAs. Both the 
PcG proteins and histone modifications could be assessed using a ChIP assay, with kits 
for the assessment of these features commercially available.  Evaluating changes in 
either the expression of the PcG proteins, or their presence across the INK/ARF locus 
could provide valuable understanding of the mechanism by which ABCB5β knockdown 
leads to decreased p16 expression.  
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In addition to the continuation of the study of ABCB5β knockdown HMECs described 
above, the effects of ABCB5β in other endogenously expressing cell lines could be 
evaluated, for example, the A431 and K562 cell lines described in Chapter 3. 
Knockdown of ABCB5β in these cells will allow the comparison of knockdown in cells 
expressing both mRNA and protein (A431 and K562) and cells expressing only mRNA 
(HMEC). Similar experiments could be carried out upon the two cell lines to the ones 
described for HMECs in this study, such as changes in proliferation and changes in 
expression of p16 (depending on the p16 status of the cell lines). If similar changes are 
apparent in the cell lines upon knockdown of ABCB5β, a system would be provided 
wherein the cellular changes resulting from ABCB5β knockdown can be studied in a 
more ‘cancer like’ environment, in comparison to the ‘normal cells’ used within this 
investigation. 
 
Further to the techniques described above, RNA sequencing (RNA-seq) could be 
utilised to further understand the cellular response to ABCB5β knockdown. RNA-seq on 
total RNA extracted from HMECs transfected with siRNAs targeting ABCB5β would 
allow the changes in gene expression, miRNAs and other ncRNAs (non-coding RNAs) 
to be studied in detail. Although each siRNA targeting ABCB5β will have its own array 
of off target effects, these can be corrected for by the use of the multiple siRNAs, each 
of which has a different target sequence, for example Ambion-2 and Ambion-3, which 
were used in this study. By eliminating the changes seen in mRNA, miRNA and 
ncRNA levels that are not shared by all ABCB5β targeting siRNAs, only the changes 
due to the downstream effects of ABCB5β mRNA reduction will remain. These results 
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can in turn be compared to data collected from HMECs which have had p16 expression 
reduced (siRNA targeting p16) or increased (siRNA targeting CBX7), allowing the 
cellular changes which occur following ABCB5β knockdown to be accurately compared 
to the changes observed when p16 itself is directly modulated. Bioinformatic analysis of 
the resulting list of genes, and their changes in expression, for example by Ingenuity 
Pathway Analysis (IPA; see Section 5.2.3.2) could be used to identify potential links 
between the ABCB5β and p16, and inform changes, or conformations in the possible 
mechanisms outlined in Section 4.3.2. 
 
Another possible avenue for the use of RNA-seq is to assess the changes that happen in 
young vs. old (early passage to late passage) HMECs. As increasing expression of 
ABCB5β over time has previously been demonstrated, a more in-depth analysis of these 
changes may provide valuable insights into the changes occurring. Any data could then 
be compared to the previous results, for example: how similar are the older HMECs 
compared to HMECs which have has the expression of p16 induced via CBX7 
knockdown.  
 
Any putative intermediates of the ABCB5β – p16 relationship found by RNA-seq, or 
any other technique, should subsequently be investigated in HMECs via both 
knockdown and overexpression experiments, so that their relationship, if any, to the 
proteins of interested can be properly established. Analysis of the pathway linking 
ABCB5β and p16 may provide potential targets for therapy, in which p16 expression 
could be modulated. Indeed, various components of the mechanism may already have 
known chemical modulators that could be quickly and efficiently tested for efficacy.  
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Chapter Five 
5  Oncogenic miRNAs, p16 
and basal-like breast 
cancer 
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5.1 Introduction 
Basal-like breast cancers (BLBCs) account for around 15 – 20 % of all breast cancers, 
and commonly present at grade-3 with a clinically aggressive phenotype making them a 
priority for treatment (Fulford et al., 2006). The majority of BLBCs belong to the triple 
negative breast cancer (TNBC) subtype of breast tumours, which lack expression of 
oestrogen receptor (OR), progesterone receptor (PR) and human epidermal growth 
factor receptor (HER2) (Abd El-Rehim et al., 2004, Nielsen et al., 2004, Abd El-Rehim 
et al., 2005), although BLBCs are also defined by their expression of CK5/6 and 17, 
EGFR, VEGF and c-kit (Nielsen et al., 2004, Brenton et al., 2005, Linderholm et al., 
2009). Unlike other types of breast cancer, BLBCs cannot be treated with targeted 
therapies such as trastuzumab, tamoxifen or aromatase inhibitors, because they lack OR 
and HER2 expression. This means that surgical resection of the tumour, generic 
chemotherapy and radiotherapy are often the only treatments available.  
 
As described in Chapter 1, p16 is an important regulator of the normal cell cycle, 
controlling passage through the R-point of the cell cycle – the main checkpoint of the 
G1/S phase transition – via its interaction with CDK4/6 (Serrano et al., 1993, Gil and 
Peters, 2006). p16 expression increases with age in vivo, causing cells to lose their 
proliferative capability and enter senescence. p16 can also trigger oncogene-induced 
senescence (OIS), in which the presence of an oncogenic signal causes up-regulation of 
p16 expression, and thus cellular senescence (Serrano et al., 1997, Lin et al., 1998). 
 
Expression of p16 is often altered in human tumours, where it can be deleted, mutated, 
or epigenetically down-regulated (Esteller et al., 2001, Forbes et al., 2006). Inactivation 
of p16 is commonly thought to be an important step in tumour development (Kamb et 
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al., 1994, Ruas and Peters, 1998). In BLBC, overexpression of wild-type p16 has 
consistently been found to correlate with a poor prognosis (Hui et al., 2000, Milde-
Langosch et al., 2001), with higher expression also suggested to confer a more 
homogeneous subgroup of BLBC (Abou-Bakr and Eldweny, 2013). Although the link 
between p16 expression in BLBC and poor prognosis has been demonstrated multiple 
times, the underlying mechanism behind this, and its relevance to the aggressiveness of 
the disease, are unknown. 
 
Recently, a genome-wide miRNA screen identified novel miRNAs involved in p16 
regulation and senescence in P6 human mammary epithelial cells (HMECs) (Overhoff 
et al., 2014). HMECs have a finite lifespan with well-documented p16-mediated 
senescence associated with stress resulting from normal serial passage in vitro (Garbe et 
al., 2009). This study identified 12 miRNAs (hsa-miR-24, hsa-miR-140-3p, hsa-miR-
212, hsa-miR-221, hsa-miR-451, hsa-miR-512-5p, hsa-miR-520h, hsa-miR-574-5p, 
hsa-miR-770-5p, hsa-miR-992, hsa-miR-1207-3p and hsa-miR-1297), which when 
transfected into HMECs, increased the expression of p16 and cellular proliferation. 
These potentially oncogenic – because they caused an increase in also cellular 
proliferation, independent of cellular stimuli – miRNAs (oncomiRs) were noted to 
change the HMECs into a more proliferative, although p16-positive, phenotype, similar 
to that of BLBCs.  
 
The expression of these 12 miRNAs were examined in 1,302 breast cancer tissue 
samples (Figure 5-1; Dr. Cleo Bishop, Barts and The London School of Medicine and 
Dentistry, personal communication) (Curtis et al., 2012). The five putative oncomiRs 
found to have the greatest dysregulation in breast cancer samples, when compared to 
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normal breast tissue samples, were selected for further study here: hsa-miR-24 (miR-
24), hsa-miR-140-3p (miR-140-3p), hsa-miR-221 (miR-221), hsa-miR-451 (miR-451) 
and hsa-miR-574-5p (miR-574). 
 
By investigating their mechanism of action it is hoped that important insights into the 
biology of BLBC will be revealed, which may provide clues for the development of 
future targeted-therapies.  
 
Figure 5-1. Expression profiles of twelve putative oncomiRs in breast cancer. 
Heat map of up-regulation (blue) and down-regulation (red) of putative oncomiRs in 
breast cancer tumour samples, compared to normal breast samples, shown as log fold 
change. miRNAs were grouped by unsupervised hierarchical clustering to compare the 
dysregulation pattern of each miRNA. hsa-miR-24, hsa-miR-140-3p, hsa-miR-221, hsa-
miR-451 and hsa-miR-574-5p were the most dysregulated miRNAs across the panel of 
breast tumours, with the dysregulation profile of hsa-miR-451 being the most dissimilar 
to that of any other miRNAs. Dr. Cleo Bishop, personal communication.  
 
5.1.1 Putative oncomiRs 
5.1.1.1 hsa-miR-24 
Although miR-24 has been widely reported to promote cancer cell proliferation and 
metastasis (Du et al., 2013, Giglio et al., 2013, Li et al., 2013a, Murata et al., 2013), it 
has contradictorily also been found to inhibit cell division in osteosarcoma through its 
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targeting of lysophosphatidic acid acyltransferase β (Song et al., 2013). Studies have 
also found that miR-24 promotes cell proliferation by directly targeting the tumour 
suppressors p16 and p27Kip1 (Lal et al., 2008, Giglio et al., 2013), potentially playing a 
role in carcinogenesis. Additionally, miR-24 has been implicated in promoting 
erythropoiesis (Wang et al., 2014), regulating aldosterone and cortisol production 
(Robertson et al., 2013), and mediating pancreatic β-cell dysfunction (Zhu et al., 
2013b). 
5.1.1.2 hsa-miR-140-3p 
Little is known currently of miR-140-3p, however, it has been identified as a potential 
blood-borne biomarker for cancer, type 2 diabetes mellitus and coronary artery disease 
(Taurino et al., 2010, Taguchi and Murakami, 2013, Collares et al., 2013). Other 
research has found that miR-140-3p is down-regulated in cutaneous squamous cell 
carcinoma, lung squamous cell carcinoma, basal cell carcinoma and ovarian cancer (Tan 
et al., 2011, Sand et al., 2012a, Sand et al., 2012b, Linley et al., 2012, Miles et al., 
2012).  
5.1.1.3 hsa-miR-221 
miR-221 has previously been reported to have an oncogenic role in glioblastoma 
multiform-initiating cells, where high expression of this miRNA was reported and 
suggested to be one of the key regulators in cell transformation (Aldaz et al., 2013). 
This miRNA is found to be consistently up-regulated in replicatively senescent 
endothelial cells (Dellago et al., 2013), and its knockdown in differentiated cells is 
reported to reduce expression of differentiation markers, and increase expression of 
stem cell markers (Aldaz et al., 2013).  
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5.1.1.4 hsa-miR-451 
At present there are multiple studies which have identified miR-451 as being either up-
regulated (osteosarcoma) (Dai et al., 2013), or down-regulated in various cancers 
(squamous cell lung carcinoma, bladder urothelial carcinoma) (Gao et al., 2011, Xie et 
al., 2012), with no role clearly identified.  
5.1.1.5 hsa-miR-574-5p 
miR-574 has been identified as significantly up-regulated in both non-small-cell lung 
cancer and oesophageal squamous cell carcinoma (Foss et al., 2011, Yang et al., 2013), 
and its presence in the blood has been suggested as a possible serum-based biomarker 
for the former (Foss et al., 2011). 
5.1.2 Aims 
The hypothesis for the investigations carried out in this chapter was that expression of 
the five putative oncomiRs previously identified may accurately model p16+ BLBC, and 
that the identification of their target genes and modes of action would point towards 
potential therapies for p16+ BLBC. To investigate the relationship between the tumour 
suppressor gene p16 and the putative oncomiRs: miR-24, miR-140-3p, miR-221, miR-
451 and miR-574. Specifically, to: 
• Recapitulate the effect of miRNAs detailed in Overhoff et al. (2014), in which 
their introduction into HMECs caused an increase in p16 expression and 
proliferation; 
• Introduce anti-miRNAs (antimiRs) targeting the miRNAs into HMECs to 
examine endogenous expression of the miRNAs and their phenotypic effects; 
• Search for potential oncomiR gene targets that could link p16 expression and 
cell proliferation using bioinformatics techniques and web-databases; and 
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• Investigate the effect of introducing miRNAs and antimiRs into the p16-positive 
BLBC cancer cell line MDA-MB-468, to model the affect of miRNAs in the 
disease.  
5.2 Results 
5.2.1 Effect of putative oncogenic miRNAs in HMECs 
In order to confirm the findings originally reported by Overhoff et al., the five putative 
oncomiRs were transfected into HMECs using the conditions previously optimised for 
the study of ABCB5 by siRNA knockdown (see Section 4.2.1). The miRNAs were 
transfected into the cells individually at 60 nM or 90 nM, alongside the negative control 
siRNA siGLO, and two positive control siRNAs targeting CBX7 and p16. Also included 
as an additional positive control was the miRNA hsa-miR-181a (miR-181a), which has 
previously been found to induce senescence in both HMECs (Overhoff et al., 2014) and 
other cells (Shin et al., 2011), although not to the same extent as CBX7 knockdown. The 
higher concentrations of RNA used in these experiments (60 nM and 90 nM compared 
to the previous concentration of 30 nM) are due to the lower potency of miRNA, with 
respect to the reduction in target gene translation, compared to that of siRNA.  
 
Upon transfection of HMECs with the control siRNAs at 60 nM targeting CBX7 and 
p16, significant increases (p = 0.0004) and decreases (p = 0.0013) in p16 intensity were 
observed compared to the siGLO control (Figure 5-2 panel A). In addition to these 
siRNAs, the positive control miRNA, miR-181a, was also found to significantly 
increase the p16 intensity of transfected cells (p = 0.0260). Transfection of all putative 
oncomiRs into HMECs at 60 nM produced a significant increase in p16 intensity 
 204 
(Figure 5-2 panel B). In addition to the miRNAs, their pool (miR-P) was also examined 
and caused the most significant change (p = 0.0019).  
 
Transfection of the HMECs with control siRNAs at 90 nM caused a significant increase 
in p16 intensity upon transfection with CBX7 targeting siRNA (p = 0.0001), and a 
significant decrease in p16 intensity upon transfection of siRNA targeting p16 (p = 
0.0053; Figure 5-2 panel C). The control miRNA miR-181a was again found to cause a 
significant increase in p16 intensity (p = 0.0016), as was observed at 60 nM. 
Transfection of all putative oncomiRs into HMECs at 90 nM again produced a 
significant increase in p16 intensity (Figure 5-2 panel D). With the higher concentration 
of miRNA, miR-24 was found to cause the most significant change in p16 intensity of 
all the putative oncomiRs.   
 
In addition to the measurement of p16 intensity, the cell number, cell area and nuclear 
area of the transfected HMECs were evaluated (Figure 5-3). Significant decreases in 
cell number were observed upon transfection of siRNA targeting CBX7 or miR-181a 
into HMECs at 60 nM and 90 nM (all p < 0.001I; Figure 5-3 panel A). A significant 
increase in cell number was also observed upon transfection of p16 targeting siRNA 
into HMECs at both concentrations (both p < 0.001).  When the putative oncomiRs 
were transfected into the HMECs, significant increases (all p < 0.001) in cell number 
were observed upon introduction of all miRNAs and their pool, at both 60 nM and 90 
nM.  
                                                
 
I Accurate p-values cannot be calculated when using a one-way ANOVA due to limitations in the software being used 
(Prism v5.0d; GraphPad Software Inc, CA). See Section 2.29.2. 
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Figure 5-2. Putative oncomiRs increase p16 levels in HMECs. 
A. HMECs transfected with 60 nM of the control siRNAs targeting CBX7 (orange) or p16 
(purple) increased and decreased p16 intensity, respectively when compared to the 
siGLO control (grey). Introduction of 60 nM control miRNA miR-181a (mauve) also 
caused an increase in p16 intensity. Median p16 intensity values (AU) are shown by the 
dotted lines. B. Transfection with all putative oncomiRs (blue) and their pool (miR-P) at 
60 nM caused significant increases in p16 intensity compared to siGLO control (grey). 
Representative images show antibody staining of p16 (green) and DAPI staining of 
nuclei (blue) 120 h post transfection. * p < 0.05; ** p < 0.01; *** p < 0.001. n = 3 biological 
repeats. 
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Figure 5-2. (continued) Putative oncomiRs increase p16 levels in HMECs. 
C. HMECs transfected with 90 nM of the control siRNAs targeting CBX7 (orange) or p16 
(purple) increased and decreased p16 intensity, respectively when compared to the 
siGLO control (grey). Introduction of 90 nM control miRNA miR-181a (mauve) also 
caused an increase in p16 intensity. Median p16 intensity values (AU) are shown by the 
dotted lines. D. Transfection with all putative oncomiRs (blue) and their pool (miR-P) at 
90 nM caused significant increases in p16 intensity compared to siGLO control (grey). 
Representative images show antibody staining of p16 (green) and DAPI staining of 
nuclei (blue) 120 h post transfection. * p < 0.05; ** p < 0.01; *** p < 0.001. n = 3 biological 
repeats. 
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Figure 5-3. Cell number, cell area and nuclear area of HMECs transfected with putative 
oncomiRs. 
A. Significant increases in cell number were observed upon transfection of all putative 
oncomiRs and their pool (miR-P) into HMECs at both 60 nM and 90 nM. B. No significant 
changes in cell area were observed upon transfection of any miRNAs into the HMECs at 
either 60 nM or 90 nM. C. Fluctuations in nuclear area were observed in cells transfected 
with the putative oncomiRs, although none of the changes were found to be significant 
at 60 nM or 90 nM. All error bars represent one SD. *** p < 0.001. n = 3 biological repeats. 
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Transfection of the positive control siRNAs targeting CBX7 and p16 into the cells 
caused respective increases, and decreases, in cell and nuclear area (Figure 5-3 panels B 
and C), in line with previous experiments in HMECs. Introduction of miR-181a into the 
HMECs produced a significant increase in cell area at both 60 mM and 90 nM (both p < 
0.001), similar to CBX7 knockdown, although this did not cause a significant increase in 
nuclear area. No significant changes in cell or nuclear area were seen upon introduction 
of any of the putative oncomiRs into the HMECs at either 60 nM or 90 nM.  
 
Introduction of the miRNAs into HMECs appears to induce a more proliferative 
phenotype, whilst increasing expression of p16. These two phenotypes are at first sight 
contradictory, as there is a well documented pathway linking p16 expression to reduced 
proliferation and senescence in HMECs (see Section 5.1), and also in most other 
primary cell types (see Section 1.15). The fact that the other two hallmarks of 
senescence (increase in cell area and nuclear area) in these cells are not present further 
compounds the issue, and points towards an uncoupling of the p16 – cell cycle arrest 
pathway. Hypothetically, this might be explained by the increase in proliferation, 
inducing an increase in p16 via a protective positive feedback loop, which then cannot 
cause subsequent cellular senescence, supporting the putative oncomiR role for these 
miRNAs. 
5.2.2 Transfection of anti-miRNAs into HMECs 
AntimiRs targeting the five miRNAs were also transfected in to the cells in separate 
experiments. This was carried out in order to examine whether any endogenous 
expression of the oncomiRs was present within the HMECs. If any of the five miRNAs 
are expressed endogenously, their depletion would be postulated to cause the opposite  
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Figure 5-4. antimiRs targeting putative oncomiRs have no effect on HMECs. 
A. Control siRNAs targeting CBX7 (orange) or p16 (purple) cause an increase in p16 
intensity and a reduction in p16 intensity, respectively when compared to the siGLO 
control (grey) at 60 nM. Introduction of 60 nM control miRNA miR-181a (mauve) also 
caused an increase in p16 intensity. Median p16 intensity values (AU) are shown by the 
dotted lines. B. Transfection with antimiRs targeting putative oncomiRs (green) at 60 nM 
showed no significant change in p16 intensity compared to siGLO control (grey). 
Representative images show antibody staining of p16 (green) and DAPI staining of 
nuclei (blue) 120 h post transfection. C. No significant changes in cell number were 
observed in cells transfected with antimiRs at 60 nM, when counted at the 120 h time 
point. All error bars represent one SD. ** p < 0.01; *** p < 0.001. n = 3 biological repeats.  
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Figure 5-4. (continued) antimiRs targeting putative oncomiRs have no effect on HMECs 
D. Control siRNAs targeting CBX7 (orange) or p16 (purple) cause an increase in p16 
intensity and a reduction in p16 intensity, respectively, when compared to the siGLO 
control (grey) at 90 nM. Introduction of 90 nM control miRNA miR-181a (mauve) also 
caused an increase in p16 intensity. Median p16 intensity values (AU) are shown by the 
dotted lines. E. Transfection with antimiRs targeting putative oncomiRs (green) at 90 nM 
showed no significant change in p16 intensity compared to siGLO control (grey). 
Representative images show antibody staining of p16 (green) and DAPI staining of 
nuclei (blue) 120 h post transfection. F. No significant changes in cell number were 
observed in cells transfected with antimiRs at 90 nM, when counted at the 120 h time 
point. All error bars represent one SD. ** p < 0.01; *** p < 0.001. n = 3 biological repeats.  
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phenotype of introducing the oncomiR, specifically: a decrease in cell proliferation, and 
a decrease in p16 intensity. These experiments were carried out at the same time as the 
ones previously described (see Section 5.2.1), therefore all of the controls are identical 
(Figure 5-4 panels A and D).  
 
Transfection of the antimiRs targeting the five putative oncomiRs had no significant 
effect on p16 intensity at 60 nM in the HMECs (Figure 5-4 panel B). The transfection 
of antimiRs into the cells did not cause any significant change in cell number (Figure 
5-4 panel C), whereas introduction of the control siRNAs and miRNA were all found to 
cause significant (all p < 0.001) increases, and decreases in cell number. 
 
When transfected into HMECs at 90 nM, the antimiRs again had no effect on p16 
intensity (Figure 5-4 panel E). There was also no significant change in the cell number 
(Figure 5-4 panel F). 
 
These results, taken together with those described in Section 5.2.1, suggest that the 
HMECs are sensitive to the expression of the five putative oncomiRs examined here: 
miR-24, miR-140-3p, miR-221, miR-451, and miR-574. The data also suggest that the 
HMECs do not express the miRNAs endogenously at P6, as the opposite phenotype 
would be expected upon transfection of the antimiRs into the cells.  
 
5.2.3 Identifying potential miRNA target genes 
5.2.3.1 Mining potential target genes from prediction programs 
To further investigate the effect of the putative oncomiRs on the expression of p16 and 
cellular proliferation, potential target genes of the five miRNAs were searched for. 
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These genes were mined from the online miRNA binding prediction comparison 
program miRWalkI (Dweep et al., 2011). 
 
The database was interrogated by searching for the targets of each miRNA individually 
in the 3’-UTR of human genes, with a comparative analysis across five prediction 
programs: miRanda, miRDB, miRWalk, miR22 and TargetScan. The predicted gene 
targets from the five programs were compared, with genes common to all prediction 
programs analysed further. The list of target genes provided a p value for each candidate 
representing the probability at which they are targeted by the miRNAsII (Appendix III). 
A total of 991 unique genes were taken forward for further analysis, each with a p value 
of less than 0.05 (400 for miR-24; 277 for miR-140-3p; 219 for miR-221; 48 for miR-
451; and 193 for miR-574).  
5.2.3.2 Evaluating miRNA potential targets 
Ingenuity Pathway AnalysisIII (IPA; Ingenuity® Systems) is a large database of up-to-
date biological scientific findings coupled with complex analysis tools capable of 
finding links between genes on the basis of expression in diseases, cellular function and 
functional pathways. A vast database of information at the analysis tool’s disposal 
makes IPA a powerful program for studying large sets of genes generated from a variety 
of sources such as RNA-seq, siRNA screens, and as in the case presented here, miRNA 
target prediction. 
                                                
 
I  The miRWalk miRNA predicted target search can be found at http://www.umm.uni-heidelberg.de/apps/zmf/ 
mirwalk/micrornapredictedtarget.html (accessed June 2013).  
II  The probability of an miRNA sequence targeting a given mRNA sequence, calculated using the Poisson 
distribution. More information can be found at http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/documentation 
.html#pv (Accessed June 2013). 
III  Ingenuity Pathway Analysis can be found at http://www.ingenuity.com/products/ipa#/?tab (accessed August 2013). 
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Figure 5-5. Heat map showing predicted targeting of candidate genes by putative 
oncomiRs. 
The top 116 candidate genes grouped by gene function. The majority of the genes are 
targeted by two or more miRNAs, with KLF8 the only gene targeted by all five.  
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Further analysis of the 991 putative target genes was carried out using IPA, in an 
attempt to identify genes involved in the regulation of p16 expression and cellular 
proliferation. The potential target genes for each miRNA were uploaded to IPA and 
used in a Core Analysis search for experimentally observed, direct and indirect links 
between the genes in the data set, in both mice and humans.  
 
In total, 294 genes linked to p16 expression and cellular proliferation were found by the 
Core Analysis performed on the 991 predicted target genes of the five miRNAs 
(Appendix). This shortlist of genes was ranked by scoring both the p value and the 
number of miRNAs targeting each gene. Higher scores were given to genes with lower 
p values that were targeted by more of the miRNAs. The top ranked genes (116) were 
then selected as candidates for further analysis in future experiments (see 5.3.3), and 
grouped by cellular function (Figure 5-5). 
5.2.4 Effect of putative oncogenic miRNAs on MDA-MB-468 cells 
To further test the effect of the putative oncomiRs on p16 expression and cellular 
proliferation, the BLBC cell line MDA-MB-468 was chosen (see Section 2.1.2.9). This 
cell line was chosen to model the effects of the oncomiRs in BLBCs, as these cancers 
frequently are found to have both a highly proliferative, aggressive phenotype, and a 
high expression of p16 (see Section 1.18.1). Any results alluding to a miRNA-related 
mechanism could be exploited to aid in the management of these aggressive tumours. 
 
To test this hypothesis, the miRNAs were transfected into the MDA-MB-468 cell line 
using the conditions optimised in Appendix IV. Each miRNA was transfected into the 
cells at 60 nM and 90 nM, alongside the negative control siRNA siGLO, and the two 
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positive control siRNAs targeting p16 and KIF11 (an essential molecular motor protein 
required for mitosis, the knockdown of which causes apoptosis). 
 
Upon transfection of the control siRNAs at 60 nM, no change in p16 intensity was 
observed with siRNA KIF11, whereas p16 intensity significantly reduced with the p16 
targeting siRNA, as predicted (Figure 5-6 panel A; p = 0.0053). A significant increase 
and decrease in cell number were observed upon transfection of siRNAs targeting p16 
and KIF11, respectively (Figure 5-6 panel C; p < 0.001). Upon transfection of putative 
oncomiRs at 60 nM, no significant variation was observed in either p16 intensity 
(Figure 5-6 panel B), or cell number (Figure 5-6 panel C). 
 
Transfection of MDA-MB-468 with control siRNAs at 90 nM displayed a significant 
increase in p16 intensity upon transfection of KIF11 siRNA (p = 0.0221), and a 
significant decrease in p16 intensity upon transfection of siRNA targeting p16 (Figure 
5-6 panel D; p = 0.0424). The increase in p16 intensity upon transfection of the siRNA 
targeting KIF11 at 90 nM is most likely indicative of a cellular response to cytotoxicity 
due to the higher concentration of siRNA used. Significant decreases in cell number 
were seen with siRNAs targeting p16 and KIF11 when transfected at 90 nM (Figure 
5-6; p < 0.001). The reduced cell number upon transfection with siRNA targeting p16 at  
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Figure 5-6. Putative oncomiRs have no effect on MDA-MB-468 cells. 
A. The positive control siRNA targeting p16 (purple) reduced p16 intensity at 60 nM 
compared to the siGLO control (grey). The killer control siRNA targeting KIF11 (red) was 
found to have significant effect on p16 intensity compared to siGLO at 60 nM. Median 
intensity values (AU) are shown by the dotted lines. B. Transfection with putative 
oncomiRs (blue) at 60 nM showed no significant change in p16 intensity compared to 
siGLO control (grey). Representative images show antibody staining of p16 (green) and 
DAPI staining of nuclei (blue) 120 h post transfection. C. No significant change in cell 
number was observed in cells transfected with putative oncomiRs at 60 nM when 
counted at the 120 h time point. All error bars represent one SD. ** p < 0.01; *** p < 0.001. 
n = 3 biological repeats.  
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Figure 5-8. (continued) Putative oncomiRs transfected at 90 nM have no effect on MDA-
MB-468 cells. 
D. The positive control siRNAs targeting p16 (purple) and KIF11 (red) reduce p16 
intensity and increase p16 intensity, respectively, at 90 nM compared to the siGLO 
control (grey). Median intensity values (AU) are shown by the dotted lines. E. 
Transfection with putative oncomiRs (blue) at 90 nM showed no significant change in 
p16 intensity compared to siGLO control (grey). Representative images show antibody 
staining of p16 (green) and DAPI staining of nuclei (blue) 120 h post transfection. F. No 
significant change in cell number was observed in cells transfected with putative 
oncomiRs at 90 nM when counted at the 120 h time point. All error bars represent one 
SD. * p < 0.05; ** p < 0.01; *** p < 0.001. n = 3 biological repeats.  
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90 nM, compared to an increase upon transfection at 60 nM, is again probably due to an 
increased level of toxicity with the higher dose of siRNA. When the putative oncomiRs 
were introduced into the MDA-MB-468s at 90 nM, again no significant changes in 
either p16 intensity (Figure 5-6 panel E), or cell number were observed (Figure 5-6 
panel F). 
 
The introduction of exogenous miRNAs may not cause any observable change in cell 
morphology and behaviour, if they are already highly expressed within the cell. This 
hypothesis may explain the lack of effect described following transfection of the MDA-
MB-468s, although this will need to be confirmed by RT-qPCR to demonstrate 
endogenous miRNA expression. 
5.2.5 Effect of anti-miRNAs on MDA-MB-468 cells 
To investigate the role of the putative oncomiRs in the MDA-MB-468 cells, antimiRs 
were used to downregulate endogenous expression. If the oncomiRs induce the p16 
positive, proliferative phenotype of the MDA-MB-468 cells, it was postulated that 
transfection of the antimiRs into the cells may reduce p16 intensity and reduce 
proliferation. When the antimiRs targeting the putative oncomiRs were introduced into 
the cells at either 60 nM or 90 nM, no significant changes in either p16 intensity (Figure 
5-7 panels B and E), or cell number were observed (Figure 5-7 panels C and F).  
 
Although the endogenous expression level of each of the five putative oncomiRs in 
MDA-MB-468s is currently unknown, this data suggests that they are not linked to p16  
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Figure 5-7. AntimiRs targeting putative oncomiRs have no effect on MDA-MB-468 cells. 
A. The positive control siRNA targeting p16 (purple) reduced p16 intensity at 60 nM 
compared to the siGLO control (grey). The killer control siRNA targeting KIF11 (red) was 
not found to have significant effect on p16 intensity at 60 nM. Median intensity values 
(AU) are shown by the dotted lines. B. Transfection with antimiRs targeting putative 
oncomiRs (green) at 60 nM showed no significant change in p16 intensity compared to 
siGLO control (grey). Representative images show antibody staining of p16 (green) and 
DAPI staining of nuclei (blue) 120 h post transfection. C. No significant change in cell 
number was observed in cells transfected with antimiRs targeting putative oncomiRs at 
60 nM when counted at the 120 h time point. All error bars represent one SD. ** p < 0.01; 
*** p < 0.001. n = 3 biological repeats.  
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Figure 5-9. (continued) AntimiRs targeting putative oncomiRs have no effect on MDA-
MB-468 cells. 
D. The positive control siRNAs targeting p16 (purple) and KIF11 (red) reduced p16 
intensity and increased p16 intensity respectively at 90 nM compared to the siGLO 
control (grey). Median intensity values (AU) are shown by the dotted lines. E. 
Transfection with antimiRs targeting putative oncomiRs (green) at 90 nM showed no 
significant change in p16 intensity compared to siGLO control (grey). Representative 
images show antibody staining of p16 (green) and DAPI staining of nuclei (blue) 120 h 
post transfection. F. No significant change in cell number was observed in cells 
transfected with antimiRs targeting putative oncomiRs at 90 nM when counted at the 120 
h time point. All error bars represent one SD. * p < 0.05; ** p < 0.01; *** p < 0.001. n = 3 
biological repeats. 
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expression and cellular proliferation in these cells, given that neither addition nor 
depletion of these miRNAs from the cells had a measurable effect on p16 expression, or 
cell proliferation.  
5.3 Discussion 
5.3.1 Summary of the findings 
In previously published work, transfection of five miRNAs into HMECs caused an 
increase in both cellular proliferation and p16 expression (Overhoff et al., 2014). In 
order to confirm and build upon these findings, HMECs were transfected with each the 
miRNAs and also their corresponding antimiRs. The HMECs were transfected with 60 
nM or 90 nM miRNA or antimiR, or with control siRNAs or control miRNA.  
 
The control siRNAs targeting p16 and CBX7, and the control miRNA miR-181a were 
used as positive controls for modulation of p16 in senescence by siRNA, and miRNA, 
respectively. The siRNA targeting CBX7 and p16 were used as controls for expression 
and depletion of p16, respectively, as before (see Section 4.2.2.1). Introduction of the 
control miRNA miR-181a caused significant increase in both p16 intensity and cell 
area, and a significant decrease in cell number, demonstrating that introduction of miR-
181a is a positive control for miRNA modulation of p16 expression (see Section 5.2.1). 
 
Introduction of all five putative oncomiRs, and their pool, into the HMECs caused 
significant increase in p16 intensity compared to the siGLO negative control, at both 60 
nM and 90 nM concentrations. The most significant changes were observed with miR-P 
and miR-24 at 60 nM and 90 nM, respectively. Introduction of all miRNAs and their 
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pool also caused significant increase in cell number, although no significant changes 
were recorded for cell or nuclear area.  
 
These results confirm the original findings, and show that the HMECs become 
surprisingly more proliferative while expressing p16 upon transfection of these 
miRNAs. Transfection of the antimiRs targeting the five miRNAs into HMECs, 
however, did not produce any phenotypic changes at either 60 nM or 90 nM, suggesting 
that the miRNAs are not expressed endogenously (see Section 5.2.2).  
 
In order to understand the mechanism of action leading to proliferation despite p16 
expression in HMECs, bioinformatic investigation of potential gene targets of the 
miRNAs was carried out (see Section 5.2.3). The miRWalk prediction comparison 
program initially identified potential targets, and significant hits were taken forward for 
further analysis by IPA. A total of 991 genes were analysed by IPA Core Analysis, with 
genes linked to cellular proliferation and p16 expression selected for more in-depth 
analysis. Potential target genes identified by IPA were ranked by miRNA targeting 
probability and the number of miRNAs targeting each gene. This stratified the 
candidates and the top 116 were designated for future study. 
 
p16 expression alongside cellular proliferation is a hallmark of BLBC. The miRNAs 
were therefore transfected into the p16+ MDA-MB-468 cell line, as a model of the 
disease. siRNAs targeting p16 and KIF11 were used as positive controls under 
optimised transfection conditions. Transfection of the positive control siRNA targeting 
p16 at 60 nM into MDA-MB-468 cells caused a significant decrease in p16 intensity, 
and increase in cell number, again establishing introduction of this siRNA as a control 
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for p16 removal in the cells. At 90 nM, however, this siRNA caused a significant 
decrease in cell number in addition to p16 intensity, most likely due to an increase in 
cytotoxicity with the higher dose of siRNA. The introduction of siRNA targeting KIF11 
significantly reduced cell number at both 60 nM and 90 nM, and increased p16 intensity 
at 90 nM, showing it to be a robust control for cell death, and transfection efficiency.  
 
The introduction of all five putative oncomiRs and their corresponding antimiRs into 
the MDA-MB-468s at both 60 nM and 90 nM failed to cause any significant changes in 
either p16 intensity or cell number. This result suggested that whether the five miRNAs 
are endogenously expressed in the cells or not, they are not likely to be as biologically 
relevant to the cellular phenotype in the MDA-MB-468s as they are in the HMECs. 
5.3.2 Discussion 
Introduction of the five putative oncomiRs into HMECs were found to cause increases 
in both p16 levels and cellular proliferation, despite these two processes being generally 
recognised as contradictory. As the transfection of antimiRs targeting the five miRNAs 
into HMECs did not induce any phenotypic changes, it is likely that they are either not 
expressed, or expressed at such low levels that their removal does not cause a 
discernable change. Performing an RT-qPCR assay to determine the presence or 
absence of these miRNAs in HMECs should be a priority for any future work. 
 
Although transfection of the five miRNAs into HMECs caused an increase in p16 
expression and cell number, neither the cell area nor nuclear area of the cells were 
significantly altered. Usually in HMECs, cells that proliferate at a higher rate also tend 
to be smaller, and contain smaller nuclei than slower cycling cells, as observed in the 
results of Chapter 4. The results from the introduction of the miRNAs therefore suggest 
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that the transfected cells are either proliferating at the same rate as the control cells, or 
that the change in the rate of proliferation is too small to cause a significant change on 
the size of the cell and its nucleus. If there was no change in the rate of proliferation 
following transfection, the higher cell number observed may be due to a lack of 
senescence in response to p16 expression; meaning that cells which would have 
normally ceased to divide will continue to divide in the transfected population.  
 
As the introduction of the miRNAs caused an increase in both cell number and p16 
levels in HMECs, the molecular pathway linking p16 activity to cell cycle arrest must 
be decoupled. p16 acts by preventing the association of CDK4/6 and cyclin D, thus 
preventing the kinase activity of D-CDK4/6 phosphorylating pRB (see Section 1.13) 
(Serrano et al., 1993, Gil and Peters, 2006). One mechanism by which the cell could 
divide in the presence of p16, would be by loss of pRB activity, either through an 
inactivating mutation, or repression of the coding RB1 gene (Figure 5-8 section 1). Loss 
of the RB1 gene was first observed in patients with familial retinoblastoma (Murphree 
and Benedict, 1984), and since then its inactivation has been repeatedly described in a 
variety of cancers (Stefansson et al., 2011, Anwar et al., 2014, McEvoy et al., 2014). 
 
One of the hallmarks of BLBC is the expression of p16 in the proliferating cells as 
previously described (see Section 1.18.2) (Hui et al., 2000). Research has shown that 
the loss of RB1 appears to be a common event in BRCA1-negative BLBC 
(Herschkowitz et al., 2008, Jönsson et al., 2012), whereas this is not the case in BRCA2 
deficient breast cancers. The high levels of p16 expression in these proliferating 
tumours cells could be explained by an OIS-like feedback loop caused by loss of pRB 
and the subsequent induction of p16 expression as a result of unrestricted cell division 
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(Figure 5-8 sections 2 and 3). Loss of pRB has previously been found to correlate with 
high p16 expression in mammary carcinoma and BLBC (Dublin et al., 1998, 
Herschkowitz et al., 2008).  
 
Among the top 116 predicted target genes related to cellular proliferation and the 
control of p16 expression were 17 whose gene products are signalling proteins, and 29 
proteins involved in gene transcription (see Section 5.2.3.2). Many of these proteins are 
likely to be involved in induction of downstream pathways, and together may regulate a 
large number of genes within the cell.  
 
Multiple transcription factor binding sites have been predicted within the promoter 
region of RB1 by SABiosciences’ (QIAGEN, NL) proprietary DECODE (Decipherment 
Of DNA Elements) databaseI, with four of the transcription factors appearing within the 
top 116 predicted target genes from IPA (PPARG, targeted by miR-24; ATF2, targeted 
by miR-140-3p and miR-451; E2F1, targeted by miR-140-3p; CREB1, targeted by miR-
140-3p and miR-221). Thus, four of the five putative oncomiRs were identified as 
having predicted transcription factor targets that are involved in RB1 expression. 
Further interrogation of the IPA analysis identified another transcriptional regulator of 
RB1, CREBBP that is targeted by miR-574 (Appendix IV). This gene was previously 
excluded during the final ranking phase as it was given a low score.  
 
                                                
 
I  The SABiosciences DECODE database entry for p16 can be found at: 
http://www.sabiosciences.com/chipqpcrsearch.php?factor=Over+200+TF&species_id=0&ninfo=n&ngene=n&nfacto
r=y&gene=RB1 (accessed June 2014). 
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The fact that all five miRNAs are predicted to target transcriptional factors of RB1 
strongly suggests that pRB depletion is a possible cause of the higher cell number and 
elevated p16 observed in transfected HMECs (Figure 5-8 section 4). These results 
mirror the phenotype seen in BLBCs and suggest that the loss of pRB causes a common 
phenotype in both cell types. Current research into the knockout of RB1 in BLBC shows 
that it commonly occurs as a result of intragenic breaks (Jönsson et al., 2012), which is 
not the case in the transfected HMECs. It is therefore hypothesised that although the 
HMECs take on an extreme BLBC-like phenotype when transfected with the oncomiRs, 
the root cause of this change is not the same as in BLBCs.  
 
The MDA-MB-468 cell line was chosen as a model of BLBC in which to carry out 
further investigation into the activity of the five oncomiRs. This breast cancer cell line 
was selected on the basis of its proliferation in the presence of p16 (Hui et al., 2000), so 
that the effect of adding or removing the miRNAs could be assessed in a different 
system to the HMECs. These experiments proved to be wholly unsuccessful, as neither 
the transfection of the five miRNAs into the cells, nor the introduction of their 
corresponding antimiRs caused any significant changes in phenotype. In light of the 
bioinformatic analysis and the reported disruption of pRB in BLBCs, the status of pRB 
expression in the MDA-MB-468s was investigated. The MDA-MB-468 cell line was 
previously been found to lack pRB expression due to a deletion mutation, and its 
absence was confirmed by western blotting (Mizuarai et al., 2011, Robinson et al., 
2013).   
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Figure 5-8. Possible mechanism describing the relationship between cell proliferation 
and p16 expression in BLBC and HMECs transfected with oncomiRs. 
1. In BLBC and MDA-MB-468 cells the RB1 gene is lost or mutated, and therefore cannot 
be transcribed. 2. Loss of pRB as a result of transcriptional inhibition or mutation of RB1 
results in the constitutive activation of the E2F transcription factors that drive cellular 
proliferation. As the E2F transcription factors no longer need to be released by pRB, the 
process is independent of D-CDK4/6 activity. 3. Uninhibited transcription of S-phase 
genes induces the expression of p16. p16 Activity blocks the association of CDK4/6 and 
cyclin D but has no effect on the rate of proliferation, as D-CDK4/6 activity is irrelevant 
due to the absence of pRB. 4. The five oncomiRs miR-24 (24), miR-140-3p (140-3p), miR-
221 (221), miR-451 (451) and miR-574 (574) are predicted to target transcriptional factors 
of RB1. Knockdown or translational repression of the transcription factors prevents 
transcription of the RB1 gene. Solid lines signify reported interactions, where as dotted 
lines signify proposed interactions. Black crosses mark miRNA, protein and functions 
not present is these cells. 
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The lack of pRB expression in the MDA-MB-468 cells, whilst unfortunate from an 
experimental standpoint, reinforces the hypothesis that the five oncomiRs act 
independently to increase cellular proliferation via reduction in pRB expression, leading 
to a positive feedback loop that induces p16 expression. If this were not the case, it is 
likely that the introduction or removal of the five oncomiRs would have caused a 
phenotypic change in the MDA-MB-468 cells.  As a result of this complication, an 
alternative cell line in which to model BLBC should be found. In fact, the HMECs may 
prove an ideal cell type in which to study this process, as gene expression analysis has 
previously shown HMECs to resemble some BLBCs (see Section 6.2).  
 
Another recent study has shown that loss of DUSP4 in BLBC can lead to activation of 
the MAPK pathway and promote a CSC-like phenotype in the cells (Balko et al., 2013).  
Constitutive activation of the MAPK pathway is a well-known cause of p16 expression 
in cells (Lin et al., 1998), and therefore the effect of this pathway may exacerbate the 
observed up-regulation of p16 in BLBC. The predicted target genes contain three 
components of the MAPK pathway (MAP3K1, MAPK7 and MAPK12), however these 
have not been found to have any association with p16 or proliferation, and are 
concerned with embryogenesis (MAPK12) (Jin et al., 2013), cardiovascular 
development (MAPK7) (Hayashi and Lee, 2004), and myoblast differentiation 
(MAPK12) (Lechner et al., 1996).  
5.3.3 Future work 
Although a strong link has been hypothesised within this chapter regarding the 
expression of p16 in BLBC, and in HMECs following transfection with the oncogenic 
miRNAs, many opportunities for future experiments based upon these findings present 
themselves. One of the first experiments to be carried out should be assess whether the 
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HMECs endogenously express any of the five oncomiRs. While the transfection of the 
antimiRs into the cells suggested that they were not present, carrying out a RT-qPCR 
assay to confirm this would allow for a clearer interpretation of the results.  
 
Another informative experiment that could be carried out in the HMECs, is to study the 
effects of long term miRNA expression, in terms of cellular growth over time and p16 
expression. The miRNA genes could be introduced into the cells using a lentiviral 
miRNA vector, allowing for constant expression to be studied. Assays could be 
performed on these cells to investigate whether other cell cycle checkpoints can halt cell 
growth in the absence of p16-mediated senescence. Long-term rates of proliferation 
could also be measured, and compared to wild type cells to determine whether the 
transfected HMECs divide at an accelerated, or equivalent rate relative to low passage 
HMECs.  
 
During the course of these experiments, the antimiRs could also be transfected into the 
HMECs to perform rescue experiments. These experiments would investigate whether 
removal of the oncomiRs restores the cell to its original phenotype of being highly 
sensitive to p16 expression. If these antimiRs experiments were successful, older cells 
stably expressing the oncomiRs, could also be tested, to see whether any changes in cell 
behaviour occur in response to long-term dysregulation of pRB. The experiments 
described here may provide an insight into whether the reactivation of pRB could be 
used as a potential therapy for BLBC.  
 
In addition to the experiments previously suggested, the hypothesis that both BLBCs 
and the oncomiRs act by dysregulation of pRB should be investigated in more detail. 
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An important first experiment would be to quantify the expression of the key genes 
identified in Section 5.3.2, namely: RB1, ATF2, E2F1, CREB1, CREBBP and PPARG; 
either by western blot or RT-qPCR. If these genes were down-regulated in HMECs after 
transfection with the appropriate miRNA, it would provide further evidence for the 
hypothesis. Additionally, as miRNAs do not always cause target mRNA degradation, 
3’UTR luciferase assays, together with target site mutagenesis for the genes should be 
carried out to ensure the miRNAs can repress these predicted target genes.  
 
If possible, the levels of the other predicted genes from the top 116 hits should be 
evaluated using luciferase assays, to discover which of these are physiologically 
relevant in the HMECs. The genes found to be affected by the miRNAs could then be 
studied in the cells, by observing their expression levels in a variety of situations; such 
as the differences between low and high passage cells, and transfected and untransfected 
cells. In addition to these genes, the expression of BRCA1 should also be evaluated, as it 
was previously found to coincide with pRB disruption in BLBC (Stefansson et al., 
2011).  
 
For more in-depth analysis of the molecular changes undergone by HMECs in response 
to transfection with the five oncomiRs, RNA-seq could be employed to examine 
changes in gene expression, miRNAs, and other ncRNAs. The technique could be 
carried out to look at the differences between untransfected HMECs and HMECs 
transfected with each of, and combinations of, the five miRNAs. The technique would 
allow recognition the molecular mechanisms at play in each condition, identify common 
pathways, and inform further study with respect to each miRNA and the downstream 
cascade of cellular changes each induces. In addition to these samples, extra RNA-seq 
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studies could be carried out in HMECs by looking for changes in the expression of 
relevant genes between young cells, old cells, and cells which have escaped cellular 
senescence. These experiments might provide insight into any similarities and 
differences in the transcriptome of cells that have escaped senescence ‘naturally’, 
compared to cells that have bypassed senescence as a result of oncomiR activity.  
 
Any extra genes or ncRNAs identified by RNA-seq should be subsequently investigated 
further by overexpression or knockdown experiments in HMECs, depending on their 
expression profiles. Detailed and careful mapping of each of the possible interacting 
genes in these pathways will allow for the mechanisms behind the enhanced cellular 
proliferation in the presence of p16 observed in transfected HMECs, and possibly the 
similar phenotype seen in BLBC, to be properly understood.  
 
The list of predicted target genes generated in this study could also be used in future 
bioinformatic studies of patient data. The expression levels of both the miRNAs and the 
predicted targets genes could be studied in patient-sample data set in order to search for 
correlations between gene and miRNA expression, and survival. In depth analysis of 
this type of data may provide novel genetic markers for disease progression, and 
therefore inform future therapy choices for patients. 
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Chapter Six 
 
 
6  General Discussion 
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6.1 ABCB5 and p16 
In Chapter 3, wild type and mutant forms of ABCB5fl and ABCB5β were transiently 
expressed in HEK293T cells in order to characterise these proteins. The proteins were 
poorly expressed and found to localise to the endoplasmic reticulum, as apparent from 
previous studies (Frank et al., 2003, Linley et al., 2012, Mathieu et al., 2014), although 
not highlighted by authors in the published data (see Section 3.3.2). In Chapter 4, 
siRNA knockdown of ABCB5β in HMECs was shown to cause a concomitant reduction 
in p16 expression. RT-qPCR and 5’ RACE PCR confirmed that ABCB5β mRNA was 
present in these primary cells, but neither ABCB5fl nor ABCB5β protein were 
detectable, leading to the hypothesis that the ABCB5β mRNA may act as a lncRNA in 
HMECs.  
6.1.1 Antibodies targeting ABCB5 
The ability to engineer expression of ABCB5fl and ABCB5β in a naïve host allowed 
the three commercially available antibodies, designated Atlas, Rockland and Sigma, to 
be validated. Only the Atlas antibody was found to accurately identify ABCB5fl and 
ABCB5β (see Section 3.2.1). Some of the prior investigations used the Rockland 
(Kawanobe et al., 2012) and Sigma (Linley et al., 2012, Mathieu et al., 2014) antibodies 
found to lack efficacy in the current study, necessitating re-evaluation of the data. 
Several of the other studies of these proteins have used antibodies generated in-house 
(Frank et al., 2003, Frank et al., 2005, Schatton et al., 2008, Ksander et al., 2014). These 
in-house generated antibodies were not available to test herein, therefore their veracity 
has not been examined alongside those that are commercially available. This poses an 
issue because most of the previous work on ABCB5fl and ABCB5β is based largely 
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upon antibody use, and the assumption that they are highly effective markers of ABCB5 
protein expression.  
 
Some studies, using polyclonal antibodies have used blocking peptides as negative 
controls (Wilson et al., 2011, Ramgolam et al., 2011). However, these do not always 
provide a true negative control. If an antibody is polyclonal, the preparation may 
contain antibodies against other proteins in addition to the immunogen (Saper and 
Sawchenko, 2003). These non-specific antibodies are likely to bind proteins other than 
the intended target. Presumably, this is the case with the Rockland polyclonal antibody 
against ABCB5, in which the number of antibodies targeting other proteins appear to 
greatly outnumber those that target ABCB5.  
 
It is also understood that no two animals will produce an identical immune response to 
the same immunogen, as each animal has its own distinct immune system, and thus will 
have a different immune response to the immunogen (Ritter, 2000, Saper and 
Sawchenko, 2003).  All the antibodies tested in this work were polyclonal; it is 
therefore theoretically possible that some of the differences in specificity observed 
between this study and those in the literature are due to differences in antibody 
composition between batches. It is more likely, however, that some of the earlier 
observations are erroneous due to the lack of specificity of the commercially available 
antibodies.  
6.1.2 Re-evaluation of published anti-ABCB5 antibody data 
As two of the three commercially available antibodies were not found to target 
ABCB5fl or ABCB5β, the conclusions of some previously published papers, which 
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used these (Kawanobe et al., 2012, Linley et al., 2012, Mathieu et al., 2014), need to be 
re-examined for accuracy.  
6.1.2.1 Does ABCB5 confer drug resistance to expressing cells? 
The 2012 study published by Kawanobe et al. used the Rockland anti-ABCB5 antibody 
to detect expression of ABCB5fl protein in stably expressing naive HEK293 cells 
(Kawanobe et al., 2012). When evaluated by western blot in Chapter 3, the Rockland 
antibody failed to detect any protein of the expected molecular weight in whole cell 
lysates of cells expressing ABCB5fl or ABCB5β, but bound to many other proteins of 
lower molecular weights in both transfected and untransfected control HEK239T cells. 
The figure reportedly showing antibody binding to ABCB5fl in the paper is heavily 
cropped, with multiple proteins are detected in each lane, no indicators of molecular 
weight, and protein detected in the untransfected control cells with lack endogenous 
ABCB5 (Kawanobe et al., 2012). 
 
However, ABCB5fl protein expression is corroborated by the use of a Myc-tagged 
ABCB5fl construct, detected by an anti-Myc antibody (Kawanobe et al., 2012). These 
data are more convincing showing a similar pattern of staining to that observed for the 
Atlas anti-ABCB5 antibody used herein. The use of the Rockland antibody in the 
published study formed a pattern of staining, although different from the pattern 
observed with the anti-Myc antibody, and resembling the lower pattern of lower 
molecular weight bands recorded for the Rockland antibody in Chapter 3. Without the 
molecular weight marker visible in the figure, however, it is impossible to determine the 
migration of the presented bands (Kawanobe et al., 2012). Similar to my findings, 
ABCB5fl expressed poorly following transient transfection, but Kawanobe et al. were 
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able to clone stably transfected cell lines, which provided more robust expression. The 
intracellular localisation of the expressed protein was not determined.  
 
The study aimed to evaluate whether ABCB5fl expressed in HEK293s could confer 
resistance to doxorubicin, paclitaxel and docetaxel; three chemotherapeutic agents 
which are thought to be substrates of ABCC1 and ABCC2 (Cui et al., 1999, Borst et al., 
2000, Huisman et al., 2005), two ABC transporters which are endogenously expressed 
within this cell line (Borel et al., 2011). The difference in resistance between the 
expressing and control cells is relatively small (two fold, whereas ABCB1 often confers 
a three fold or higher change resistance to expressing cells (Shen et al., 1986)) and 
could be accounted for by experimental variation, or changes in the cell line as a result 
of serial selection of the ABCB5fl expressing clones.  
 
Studies using cells endogenously expressing ABCB5β have previously reported the 
ability of the protein to efflux doxorubicin, with drug accumulation found to be half that 
of non-expressing cells (Frank et al., 2005). The cells (G3361 melanoma cells) were 
sorted for ABCB5β expression by fluorescence-activated cell sorting using an in-house 
generated monoclonal antibody.  The efficacy of this antibody is unknown as it was not 
available for testing herein, and the study did not use a cell line that was known to lack 
ABCB5β expression as a negative control. Given these caveats, I remain to be 
convinced that either recombinant ABCB5fl or endogenous ABCB5β can effectively 
confer drug resistance to naïve cells. 
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6.1.2.2 Is ABCB5 important in malignant melanoma? 
In both their 2012 and 2014 papers, the Regad group used the Sigma anti-ABCB5 
antibody to assess the expression of ABCB5 in MMICs (Linley et al., 2012, Mathieu et 
al., 2014). In these studies, the antibody was used for both immunofluorescence and 
immunoblot assays to identify ABCB5 expression, and its correlation to HAGE (an 
RNA helicase linked to malignancy in melanoma) expression across the cells. The 
immunoblots using the antibody in this study identified a single protein species 
migrating at around 90 kDa, equating to ABCB5β, although as the blots were cropped 
at 75 kDa, any bands at lower molecular weights are not visible. In Chapter 3, this 
antibody was unable to detect any ABCB5fl or ABCB5β protein by western blotting 
under conditions in which the Rockland antibody clearly and cleanly detects both.  
 
In these papers, the Sigma anti-ABCB5 antibody is used as a marker of ABCB5β and 
clear differences are observed when normal tissue and malignant melanoma samples are 
compared (Mathieu et al., 2014, Linley et al., 2012). From my data, the Sigma antibody 
does not appear to detect ABCB5β, which leaves me to conclude that either: I was 
provided with bad batches of antibody from Sigma (two separate batches were tested in 
total); or while the antibody may be able to mark a population of MMICs, it is not 
ABCB5β or a protein that is expressed in HEK293T cells. 
 
ABCB5β expression was first identified as a possible marker for MMICs by the Frank 
group (Schatton et al., 2008), although no immunoblots were performed in this study. 
Consequently, the results of this study and the Kawanobe study cannot be directly 
compared. All detection of ABCB5β in the Frank study was performed by flow 
cytometry and immunohistochemistry with a monoclonal antibody that was generated 
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in-house. No negative controls for the accuracy of antibody staining were used, so it is 
difficult to know how specific the detection of ABCB5β in this study was (Schatton et 
al., 2008). It is possible that the antibody may be raised against a similar peptide 
sequence to the Sigma antibody allowing the same, although incorrect, protein to be 
identified as marking MMICs in both studies.  
6.1.3 ABCB5β  and p16 expression in ageing HMECs 
The parallel rise in expression of the ABCB5β and p16 transcripts with HMEC culture 
age remains to be explained. At present, there is no published information on which 
transcription factors or cellular signals act to induce the expression of ABCB5β, or 
indeed any of the isoforms of ABCB5.  
 
Although it is questionable at present, if expression of ABCB5fl does actually confer 
drug resistance to expressing cells (Frank et al., 2005, Kawanobe et al., 2012), it is 
possible that the nuclear receptors pregnane X receptor (PXR), and retinoid X receptor 
(RXR), could induce expression of the ABCB5 isoforms in response to xenobiotic 
compounds (Kliewer et al., 2002), as these receptors are known to do for the drug efflux 
pumps ABCB1 and ABCG2 (Geick et al., 2001, Synold et al., 2001, Lemmen et al., 
2013).  
 
Multiple, though not experimentally confirmed, transcription factor binding sites have 
been identified in the 3’ region of the ABCB5 gene by SABiosciences’ (QIAGEN, NL) 
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proprietary DECODE (Decipherment Of DNA Elements) databaseI (Figure 4-17 section 
1). None of the predicted transcription factor binding sites for ABCB5 are shared with 
p16, suggesting that the coordinate expression is not simply due to both genes being 
regulated by the same transcription factor. This could have possibly accounted for their 
tandem increase in expression in ageing cells, but would not have accounted for the 
concomitant decrease in p16 observed upon knockdown of ABCB5β.  
6.1.4 ABCB5β  in stem cell maintenance  
A very recent study has suggested that ABCB5β protein is essential for corneal 
development and repair, via the maintenance of the limbal stem cell (LSC) population 
in the eye (Ksander et al., 2014). This paper contains the first reported description of an 
Abcb5-/- knockout mouse, which was engineered to lack expression of both ABCB5fl and 
ABCB5β. These mice are reported to be physically indistinguishable from the wild type 
animals (Ksander et al., 2014).  
 
This work was carried out by the Frank group, who have extensively used in-house 
generated monoclonal antibodies, which were not available for testing, to assess 
ABCB5β and ABCB5fl protein expression in multiple tumours and cell types (Schatton 
et al., 2008, Frank and Frank, 2009, Volpicelli et al., 2014). The antibodies were used 
for western blotting and immunofluorescence, alongside RT-PCR, to demonstrate the 
knockout of ABCB5β. It should be noted that the immunofluorescence data published in 
                                                
 
I  The SABiosciences DECODE database entry for ABCB5 can be found at: http://www.sabiosciences.com 
/chipqpcrsearch.php?species_id=0&nfactor=n&ninfo=n&ngene=n&B2=Search&src=genecard&factor=Over+200+T
F&gene=ABCB5 (accessed January 2014). 
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this paper appears to be intracellular, as with their previous work (see Section 3.3.2) 
(Ksander et al., 2014).  
 
Histological examination of the knockout animals’ eyes revealed various developmental 
abnormalities, such as reduced epithelial cell numbers, defects in epithelial tight 
junctions, a disorganised basal cell layer, and increased cornea fragility. These 
observations, and subsequent experiments, identified an important role for the Abcb5 
gene in maintaining the LSC population. Additionally, the grafting of human or murine 
LSCs with endogenous ABCB5+ (or Abcb5+) expression to LSC-deficient mice was able 
to fully restore the cornea. Only ABCB5+ (or Abcb5+) LSCs had this restorative effect, 
as apposed to LSCs which lacked endogenous expression of the protein. 
 
Knockout of Abcb5β in LSCs was found to cause enhanced proliferation and apoptosis, 
leading to a reduction in the number of quiescent LSCs available for corneal 
differentiation and wound healing (Ksander et al., 2014). Knockout of Abcb5β in LSCs 
increased cellular proliferation, similar to the phenotype following the knockdown of 
ABCB5β in HMECs. It would be interesting to explore whether these observations in 
different cell types are related. This could be achieved by RNA-seq methodology 
outlined in Section 4.3.3, where changes in both HMEC and LSC RNA expression 
patterns after ABCB5β knockdown could be compared. 
 
Studies have previously identified senescence to be important in wound healing (Jun 
and Lau, 2010) and embryonic development (via p21 as apposed to p16) (Muñoz-Espín 
et al., 2013). The finding that Abcb5β is essential for the development and healing of 
murine eyes by LSCs could be an indication of a more ubiquitous role for expression of 
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ABCB5β in mechanisms of senescence. Future experiments could investigate a possible 
role for ABCB5β in these processes of senescence by studying differences in wound 
healing between wild type and ABCB5β-null cells. 
 
It should be noted, however, that some of the changes in LSC phenotype were also seen 
upon blockade of Abcb5β by antibodies (although not antibodies tested herein), 
suggesting an active role for the Abcb5β protein within the cells (Ksander et al., 2014). 
This result could suggest that the ABCB5β protein is relevant in HMECs, although 
present at undetectable levels. If this were the case, it would suggest that ABCB5β is an 
extremely potent effector of the cell cycle, if such small changes in protein level were 
found to cause such a drastic change in cellular phenotype. 
6.2 Oncogenic miRNAs and BLBC 
In Chapter 6, the effect of five putative oncomiRs on p16 expression and cellular 
proliferation in HMECs and a model of BLBC were examined. The five putative 
oncomiRs were found to cause an increase in cellular proliferation, and subsequent 
response of p16 expression, confirming their oncogenic status. Bioinformatic analysis 
suggested that the oncomiRs act by disrupting expression of the pRB gene RB1, 
allowing unrestricted cellular proliferation, even in the presence of the potent tumour 
suppressor p16.  
6.2.1 HMECs as a model for BLBC 
As discussed in Section 5.3, one of the aims of this project was to identify an alternative 
cell type to the HMECs in which to model BLBC. The MBA-MB-468 cell line was 
chosen, as it both expresses p16 and continues to divide, in a similar manner to the 
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cancer subtype. The experiments that introduced the five oncomiRs and their respective 
antimiRs into these cells, found no changes in cellular phenotype or proliferative rate. 
This is likely to be due to the lack of pRB expression in this cell line. Other research 
indicates that HMECs may in fact be an excellent cell type in which to construct a 
model of BLBC, as the cells share many of the same expression characteristics (Perou et 
al., 1999, Perou et al., 2000).  
 
These studies from the Botstein lab showed that both HMECs and BLBCs highly 
express a cluster of IFN-regulated genes, including STAT1 and LOX, which are known 
to increase proliferation in expressing cells (Perou et al., 1999, Sun et al., 2007, Wang et 
al., 2013). The induction of these genes in HMECs coincides with growth arrest as a 
result of premature senescence, suggesting that this gene cluster may be involved in the 
activation of OIS, thereby laying the groundwork for cellular transformation (Perou et 
al., 1999). Indeed, a high level of STAT1 expression was detected in many of the breast 
cancer samples used in the study, as a result of the IFN-regulated cluster previously 
mentioned (Perou et al., 1999). STAT1 has been suggested to play a role in the 
carcinogenic process which breast cells undergo to become tumourous, although the 
exact mechanism is currently unknown (Perou et al., 1999).  
 
Overall, these data point to HMECs as an ideal cell type in which the stepwise 
transformation of normal breast cells to breast cancer cells could be modelled and 
studied to gain an understanding into the cellular mechanisms at play in the process. 
Additional work to identify a cell line that can be used as a model of established disease 
may be prudent for future study of the oncomiRs, although for the time being the 
 243 
HMECs may actually provide a wealth of information about the action of the oncomiRs, 
and about the transformation of breast cells in general.  
6.2.2 OncomiRs in p16-associated disease 
In addition to the possible mechanisms of oncomiR and p16 interaction proposed in 
Section 5.3, which were hypothesised as a result of the predicted target genes, the five 
oncomiRs have all previously been linked to age-related disorders which are either 
known to, or thought to, involve p16.  
 
All five oncomiRs have been reported to be disregulated in cancers, although this could 
be due to the large number of changes in gene expression commonly observed in 
transformed cells. miR-24, miR-221, miR-451 and miR-574 are, however, all up-
regulated in various cancers (Foss et al., 2011, Du et al., 2013, Aldaz et al., 2013, Dai et 
al., 2013), with miR-221 suggested to hold an actively oncogenic role, especially in 
glioblastoma multiform (Aldaz et al., 2013). The altered expression of the oncomiRs 
observed in a variety of cancers suggests strong links to cellular proliferation.  
 
In addition to their dysregulation in cancer, the oncomiRs have been associated with 
other age-related diseases linked to the up regulation of p16 expression such as type 1 
diabetes mellitus (miR-24) (Zhu et al., 2013b), type 2 diabetes mellitus (miR-140-3p) 
(Collares et al., 2013) and coronary heart disease (miR-140-3p) (Taurino et al., 2010). 
These studies are consistent with a role for these oncomiRs in the induction of cellular 
senescence via expression of p16.  
 
The oncomiRs can clearly act by different mechanisms in different cell types to produce 
disparate effects, such as miR-24 being able to promote (Giglio et al., 2013), or inhibit 
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(Song et al., 2013), cancer cell proliferation, in keratinocytes and osteosarcoma, 
respectively. A important point for future study should be to identify the genes, which 
are responsible for driving the cellular phenotypes observed upon oncomiR expression. 
This could be carried out by transfecting a panel of cancer cells from a range of relevant 
tissues with the oncomiRs, and examining the changes in gene expression and the 
corresponding cellular phenotype which occur compared to untransfected control cells. 
The cross-referencing of this dataset could reveal which genes are key for driving the 
proliferative phenotypes. The aim of this experimental plan would be to provide 
possible candidate genes for further investigation, and potentially identify new 
therapeutic targets.  
6.3 Concluding remarks 
The experiments described in this thesis have provided important insights into 
mechanisms of p16 regulation, which will inform future work around this topic.  
 
Finding a cell line in which ABCB5fl and ABCB5β can be efficiently expressed 
transiently would provide an avenue for further research into the intriguing isoforms of 
this protein. The experiments here described were not able to establish the HEK293T 
cell line as an effective host for the expression of these proteins, although they did raise 
questions about, and provide useful insights into, the interpretation of data previously 
published from other laboratories. The efficacies of previously described antibodies are 
clearly questionable, and the practice of solely relying on antibody binding to mark 
ABCB5β expression for expansive studies is improvident. Antibodies are biological 
molecules and are not infallible in the assessment of protein expression. 
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The knockdown of ABCB5β mRNA by siRNA has been demonstrated to cause a 
concomitant reduction in p16 expression. This result has added to the growing body of 
evidence suggesting that products of the ABCB5 gene have a variety of downstream 
implications in addition to the possible transport of substrates across membranes by 
protein products of the gene. The observation that the ABCB5β protein does not appear 
to be present within the HMECs was surprising, especially as previous studies 
examining the role of ABCB5β in cells have suggested that the effects of expression are 
mediated at the protein level, with changes in cellular phenotype observed upon 
blockade with an ABCB5β-targeting monoclonal antibody. The simplest interpretation 
of the data reported herein is that the ABCB5β mRNA can act as a lncRNA. Future 
studies to confirm the exact nature of the relationship between ABCB5β and p16 
expression will be critical to understanding the mechanism of action.  
 
Providing further insights into the mechanism of p16 expression and cellular 
proliferation in cancer, five oncomiRs have been identified which contradictorily 
increase both of these factors in HMECs. The recognition that these oncomiRs can 
cause the cell to enter an OIS-like feedback-loop as a result of their expression has 
provided an exciting opportunity to use these cells as a model of breast cell 
transformation. The bioinformatic identification of predicted gene targets for each of the 
oncomiRs has provided a basis on which future studies can be systematically carried 
out, to gain a real insight into the processes that go into the formation and progression 
of these aggressive breast tumours. 
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Appendices 
Appendix I. ABCB5fl and ABCB5β  sequences submitted for TaqMan 
and siRNA generation. 
 
Appendix I. ABCB5fl and ABCB5β  sequences submitted for TaqMan and siRNA 
generation. 
A. 1005 nt sequence unique to ABCB5fl. B. 193 nt sequence of ABCB5β  not present in 
ABCB5fl.  
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Appendix II. Optimisation of HMEC seeding density 
Due to the small area of 384-well plates (the surface area of each well is 0.087 cm2), it 
is important that each step of the siRNA transfection protocol is precisely optimised. 
The first step was to establish the appropriate seeding density for the cells. The required 
seeding density is one at which the cells would still be sub-confluent after 120 h (the 
experiment endpoint), to allow for an increase in proliferation to be observed, but for 
there to be enough cells to also be able to measure reduction in cell proliferation. Unless 
otherwise stated, all of the following experiments were carried out in HMEC P6, at 
which stage there is a mixed population of both proliferative (p16 negative) and 
senescent (p16 positive) cells, allowing changes in their relative proportions to be 
measured.  
 
Cells were seeded in 384-well format at five different densities (5,000 – 15,000 cm-2), 
the media was changed after 48 h and the cells were fixed at the 120 h time point 
(Appendix II-I panel A). The 10,000 cm-2 seeding density was chosen for future 
experiments, as the resulting final cell number (2348 ± 283) allowed for measurement 
of both increase and decrease in cell proliferation following siRNA transfection. 
 
To control for edge effects and thereby assess whether the entire plate could be used for 
experimental set-up, an entire plate was seeded at 10,000 cm-2 and the cells fixed and 
counted after 120 h. The data from a quarter of the plate is shown for row-to-row and 
column-to-column variability (Appendic II-I panel B). With the exception of the two 
outermost rows (A and B), and the two outermost columns (1 and 2), there was little 
variability found across the plate. The reduction in cell number in the outermost wells of  
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Appendix II-I. Seeding density optimisation for HMEC transfection in 384-well format. 
A. HMECs seeded at increasing densities in wells of a 384-well plate were fixed, stained 
with DAPI and counted after 120 h. B. To assess well-to-well variability over the plate, 
cells seeded at 10,000 cm-2 were counted after 120 h in both the rows (A – H) and 
columns (1 – 12). Both rows A and B, and columns 1 and 2 were found to have a 
consistently lower cell number after 120 h than any other row or column. Error bars 
represent one SD. n = 2 biological repeats. 
 
the plate can be explained by the edge effect, in which evaporation of medium from the 
edge of the plate can cause reduction in cell growth. Accordingly, the outer wells (rows 
A, B, O, P and columns 1, 2, 23, 24) were not used as experimental wells for the 
remainder of this study. 
 
The next step of the optimisation procedure was to find the correct volume of 
transfection reagent to use per well to provide a significant knockdown of target gene 
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Appendix II-II Optimisation of transfection reagent volume for HMEC transfection. 
A B D and E. HMECs were treated with transfection reagent as indicated (HiPerFect Only 
- black columns) or HiPerFect with 30 nM siRNA (siGLO – grey columns; CBX7 – orange 
columns; p16 – purple columns). Cells were fixed 120 h post transfection, stained with 
DAPI and imaged using an IN Cell 1000 microscope at 10x magnification (GE Healthcare, 
UK). Nuclei were counted from the resulting images using Developer Toolbox 1.7 (GE 
Healthcare, UK). C. Transfected cells were imaged 48 h post transfection using an IN Cell 
1000 microscope to assess transfection efficiency. The black box represents the 
zoomed area. Brightfield images with red (siGLO) overlay. Error bars represent one SD. * 
p < 0.05, ** p < 0.01, *** p < 0.001. n = 3 biological repeats. 
 268 
expression, without causing cellular cytotoxicity. To optimise the quantity of 
transfection reagent (HiPerFect; QIAGEN, NL) to be used, cells were treated with 
increasing amounts of HiPerFect, and a constant concentration of 30 nM siRNAs 
targeting three control genes (Cyclophilin B, CBX7 and p16), alongside untransfected 
cells and cells treated with the transfection reagent alone (HiPerFect only), as negative 
controls.  
 
Cytotoxicity as a consequence of excessive transfection reagent dose resulted in a 
reduction in cell number when the volume of transfection reagent was at 0.3 µL well-1 
and above, with a stepwise increase in cytotoxicity with HiPerFect only (p < 0.05 to p 
<0.001)I and siGLO (p < 0.01 to p < 0.001) between 0.30 µL well-1 and 0.40 µL well-1 
(Appendix II-II panels A and B). Fluorescent siGLO siRNA was used to assess 
transfection efficiency in cells 48 h post transfection (Appendix II-II panel C). The 
number of fluorescent foci – siGLO-HiPerFect complexes – per cell were observed to 
increase with increasing volume of transfection reagent up to 0.3 µL well-1, after which, 
all HiPerFect volumes were comparable. A stepwise increase in the predicted 
phenotypes following transfection with siRNAs targeting CBX7 and p16 was seen with 
volumes of transfection reagent between 0.15 µL well-1 and 0.25 µL well-1 (both p < 
0.001), after which, increasing the amount of transfection reagent made no difference to 
the cell number (Appendix II-II panels D and E). 
 
                                                
 
I Accurate p-values cannot be calculated when using a one-way ANOVA due to limitations in the software being used 
(Prism v5.0d; GraphPad Software Inc, CA). See Section 2.29.2. 
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The volume of 0.25 µL well-1 of transfection reagent was chosen for all future siRNA 
transfections in HMECs because it was found to give the strongest knockdown 
phenotype with no measurable toxicity.  
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Appendix III. mRNA sequences submitted for RNA secondary 
structure prediction. 
 
Appendix III. mRNA sequences submitted for RNA secondary structure prediction. 
A. Bases 1 – 500 of ABCB5β . B. Bases 1601 – 2100 of ABCB5fl. C. Bases 2501 – 3000 of 
ABCB5fl. 
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Appendix IV. Optimisation of MDA-MB-468 transfection 
As previously described (see Appendix II), it is critical to optimise seeding of 384-well 
plates for RNA transfection. As the MDA-MB-468s already express p16, it was 
hypothesised that introduction of the miRNAs would have little or no effect upon the 
level of p16 and cell proliferation at the experiment end point (120 h), where as the 
antimiRs may reduce the level of p16 and alter cellular proliferation.  
 
Cells were seeded in 384-well format at seven different densities (5,000 – 35,000 cells 
cm-2), the media was changed after 48 h and the cells were fixed after 120 h (Appendix 
IV-I panel A). The 30,000 cells cm-2 seeding density was chosen for future experiments, 
as the final cell number (10655 ± 1381) would allow for changes in cell proliferation 
following miRNA transfection to be visualised. The two outermost rows (A and B) and 
columns (1 and 2) were omitted to eliminate the edge effect from the experiments (as 
described in Appendix II; Appendix IV-I panel B). 
 
The next step of the transfection optimisation was to determine the ideal volume of 
transfection reagent to use per well to provide a significant knockdown of target gene 
expression without causing cellular toxicity. These experiments were carried out in 
MDA-MB-468 cells as previously described for HMECs (see Appendix II), although 
with both 60 nM and 90 nM concentrations of siRNA (Appendix IV-II). 
 
In light of these optimisation experiments, 0.2 µL well-1 of HiPerFect was chosen for all 
future si/miRNA experiments at both 60 nM and 90 nM in MDA-MB-468 cells, as it 
was found to give the strongest knockdown with no significant toxicity. 
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Appendix IV-I Seeding density optimisation for MDA-MB-468 transfection in 384-well 
format. 
A. MDA-MB-468s seeded at increasing cell densities in wells of a 384-well plate were 
fixed and counted after 120 h. B. To assess well-to-well variability over the plate, cells 
seeded at 30,000 cm-2 were counted after 120 h in both the rows (A – H) and columns (1 – 
12) of a quarter of the plate. The outer rows (A and B) and columns (1 and 2) were found 
to have consistently lower cell numbers after 120 h than any other row or column. Error 
bars represent one SD. n = 2 biological replicates. 
 
As the transfection of siRNA targeting p16 at 60 nM was found to cause an increase in 
cell number with lower concentrations of HiPerFect, it can be concluded that although 
the MDA-MB-468 cells proliferate whilst expressing p16 they remain responsive to 
changes in its expression level. 
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Appendix IV-II. Optimisation of transfection reagent volume for MDA-MB-468 
transfection. 
A. MDA-MB-468s were treated with transfection reagent as indicated (HiPerFect Only; 
black columns) or HiPerFect with 60nM siRNA (siGLO – grey columns; p16 – purple 
columns; KIF11 – red columns). Cells were fixed 120 h post transfection, stained with 
DAPI and imaged using an IN Cell 1000 microscope at 10x magnification (GE Healthcare, 
UK). Nuclei were counted from the resulting images using Developer Toolbox 1.7 (GE 
Healthcare, UK). Error bars represent one SD, * p < 0.05, ** p < 0.01, *** p < 0.001. n = 2 
biological repeats. 
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Appendix IV-II. (continued) Optimisation of transfection reagent volume for MDA-MB-468 
transfection. 
B. MDA-MB-468s were treated with transfection reagent as indicated (HiPerFect Only; 
black columns) or HiPerFect with 90nM siRNA (siGLO – grey columns; p16 – purple 
columns; KIF11 – red columns). Cells were fixed 120 h post transfection, stained with 
DAPI and imaged using an IN Cell 1000 microscope at 10x magnification (GE Healthcare, 
UK). Nuclei were counted from the resulting images using Developer Toolbox 1.7 (GE 
Healthcare, UK). Error bars represent one SD, * p < 0.05, ** p < 0.01, *** p < 0.001. n = 2 
biological repeats. 
Appendix V. Potential mRNA target genes linked to cellular proliferation and p16 by IPA Core Analysis. 
Appendix V-I. Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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 Appendix V-I. (continued) Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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Appendix V-I. (continued) Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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Appendix V-I. (continued) Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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 Appendix V-I. (continued) Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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Appendix V-I. (continued) Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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Appendix V-I. (continued) Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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 Appendix V-I. (continued) Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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Appendix V-I. (continued) Predicted target genes of hsa-miR-24 based upon miRWalk target comparison. 
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Appendix V-II. Predicted target genes of hsa-miR-140-3p based upon miRWalk target comparison. 
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Appendix V-II. (continued) Predicted target genes of hsa-miR-140-3p based upon miRWalk target comparison. 
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Appendix V-II. (continued) Predicted target genes of hsa-miR-140-3p based upon miRWalk target comparison. 
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Appendix V-II. (continued) Predicted target genes of hsa-miR-140-3p based upon miRWalk target comparison. 
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Appendix V-II. (continued) Predicted target genes of hsa-miR-140-3p based upon miRWalk target comparison. 
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Appendix V-II. (continued) Predicted target genes of hsa-miR-140-3p based upon miRWalk target comparison. 
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Appendix V-III. Predicted target genes of hsa-miR-221 based upon miRWalk target comparison. 
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Appendix V-III. (continued) Predicted target genes of hsa-miR-221 based upon miRWalk target comparison. 
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Appendix V-III. (continued) Predicted target genes of hsa-miR-221 based upon miRWalk target comparison. 
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Appendix V-III. (continued) Predicted target genes of hsa-miR-221 based upon miRWalk target comparison. 
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Appendix V-III. (continued) Predicted target genes of hsa-miR-221 based upon miRWalk target comparison. 
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Appendix V-IV. Predicted target genes of hsa-miR-451 based upon miRWalk target comparison. 
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Appendix V-V. Predicted target genes of hsa-miR-574 based upon miRWalk target comparison. 
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Appendix V-V. (continued) Predicted target genes of hsa-miR-574 based upon miRWalk target comparison. 
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Appendix V-V. (continued) Predicted target genes of hsa-miR-574 based upon miRWalk target comparison. 
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Appendix V-V. (continued) Predicted target genes of hsa-miR-574 based upon miRWalk target comparison. 
Appendix VI. Putative oncomiR target genes predicted by IPA 
 
Appendix VI. Predicted oncomiR target genes linked to p16 expression and cell 
proliferation by IPA. 
Blue rows mark the top 116 genes selected for future study, based upon their score. 
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Appendix VI. (continued) Predicted oncomiR target genes linked to p16 expression and 
cell proliferation by IPA. 
Blue rows mark the top 116 genes selected for future study, based upon their score. 
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Appendix VI. (continued) Predicted oncomiR target genes linked to p16 expression and 
cell proliferation by IPA. 
Blue rows mark the top 116 genes selected for future study, based upon their score. 
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Appendix VI. (continued) Predicted oncomiR target genes linked to p16 expression and 
cell proliferation by IPA. 
Blue rows mark the top 116 genes selected for future study, based upon their score. 
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Appendix VI. (continued) Predicted oncomiR target genes linked to p16 expression and 
cell proliferation by IPA. 
Blue rows mark the top 116 genes selected for future study, based upon their score. 
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Appendix VI. (continued) Predicted oncomiR target genes linked to p16 expression and 
cell proliferation by IPA. 
Blue rows mark the top 116 genes selected for future study, based upon their score. 
 	  
